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ABSTRACT 
 
Massive screens of chemical libraries for antimalarial activity have identified thousands of 
compounds that exhibit sub-micromolar potency against the blood stage of the malaria 
parasite Plasmodium falciparum. Triaging these compounds to establish priorities to take 
forward for development requires additional information regarding their activity. Key 
amongst their pharmacodynamics (PD) properties is the rate of kill– with a rapid cytocidal 
effect specifically identified as a key requirement for a Single Exposure Radical Cure and 
Prophylaxis (SERCaP) product. Compounds that exert an immediate cytocidal effect 
rapidly reduce parasite burden to ameliorate the morbidity and mortality of disease. With 
the overall aim to accelerate drug screening by validating a rapid rate of kill, the 
validation of a novel, quick (6hr) and potentially scalable bioluminescence rate of kill 
(BroK) assay is described here that demonstrates a good correlation with in vitro 
recrudescence-based rate of kill data and available in vivo clinical findings. The BRoK assay 
was used to screen the Medicine for Malaria Venture Malaria Box to identify compounds 
with rapid cytocidal activity. Seventeen compounds have an initial rate of kill greater than 
artemisinins, with a further 39 compounds exhibiting a rate of kill between chloroquine 
and artemisinins. These compounds represent potential Target Candidate Profile, 
compounds for a SERCaP product. This work highlights the opportunity for the BRoK assay 
as a hit discovery tool. In addition, the potential for this assay in lead validation through 
structure activity relationship studies are highlighted.   
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CHAPTER 1: Introduction  
1.1 Malaria: a major public health challenge  
 
Malaria is an infectious disease caused by the obligate intracellular protozoan parasite 
Plasmodium falciparum and transmitted by the mosquito vector Anopheles. It is a 
significant public health problem, transmitted in 97 countries (Figure 1.1) with 
approximately 3.3 billion people at risk which amounts to half of the world population 
(Roll Back Malaria, 2014; White et al., 2014; WHO, 2014). Approximately 198 million 
malaria cases (range between 124 to 283 million) were reported in 2013 with 584,000 
deaths (range between 367,000-755,000), of which 86% of the morbidity and 90% of the 
mortality occurred in Africa, mainly in young children under 5 years of age (Roll Back 
Malaria, 2014; White et al., 2014; WHO, 2014). Malaria is a leading cause of death of 
children in endemic areas and the most significant parasitic disease in tropical and sub-
tropical regions of Africa (White et al., 2014). 
 
0.1
Figure 1.1: The global distribution of malaria 
A world map showing the global distribution of malaria burden (source- modified from WHO, 2014). 
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These figures, however, are based upon WHO reports and it is thought that mortality 
rates could be as high as one million per year (Murray et al., 2012; Verma et al., 2013). 
Malaria has been recognised as a major public health problem from the early 20th 
century. It was once prevalent in 178 countries across the globe (Feachem et al., 2010). 
World Health Organization (WHO) launched the Global Malaria Eradication Program in 
the 1950s in all parts of the world apart from Africa. This campaign relied on vector 
control with the use of insecticide dichlorodiphenyltrichloroethane (DDT) and mass 
administration of chloroquine (CQ) chemoprophylaxis, which succeeded in eliminating 
malaria from Europe, Canada,  Russia, the Caribbean and parts of Asia (Hay et al., 2004; 
Faechem et al., 2010; Najera et al., 2011; White, 2014). However, because of the 
technical, financial and administrative issues, this campaign was abandoned in 1969 
leaving Africa, facing a significant health burden from malaria. Chloroquine (CQ) and DDT 
resistance also emerged during this time in Africa, which led to a three-fold increase in 
recorded deaths from malaria through the 1980s and 1990s to a peak in 2004 (Figure 1.2) 
(Faechem et al., 2010; Hay et al., 2004; Murray et al.,2012; White, 2014).  Despite these 
setbacks, control efforts have recently focused on technical developments that have led 
to renew a global focus on malaria control scale-up activities and, as a result, malaria 
deaths have declined significantly over the last decade (Table 1.1). These achievements 
were propelled by the Roll Back Malaria (RBM) initiative (in partnership with WHO, UNDP, 
UNICEF and the World Bank), launched in 1998, which designed control strategies to 
eliminate malaria. Whilst emphasizing the strengthening of local health systems, several 
control intervention coverages were provided, including the wider availability of rapid 
diagnostic tests (RDTs), treatments and chemoprophylaxis with artemisinin combination 
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therapies (ACTs), and vector controls such as Insecticide Treated Nets (ITNs) and Long 
Lasting Insecticide Nets (LLINs).  
 
0.2
Figure 1.2: Global malaria mortality trends 
Different curves (color coded) show malaria mortality trends by age and geographical region over time. 
Malaria mortality rates raised through the 1980s and early 1990s to a peak in 2004 with a 32% from this 
peak by 2010 (source- Murray et al., 2012). 
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Table 1.1: Malaria morbidity and mortality rates   
 Significant reduction in overall morbidity and mortality of malaria over the last 13 years and the millennium 
development goals set for 2015 (source- WHO, 2014). 
 
As mentioned earlier, malaria transmission is restricted to 97 countries of which 67 
countries are reversing the incidence of malaria. Of these, 55 countries are likely to meet 
the Millennium Development Goals (MDGs) set by RBM and World Health Assembly, 
which aim at a 75% reduction in malaria case incidence by 2015 (WHO, 2014). However, 
the recent global economic crisis has led to reduction in funding and resources for malaria 
KEY MALARIA STATISTICS FROM 2000 TO 2013 
Average malaria infection 
prevalence declined 46% in 
children aged 2–10, from 26% 
to 14% in 2013 
The number of malaria 
infections at any one time 
dropped 26%, from 173 
million to 128 million in 2013 
Malaria mortality rates have 
decreased by 47% worldwide and by 
54% in the WHO Africa Region 
MILLENNIUM DEVELOPMENT GOALS (MDG) BY 2015 
Malaria mortality rates are projected to 
decrease by 55% globally and by 62% in the 
WHO Africa Region. 
Malaria mortality rates in children aged under 
5 years are projected to decrease by 61% globally and 
67% in the WHO Africa Region. 
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control and this underscores a real and imminent threat to the striking reversal of malaria 
mortality. Furthermore, emerging resistance to ACTs and insecticides in malaria endemic 
countries pose a direct threat to the huge inroads made recently (WHO, 2014). These 
challenges, together with poor local health systems, lack of sufficient data on the real 
impact of malaria case incidence and administrative issues raise enormous doubts, if not 
addressed promptly, that will make it unlikely to achieve the MDGs established for 
malaria control by 2015 and even harder to meet the ambitious future targets set for 
elimination. 
1.2 The genus Plasmodium  
 
Plasmodium is a genus of Apicomplexa, which are unicellular eukaryotic organisms 
(protozoa). Apicomplexa are a diverse group that also includes organisms such as 
Cryptosporidium, Coccidia and Haematozoa. A large proportion of Apicomplexa are 
parasitic organisms of vertebrate hosts. Plasmodium is the aetiological agent of human 
malaria. Five species of this genus are known to cause malarial infections in human; P. 
vivax, P. malariae, P. ovale, P. knowlesi and P. falciparum (Sutherland et al., 2010). 
1.2.1 Plasmodium falciparum  
 
P. falciparum is the most virulent of malaria parasites that infect humans. P. falciparum is 
not as widespread as P. vivax (Gething et al., 2011), but it is responsible for almost all 
malaria deaths (Gething et al., 2011; White, 2014). Sub-Saharan Africa has the heaviest 
malaria burden due to the predominance of P. falciparum in this continent where it 
accounts for some 70% of cases. P. falciparum causes malignant, tertian or falciparum 
malaria in humans which leads to serious life threatening pathological conditions such as 
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severe anaemia, respiratory distress, organ failure, and intrauterine growth retardation in 
pregnancy and cerebral malaria (White, 2014). Due to such potential consequences of P. 
falciparum infection, rapid and effective treatment is vital. However, due to the spread of 
the multi-drug resistant (MDR) parasite strains globally in general, and in particular, 
recent reports of evolving resistance to artemisinins in South-East Asia, treatment of P. 
falciparum is becoming increasingly difficult and continues to be responsible for 
thousands of deaths each year, particularly in children under 5 years of age (Dondorp et 
al., 2008).  
1.2.2 Plasmodium vivax 
 
P. vivax is the most widely distributed of the malaria parasites and accounts for a 
significant morbidity burden (Gething et al., 2012), with an estimated 2.49 billion people 
at risk of acquiring infection (Battle et al., 2012). Infection with P. vivax occurs 
predominantly in South East Asia and the Western Pacific, although a number of cases are 
also found across Africa and South America (Hey et al., 2004). P. vivax forms an 
asymptomatic dormant liver stage (hypnozoites) with an incubation period ranging 
between weeks to months and may last for years (Price et al., 2007). These dormant 
stages often result in relapses causing infection (Walker et al., 2014). P.vivax has a 
preference for the invasion of reticulocytes, as opposed to P. falciparum which has a 
broader erythrocyte age invasion range (Price et al., 2007; Simpson et al., 1999) and this 
might be one of the reasons for limiting its infectious potential. Whilst not normally 
associated with the severe manifestations of P. falciparum malaria, P. vivax infection can 
be serious in the event of a splenic rupture. Nevertheless, it can cause respiratory 
distress, severe anaemia, coma (Genton et al., 2005) and intrauterine growth retardation 
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similar to P. falciparum (White, 2014). P. vivax blood stage infections can be treated with 
CQ and ACTs where CQ is resistant. The current gold standard for preventing P. vivax 
relapse is Primaquine (PQ), which has hypnozoitocidal activity. However, significant 
concerns are associated with this drug due to its haemolytic activity in glucose-6-
phosphate dehydrogenase (G6PDH) deficient humans.  
1.2.3 Plasmodium ovale 
 
P. ovale is a rare protozoan parasite; closely related to P. falciparum and P. vivax and 
distributed across South East Asia, sub-Saharan Africa, the Indian subcontinent and the 
Western Pacific (Fuehrer et al., 2010; Kawamoto et al., 1996; Sutherland et al., 2010). P. 
ovale has a typical incubation time between 12 to 20 days, and like P.vivax, it is also 
characterised by dormant liver stage hypnozoites (with incubation time from weeks, 
months to years) which can subsequently lead to a relapse after infection (Sutherland et 
al., 2010). It is responsible for causing tertian malaria in humans; however, assessment of 
its actual malaria burden is difficult to estimate due its problematic diagnosis. Co-
infections of P. ovale can be encountered together with P. falciparum, P. vivax and P. 
malariae (Win et al., 2002) although most P. ovale infections last for less than two weeks 
and parasitaemia rarely reaches a sufficient level which is required to induce clinical 
episodes. This, in combination with a 49-hour erythrocytic stage, results in P. ovale 
infections often remaining asymptomatic (Mueller et al., 2007). CQ is the current gold 
standard for the treatment of uncomplicated malaria caused by P. ovale, and as described 
above, PQ is required to eliminate hypnozoites (Kantele and Jokiranta, 2011; Walker et 
al., 2014). 
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1.2.4 Plasmodium malariae 
 
P. malariae is responsible for the mildest and most persistent form of malaria infection, 
often called benign malaria. Its infection can be found in combinations with P. falciparum 
and P. vivax (Westling et al., 1997); however a typical Infection caused by this species 
shows synchronised schizogony from the beginning, with febrile paroxysms normally 
occurring in the late afternoon, separated by 72 hour intervals, and is known as quartan 
malaria. The parasitaemia in erythrocytes rarely exceeds 1% due to the spontaneous 
remission of parasites and thus remains asymptomatic in the blood and, if not treated, 
infection can even persist for decades (Bartolini and Zammarchi 2012; White, 2014). Due 
to its low prevalence, milder clinical manifestations, difficulty in diagnosis and lack of in 
vitro studies, P. malariae is perhaps the least studied human malarial parasite species and 
the reason why it is frequently under reported (Mueller et al., 2007; Singh et al., 2004; 
Smith et al., 1993). CQ or ACTs are the recommended medication for the infections 
caused by P. malariae (CDC, 2013). 
1.2.5 Plasmodium knowlesi 
 
P. knowlesi is a parasite primarily thought to be of primate origin causing infection in 
Macaca fascicularis (Lee et al., 2009). The vectors of this parasite are Anopheles latens 
and Anopheles cracens (subgroups of the leucosphyrus group of Anopheles) which are 
zoophilic in nature (Singh and Daneshvar, 2013) and thus naturally acquired human 
infections of this species were consequently considered rare in South-East Asia until a 
2004 outbreak in Sarawak, Malaysia (Antinori et al., 2013; Singh et al., 2004; Singh and 
Daneshvar, 2013; White, 2008). It was reported that P. knowlesi was responsible for 
about ~60-70% of human malaria cases in Borneo, Malaysia in 2008 (Antinori et al., 2013).  
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These infections can now be found in almost all other countries in South East Asia, and 
consequently, P. Knowlesi is now classified as the fifth human malaria species (Antinori et 
al., 2013; Figtree et al., 2010; Singh and Danesh, 2013; Van-Hellemond et al., 2009; 
White, 2008). P. knowlesi has a relatively short 24 hour erythrocytic stage cycle (Antinori 
et al., 2013; Singh and Danesh, 2013) and can, however, attain a high parasitaemia 
quickly, which results in severe symptoms. The symptoms of infection are comparable to 
severe malaria caused by P. falciparum with the exceptions of severe anaemia and 
cerebral malaria (Singh and Danesh, 2013; Antinori et al., 2013). P. knowlesi shares 
certain morphological features with P. falciparum and P. malariae, thus making it difficult 
to accurately identify it by microscopy. PCR is the most reliable source for detecting and 
diagnosing P. knowlesi infection (Kantele and Jokiranta, 2011), although this is not a rapid 
diagnostic method. Microscopy still remains the most widely used method in rural areas, 
and this could affect our understanding of the epidemiology of this species. Since there is 
no evidence of drug resistance in P. knowlesi, CQ is very effective in the treatment of 
uncomplicated knowlesi malaria infections in humans (Daneshvar et al., 2010).  
1.3 Malaria transmission 
 
1.3.1 The Anopheles vector and factors affecting transmission  
 
Malaria is transmitted almost exclusively to human hosts through the bite of an infected 
Anopheles mosquito, which belongs to the subfamily Anophelinae (Autino et al., 2012; Su 
et al., 2007; Toure et al., 2004). There are over 400 species of the Anopheles genus, of 
which over 100 are vectors for malaria (CDC, 2012). Malaria transmission intensity 
depends on various factors related to the parasite, the vector, the human host, and the 
environment and thus, only around 20 of the 400 Anopheline species are regarded as 
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good vectors of human infection (White et al., 2013; WHO, 2014). The main Anopheles 
vectors Anopheles gambiae, Anopheles arabiensis and Anopheles funestus are strictly 
anthropophilic in nature and thus recognised as the most effective vectors of human 
malaria (CDC, 2012). These vectors are long-lived, occur in high densities in tropical 
climates, adaptable to environmental change and robust against them, breed readily and 
are anthropophagic. Their widespread distribution in Sub-Saharan Africa explains why 
90% of malaria mortalities are reported in this region (White et al., 2013). These species 
bite during the night and are most active at dusk and just before dawn mostly endophagic 
(feed indoors), although some might be both endophagic and exophagic (feed outdoors) 
(Pates and Curtis, 2012; Zimmerman et al., 2013). The first three stages of the mosquito’s 
life cycle occurs in water; although dependent on the preference of each Anopheles 
mosquito, however, in general, they are capable of breeding in most locations with slow 
moving water. As this may be fresh or saline water, lakes or small pools, rice paddies or 
rivers, effects to curtail the breeding of mosquitoes are difficult to implement (CDC, 2012; 
Zimmerman et al., 2013).  
Many factors affect the rate of malaria transmission, including temperature and humidity, 
time of the season, the longevity of the mosquito’s life cycle and its feeding habits. Insect 
and parasite physiology limits malarial transmission to temperatures between 17-34οC. 
This temperature range with humidity in temperate regions provide optimum conditions 
for Anopheles mosquitoes to hatch eggs in a few days as opposed to cold or very hot 
regions where it may take longer (e.g. weeks) or may be detrimental to parasite 
development. This explains the high transmission burden of parasite in tropical regions 
compared to colder regions and further elucidates the trend of parasite transmission that 
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often peaks in autumn as opposed to summer (Mordecai et al., 2013; Yamana and Eltahi, 
2013). Malaria transmission peaks during and directly after the rainy season. This is due 
the availability of temporary rain pools to the mosquito, which they use as a breeding 
ground (CDC, 2012). Depending upon environmental conditions, malarial parasites have 
an extrinsic incubation period (parasite development inside the mosquito host) of 
between 10-21 days. Thus, long-lived vectors have higher disease transmission rates in 
endemic regions as the parasite goes through an extrinsic incubation phase ensuring the 
vectors have sufficient time to transmit the parasite to the human host (White et al., 
2014). 
The majority of Anopheles mosquitoes are both anthropophilic and zoophilic. Areas, 
where anthropophilic species are prominent have been demonstrated to have higher 
transmission intensity as compared to those where zoophilic tendencies are more 
common (CDC, 2012). Transmission intensity is generally measured by determining the 
Entomological Inoculation Rate (EIR) which is the average number of infectious bites per 
individual per unit time (Okello et al., 2006; Smith et al., 2001; Talisuna et al., 2012). In 
low malaria transmission areas, transmission intensity can also be estimated by parasite 
prevalence (Beier et al., 1999). Malaria transmission is more likely to be seasonal and less 
intense across (unstable transmission) Asia and South and Central America where people 
may receive up to 1 infectious bite per year, explaining almost the same prevalence of P. 
falciparum and P. vivax although the latter is more common in these areas (Gething et al., 
2011). The cooler temperatures in these areas explain why P. vivax is more prevalent, 
since P. vivax can survive at lower temperatures and higher altitudes as compared to P. 
falciparum (WHO, 2013). More intense, stable malaria transmission occurs in Africa, 
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south of the Sahara and in parts of Oceania. These regions are warmer where P. 
falciparum predominates and thus EIR is much higher (i.e. >200 infectious bites per year) 
(CDC, 2012; Gething et al., 2011). 
In those regions where malaria transmission is stable, malaria mortality and morbidity are 
pronounced in early childhood (i.e. children under five years of age), because the younger 
children are considered immunologically naive to the malaria parasite. As age increases 
subsequent malarial infections become milder leading to asymptomatic infections in 
adulthood (Dondorp et al., 2008, Sarda et al., 2009). This is reflected by the fact that 
those who live in malaria endemic countries with high transmission rates develop 
premunition through recurrent exposure (Figure 1.3). Although this protection does not 
ensure sterile immunity to the disease, it provides partial protection for those regularly 
exposed to the parasite and thus it prevents symptomatic disease despite the persistent 
presence of malarial parasites (Doolan et al., 2009; Weatherall et al., 2002). Although the 
acquired immunity develops rapidly in infants, children under five account for the 
majority of the malaria incidences especially in holoendemic nations (Aponte et al., 2007). 
This is because the children under five have not yet acquired a sufficient level of natural 
immunity offered through repeated exposure so experience the severe and often fatal 
symptoms (White et al., 2014).  
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Figure 1.3: The immuno-epidemiology of malaria in relation to age  
The different age groups at which, severe, mild and asymptomatic malaria parasitaemia occurs in areas of 
high malaria transmission. The stages of infection state are shown above the graph. Full susceptibility is pre-
infection, partial immunity is post a single infection while partial premunition and premunition occurs after 
~2-3 and 4 or more infections respectively (Source- White et al., 2014). 
 
For non- immune travelers visiting endemic states or people living in unstable malaria 
transmission regions, full protective immunity from malaria is not acquired. This lack of 
protective immunity leads to symptomatic disease in all age groups (Crawley et al., 2010; 
White at al., 2013). Within unstable malaria transmission regions, environmental, 
economic and social challenges render the regions prone to epidemics, which can result 
in substantial mortality at all age groups (White at al., 2013). Pregnant women are also 
prone to malaria infection due to pregnancy related immunosuppression and this explains 
why they have an elevated rate of stillborn and maternal deaths whilst semi-immune 
pregnant women have an elevated rate of miscarriage and low birth weight in areas of 
stable malaria transmission (Kakkilya, 2011). Malaria and HIV are inextricably linked; 
children born from mothers with both human immunodeficiency virus (HIV) and malaria 
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have an increased chance of contracting HIV, as placental parasitaemia increases the 
chance of HIV crossing the placenta (Newman et al., 2009). Similarly, those with HIV are 
at a greater risk of contracting malaria due to immunosuppression and a reduction in 
efficiency of antimalarial medication as a result of the virus (Cuadros et al., 2011).  
1.4 Life cycle and biology of P. falciparum  
 
The life cycle of P. falciparum is complex (Figure 1.4), requiring a human host and 
Anopheline vector for its completion. Within both the host and the vector, the life cycle is 
characterized by multiple morphological changes as the parasite invades, colonises and 
then replicates within a diverse range of host environments.  
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Figure 1.4: The life cycle of the human malaria parasite P. falciparum 
 Female Anopheles mosquitos serve as a vector and humans as the vertebrate host, with different stages in 
both vector and human host are shown (Source- MMV website http://www.mmv.org). 
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1.4.1 Asexual life cycle of P. falciparum  
1.4.1.1 Hepatic stage/ pre-erythrocytic phase 
 
The life cycle begins with the bite of an infected female Anopheline mosquito (Figure 1.4). 
The mosquito injects an anticoagulant and sporozoites into the bloodstream of a human 
(Amino et al., 2006; Bannister and Mitchell, 2009; Frevert, 2004). Sporozoites migrate 
into the microvasculature and are carried through the blood system to the liver. Here, 
sporozoites transverse through multiple hepatocytes before they infect a final one, and 
form a parasitophorous vacuole (PV) (Prudêncio et al., 2006). With the help of PV or by 
disrupting the cell membrane, sporozoites cross the liver sinusoid barrier by evading the 
host’s immune defense (i.e. remains hidden from attacks by phagocytic cells and küpffer 
cells) (Amino et al., 2008). Following hepatocyte invasion, sporozoites multiply asexually 
to produce thousands of merozoites within the PV membrane (Meister et al., 2011; 
Prudêncio et al., 2006). This process of replication and maturation within the liver takes 
between 5-8 days (White et al., 2014) and this process is called intrahepatic schizogony or 
the pre-erythrocytic phase. The schizont within the hepatocytes ruptures through 
mediation by cysteine proteases, releasing thousands of merozoites into the sinusoidal 
lumen ready to invade erythrocytes (Frevert, 2004). The hepatic/pre-erythrocytic phase 
of P. falciparum life cycle is asymptomatic in humans.  
1.4.1.2 Erythrocytic stage 
1.4.1.2.1 Erythrocytes invasion  
 
The asexual erythrocytic stage of P. falciparum commences when small extracellular 
merozoites invade erythrocytes (Figure 1.5) This is a multi-stage complex process 
facilitated by the interaction of merozoites surface proteins (MSPs) and invasion 
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organelles (i.e. dense granules, rhoptries and micronemes) present at the apical end of 
the parasite (Bannister and Mitchell, 2009; Cowman and Crabb, 2006; Morrissette and 
Sibley, 2002; Silvie et al., 2008). These invasion organelles, rhoptries and micronemes are 
orientated towards the erythrocyte. The content of these organelles (adhesive proteins 
and membrane altering agents) help in erythrocyte capture, junction formation, 
migration through RBC membrane to create a PV with host erythrocyte. As the 
merozoites move through a moving junction, adhesins and other surface proteins are 
shed and finally the parasite reside within a PV located within the host RBC (Cowman and 
Crabb, 2006; Haldar et al., 2006).  
1.4.1.2.2 Ring forms  
 
Following RBC invasion, the dense granules are pushed towards the surface of the 
parasite to further increase the area by releasing their contents to the PV (Bannister et 
al., 2000) and thus the parasite enlarges, loses the invasive organelles and start 
intraerythrocytic development (Bannister and Mitchell, 2009). Based on the morphology 
of the early intraerythrocytic parasite, it’s often referred as ring forms and/or “ring” cells, 
for up to the first 24 hours post invasion (Figure 1.5) (Bannister and Mitchell, 2009; Haldar 
et al., 2006).  
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Figure 1.5: Intraerythrocytic development (48 hour cycle) of P. falciparum  
The image shows different stages of P. falciparum inside the human host from extracellular merozoites 
invading mature RBCs to schizont burst (Source- Halder et al., 2006). 
 
Over the first 24 hours, the parasite starts a programme of host erythrocyte modification. 
The parasite ingests the cytoplasm and transfers the cell’s haemoglobin to the parasites 
acidic digestive vacuole where it is degraded by the proteases (Bray et al., 2005; Tilley et 
al., 2011). This digestion result in potentially toxic haem waste product (haematin) that is 
converted to biologically inert haemozoin by the parasite through lipid mediated 
crystallization (Tilley et al., 2011; White et al., 2014). The parasite goes through a major 
remodeling of the host RBCs as essential for its survival. During the ring and trophozoite 
development, the parasites feed on host cells; it also exports numerous proteins in the 
host cell cytoplasm and membrane of the erythrocyte and into structures called the 
Maurer’s clefts (Haldar et al., 2006).  As a result, this transforms the erythrocyte surface, 
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which allows the parasite to consume nutrients and export waste product (Bannister and 
Mitchell, 2009; Goldberg and Cowman, 2010).  
1.4.1.2.3 Parasite-induced changes to the host erythrocyte: its associated virulence and 
pathology 
 
Adherence of mature infected erythrocytes (IE) (schizonts/trophozoite stages) of P. 
falciparum to microvascular endothelial cells is directly responsible for the virulence and 
pathology of human malaria. The pathogenesis of P. falciparum is a complex interplay of 
parasite-induced structural, biochemical and mechanical modifications of the RBCs and 
microcirculatory abnormalities along with local and systemic immune reactions that lead 
to life-threatening complications in humans (Grau et al., 2003; Maier et al., 2009). There 
are several pathophysiological factors that are responsible for the development of severe 
malaria and life-threatening complications in humans, which include the parasite 
biomass, cytoadherence, altered erythrocyte deformability and fragility of parasitized 
erythrocytes, malaria toxins and inflammatory response, thrombocytosis, endothelial 
injury and activation (Chen et al., 2000).  
P. falciparum has the ability to evade the host’s immune system through clonal antigenic 
variation of a key virulence factor, P. falciparum erythrocyte membrane protein 1 
(PfEMP1). PfEMP1 is exported to electron dense knob structures anchored into the 
infected erythrocyte plasma membrane. Here, PfEMP1 acts as an adhesive ligand for a 
wide range of host proteins (Pasternak and Dzikowski, 2009; Kyes et al., 2001), critical of 
these is adhesion to proteins expressed on the surface of endothelial cells of the 
microvasculature. P. falciparum also adheres IE to uninfected erythrocytes called 
rosetting (David et al., 1988). Mild modification of adherence and deformability can be 
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observed in the ring stage IE, which can, however, circulate in the blood vessels, but this 
is substantially developed in trophozoite and schizonts stage where these mature forms 
sequester and block the microvasculature, ultimately preventing circulation in the 
peripheral vasculature (Buffet et al., 2011; Maier et al., 2009). The sequestration of the 
schizonts/trophozoite (mature forms) of P. falciparum is determined by their adherence 
to different blood and endothelial cells, platelets and fresh uninfected RBCs while 
multiple host receptors are responsible for recognizing and mediating these interactions. 
As a result, of all these pathophysiological factors, cerebral malaria, hypoglycaemia, 
metabolic acidosis, renal failure, and respiratory distress can be observed mostly in 
infections with P. falciparum (Miller et al., 2002).  
Several molecules present at the plasma membrane of the IE are known to contribute in 
adherence, several of whose function is not entirely known. However, it is evident that 
some of these proteins (e.g. knob-associated histidine rich protein, KAHRP and PfEMP3), 
are essential for the parasite’s survival as studies that cause gene disruption have 
resulted in parasite death but the reason for this still remains unclear (Cowman et al., 
2012; Crabb et al., 1997a; Crabb et al., 1997b). Nevertheless, P. falciparum erythrocyte 
membrane protein 1 (PfEMP1), encoded by the large and diverse Var multigene family, is 
the key parasite adherence receptor for P. falciparum (Barusch et al., 1995; Buffet et al., 
2011; Pasternak and Dzikowski, 2009; Kyes et al., 2001 Smith et al., 1995).  PfEMP1 is 
perhaps best known to mediate adhesion to the CD36 receptor present on endothelial 
cells of the microvasculature (Rowe et al., 2009). Adherence of IE to endothelial cells is 
also mediated by several other molecules which includes intercellular adhesion molecule-
1 (ICAM-1), Thrombospondin (TSP), a endothelial leukocyte adhesion molecule-1 (ELAM-
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1) vascular cell adhesion molecule-1 (VCAM-1) and chondroitin sulphate (CSA) (Hasler et 
al,. 1990; Ockenhouse et al., 1991; Rogerson et al., 1995) but CD36 appears to be the key 
receptor for adhesion of IE to the microvascular endothelium cells (Baruch et al., 1997). 
PfEMP1-mediated adherence results in tissue sequestration of IE, which removes them 
from the peripheral blood circulation (Barusch et al., 1995; Pasternak and Dzikowski, 
2009; Kyes et al., 2001; Scherf et al., 2008). Parasite sequestration, leading to adhesion of 
the microvasculature, ultimately leads to the pathology of severe disease (see below). 
Further, the clonal antigenic variation of PfEMP1 facilitates the development of chronic 
infection of a human host in the face of the host immune response to IE (Kyes et al., 2001; 
Scherf et al., 2008).  
1.4.1.2.4 Late trophozoite and schizogony 
 
Multiple rounds of nuclear division occur in late trophozoites (24-36 hours post infection, 
hpi), resulting in the segmented schizont stage (36-48 hpi). The parasite goes through 
many rounds of mitosis to generate 16-32 nuclei around which daughter merozoites are 
formed. Once the schizont matures, the infected erythrocyte ruptures at 44-48 hpi 
releasing merozoites into the blood stream ready to invade erythrocytes to restart the 
cycle (Haldar et al., 2006).  
1.4.2 Sexual differentiation 
 
During the erythrocytic stage, a few reinvading merozoites commit to differentiate into 
gametocytes to start the sexual life cycle (Bousema and Drakeley, 2011). Gametogenesis 
takes some 10 days within the IE, resulting in the development of male 
(microgametocytes) and female (macrogamtocytes) stages that circulates in the blood 
and are taken up by the mosquito vector during a blood meal (Figure 1.4). The male 
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gametocyte divides to rapidly produce many motile flagellated microgametes with long 
motile flagella within 8- 15 minutes in a process termed exflagellation. This motility 
enables them to make contact with female macrogametes for fertilization (Simonetti, 
1996; Vlachou et al., 2006).  Fusion of the male microgametes and female macrogametes 
takes place within the midgut of the mosquitoes forming a zygote within 60 minutes of 
taking the blood meal (Hurd et al., 2005). The zygote (after about 10-25 hours) undergoes 
meiotic nuclear division, elongates and develops into a motile ookinete. This ookinete 
penetrates the midgut epithelial cells of the mosquito and develops into a sessile oocyst 
(Anand and Puri, 2005). During the early stage, oocysts are covered by amorphous thick 
capsules that become thinner and stretch when the oocyst matures (Simonetti, 1996). 
Hereafter, the oocyst undergoes multiple rounds of asexual replication that results in the 
production of thousands of sporozoites in the intercellular space between the basal 
lamina and mid-gut epithelium. Further maturation occurs and the oocyst ruptures, 
releasing sporozoites into the haemolymph of the mosquito within a period of 7-12 days 
(Simonetti, 1996). The mature sporozoites migrate within the haemocoel finally invading 
the salivary glands of the mosquito within two days and hereafter reach the mosquito’s 
stored saliva in readiness for transmission to a vertebrate during a subsequent blood 
meal. 
1.5 Clinical features 
 
The WHO classified malaria into two categories, uncomplicated (mild) and complicated 
(severe) disease (WHO, 2014). Severe and mild infections are caused by P. falciparum, P. 
vivax and P. knowlesi, whereas P. malariae and P. ovale only induce mild infection.  
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1.5.1 Uncomplicated malaria  
 
Uncomplicated malaria is the most common form of the disease. It is not immediately life 
threatening, however, rapid and effective treatment is required to avoid disease 
progression into severe malaria. Generally, individuals with a history of exposure 
(premunition) typically remain asymptomatic or may present with uncomplicated malaria 
with the typical symptoms such as headache, fatigue, muscle aches, abdominal 
discomfort, chills, sweating and irregular fever (Bartolini and Zammarchi, 2012; Rubin and 
Strayer, 2011; White et al., 2014). These symptoms arise as a result of pyrogens 
(haemozoin and GPI-linked proteins) released into the blood stream as the merozoites 
rupture (Chen et al., 2000; Grobusch and Kremsner 2005).  
1.5.2 Severe malaria  
 
Severe malaria is a medical emergency which induces several complex and life 
threatening complications. It involves any of the central nervous system, pulmonary 
system, renal system or haematopoietic system alone or in combination and, if not 
treated promptly and aggressively, 10 to 20% cases are fatal (Bartolini and Zammarchi 
2012; Shanks, 2010). Severe malaria is associated with the presence of three overlapping 
clinical symptoms; cerebral malaria, severe anaemia and respiratory distress (Cunnington, 
2013). One of the most prominent causes of death is due to IE sequestration in the 
microvasculature of crucial organs such as the brain (cerebral malaria), heart and lungs 
(Idro et al., 2007). As indicated above, during an infection with P. falciparum PfEMP1 
mediates adherence to endothelial surfaces of blood vessels via receptors such as ICAM1 
in the brain, CSA in the placenta and CD36 in most other organs (Cooke et al., 2000; 
Buffet et al., 2011; Barusch et al., 1995; Tilleya et al., 2011). This results in the 
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development of fibrin, thrombus and micro infarcts, which can cause encephalopathy, 
congestive heart failure and pulmonary oedema (Rubin and Strayer, 2011). Moreover, 
significant amounts of cytokines, such as interferon-gamma (IFN-γ), are produced during 
the infection. This causes the suppression of erythropoiesis, therefore, inducing hypoxia 
and high levels of nitric acid. This further promotes rosetting of the parasitized RBCs, 
resulting in sequestration in specific organs like the brain for cerebral malaria (Weatherall 
et al., 2002) or may cause damage to other tissues (Clark et al., 2006). Acute anaemia is 
the main manifestation of severe malaria in young children (White et al., 2014). It is 
caused by erythrocytic destruction and decreased erythrocyte production due to the 
disruption of multiple pathways (i.e. failure of bone marrow to produce more 
erythrocytes) (Menendez et al., 2000). Infected erythrocytes are destroyed by the 
parasite whilst non-infected erythrocytes are phagocytised by a complement induced 
immune response (Autino et al., 2012; Stoute et al., 2003). Thus, the level of circulating 
reticulocytes is reduced, indicating a decreased response to erythropoietin and, 
therefore, a decline in the production of RBCs (Makintosh et al., 2004). 
 Metabolic acidosis is a one of the key clinical features of severe malaria, which results in 
respiratory distress. Hypovolaemia, due to anaemia and capillary obstruction, results in 
decreased oxygen delivery. Consequentially, cells are unable to metabolise aerobically 
thus anaerobic metabolism results (White et al., 2014). This leads to the accumulation of 
lactic acid causing metabolic acidosis and respiratory distress (Makintosh et al., 2004; 
White et al., 2014).  
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1.6 Malaria control strategies   
 
The past decade has seen unprecedented efforts undertaken for malaria control that 
include RDTs, treatments, earlier chemoprophylaxis, vector control and vaccine trials. 
With all these efforts, as described, the overall morbidity and mortality rates for malaria 
have fallen (Alonso and Tanner, 2013; WHO, 2014). 
1.6.1 Diagnosis of malaria  
 
The gold standard for the diagnosis of malaria is microscopic examination of Giemsa-
stained thin or thick blood smears (Wongsrichanalai et al., 2007). This is a simple, 
inexpensive and commonly used method in low to moderate transmission regions 
(Wongsrichanalai et al., 2007). However, a lack of quality control and poorly maintained 
laboratory equipment has led to degraded diagnostic smears, which has significantly 
affected both sensitivity and specificity of routine diagnosis (Guerin et al., 2002; 
Wongsrichanalai et al., 2007). Alternative diagnostics using molecular methods (i.e. DNA 
probes, detection of malaria antibodies and PCR) have been developed over the last two 
decades (Wongsrichanalai et al., 2007), which provides a high degree of sensitivity and 
accurate speciation of Plasmodium spp compared to microscopic techniques (Walker et 
al., 2014). Whilst these techniques are more sensitive and reproducible than conventional 
microscopy, their high cost and complicated procedures has limited their use in the field 
(Coleman et al., 2006; Makler et al., 1998; Perandin et al., 2004). RDTs require minimum 
training and skills and thus serves as a useful tool in rural areas (Crawley and Nahlen, 
2004). The principle of RDTs relies on an immunochromatography method with 
monoclonal antibodies that target species-specific malarial antigens such as P. falciparum 
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Histidine-Rich Protein 2 (PfHRP2). PfHRP2-based RDTs are better, or at least as good as, 
conventional microscopic methods in the diagnosis of falciparum malaria (White et al., 
2014). However, the latest generation of tests has been developed based on the 
detection of parasite lactate dehydrogenase (pLDH). These tests are highly effective in the 
diagnosis of both P. falciparum and P.vivax infections, although it shows low sensitivity at 
P. vivax densities of lower than 200/µL in blood (White et al., 2014). Although RDTs are 
very useful because of their simplicity and speed, their high unit cost, inability to quantify 
parasitaemia and low sensitivity to other Plasmodium infections identifies a need to 
advance diagnostic tools alongside other control interventions (Chong at al., 2013; Gatti 
et al., 2007).  
1.6.2 Vector control  
 
Vector control is a cornerstone in any control policy- the key being a break in the 
transmission cycle. It is particularly important in areas of high transmission, such as Africa, 
where resistance to antimalarial drugs is common (White et al., 2014). Different 
approaches have been adapted to scale-up vector-control interventions; however, only 
insecticide-based vector-control stands out as a conventionally applied methodology. 
These methods include the use of indoor residual spraying (IRS) and ITNs (The malERA 
Consultative Group on Vector Control, 2011), which rely on insecticides such as DDT, 
pyrethroids, organophosphates and carbamates. IRS is an effective malaria control 
method that was widely used during the late 20th century, which led to malaria 
elimination from many temperate regions across the globe (Karunamoorthi, 2011; Pates 
and Curtis, 2005). Despite the contribution of IRS to malaria control and elimination 
efforts over the last 60 years, IRS use has declined in recent years due to various concerns 
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such as reduced funding, harmful effects of DDT on the environment and human health 
and insecticide resistance (WHO, 2006). ITNs have evolved to become the most widely 
used vector control method after the reduction in IRS use. Among the four classes of 
insecticides being used, pyrethroids are the only option available for treating bed nets 
due to its fast action and non-toxic properties (Balmert et al., 2014; White et al., 2014). 
The deployment of pyrethroid-treated LLINs in endemic regions has made significant 
inroads in controlling malaria transmission over the past decade in Asia and Africa 
(Balmert et al., 2014; Karunamoorthi, 2011; White et al., 2014). LLINs are thought to have 
a mass effect and hence serve as the current gold standard in control methods (Godfray, 
2013). LLINs are only useful against those Anopheline species that bite at night and hence 
this limits its use against those which bite in the early evening/morning. In those regions 
where LLINs are useful and are regularly used, concerns have arisen that mosquitoes will 
adapt different biting trends. Furthermore, the use of DDT and pyrethroids in agriculture 
in West Africa has been shown in recent studies to provide selection pressure that has 
driven mosquitoes to develop resistance (Ranson et al., 2011).  
1.6.3 Vaccine development  
 
Vaccine development against malaria is a challenge, although many lines of evidence 
indicate that humans can be vaccinated against malaria (Schwartz et al., 2012). The 
premunition (Figure 1.3) normally developed against malaria and the observed protective 
immunity in murine models are examples that have encouraged many attempts at 
vaccination against P. falciparum (Hill, 2011; Heppner, 2013; Finney et al., 2014). Whilst 
knowing that vaccine development against malaria is a difficult task, many design 
strategies and approaches have been adopted. Owing to the multistage complex life cycle 
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of Plasmodium, three different approaches have been employed in an attempt to develop 
an effective vaccine. These approaches include Pre-erythrocytic stage, erythrocytic stage 
and transmission blocking vaccines (TBV) against the sexual stage (Birkett et al., 2013; Hill, 
2011; Guilbride et al., 2010; Targett and Greenwood, 2008). Currently, RTS, S/AS01 (Pre-
erythrocytic stage) is the most promising candidate (Figure 1.6) under development. 
Modern pre-erythrocyte vaccine development stems from immunization studies of mice 
in the 1960s using irradiated sporozoites to induce immunity against Plasmodium 
infection (Hill, 2011; Schwenk and Richie, 2011). The identification and cloning of CSP (the 
major component of the sporozoites coat) in the early 1980s with subsequent studies led 
to the development of Spf66, a peptide-based vaccine as the first sporozoites based 
vaccine (Hill, 2011). 
 
0.6
Figure 1.6: The malaria vaccine pipeline  
The candidate malaria vaccines pipeline target different stages of P. falciparum and P. vivax (Source-WHO, 
2014). 
27 
 
Apparently this candidate showed efficacy in monkeys and human, but failed to 
demonstrate any protection during successive field trials in Asia and Africa (Hill, 2011). 
However, these field trials of SPf66 has set a platform in terms of improved field 
technologies for successive studies, which led to the development of a new formulation 
of the P. falciparum CS protein called RTS, S (Hill, 2011). Following subsequent trials, this 
hybrid protein was formulated a multi-component adjuvant named AS01. Its central 
repeat region flanked by conserved motifs of CSP (R) and C-terminal region known to 
contain T cell epitopes (T) fused in turn to the hepatitis B surface antigen (S) that yielded 
a yeast-expressed protein RTS (Stoute et al., 1997). To enhance immunogenicity and 
efficacy, RTS was co-expressed with unfused S protein and adjuvants AS01/AS02 (contains 
liposomes) (Hill, 2011; Schwenk and Richie, 2011; Targett and Greenwood, 2008; 
Heppner, 2013). RTS, S when administered with the AS01 (the most effective adjuvant), 
showed sterile efficacy of 30-50%, although with some concerns regarding the longevity 
of this protection (Bejon et al., 2013; Moorthy et al., 2013; Hill, 2011). RTS, S/AS01 is the 
most effective vaccine candidate that has led the way over the past decade. It has been 
evaluated in Phase-III clinical trials in seven endemic countries and is currently under 
regulatory review (WHO, 2014; Bejon et al., 2013; Hill, 2011).  
1.7 Antimalarial drugs  
 
In the absence of an effective vaccine, antimalarial drugs are critical components of any 
programme directed at the control and eradication of malaria. However, continued 
evolving resistance to antimalarial drugs is a recurring problem (Table 1.2). The first drug 
introduced widely for the treatment of malaria was Quinine (QN), which dates back to the 
early 1800s. However, the bark of Cinchona tree (original source of QN) had already been 
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used in the treatment of fever since the beginning of the 17th century (Meshnick and 
Dobson, 2001; Wiesner et al., 2003). QN remained an important and effective treatment 
for malaria (and is still used in the UK today), but the first case of resistance was 
encountered in 1910. This resistance was widely feared and scientists initiated a search to 
discover a substitute for QN to treat severe malaria. As a result, chloroquine (CQ) was 
synthesised in 1934 but was not used clinically until 1945 as initially it was considered 
toxic. CQ was the first drug to be discovered in 4-aminoquinolines class. CQ safety, 
effectiveness and importantly its cheapness, led to its worldwide adaptation for the 
treatment of malaria (Famin and Ginsburg, 2002; Famin et al., 1999; Wiesner et al., 2003). 
Antimalarials  Resistance  
Quinine  
-  introduced in 1632 -  1st case of resistance: 1910 
Chloroquine  
-  introduced in 1945 -  1st case of resistance: 1957 
Proguanil  
-  introduced in 1948 -  1st case of resistance: 1949 
Sulfadoxine- Pyrimethamine  
-  introduced in 1967 -  1st case of resistance: 1967 
Mefloquine  
-  introduced in 1977 -  1st case of resistance: 1982 
Atovaquone  
-  introduced in 1996 -  1st case of resistance: 1996 
 
2
Table 1.2.: Antimalarials and resistance  
This list provides common antimalarials, with the year they were first introduced in and their first case of 
resistance encountered (Source- MMV website http://www.mmv.org). 
 
In 1957, however, the first case of CQ resistance was encountered (Table 1.2). Currently, 
CQ resistant strains of P. falciparum are common in all endemic countries and pose a 
significant problem for malaria control. During World War II, proguanil (pyrimidine 
derivative) also emerged from the antimalarial pipeline (MMV, 2015). Proguanil was a 
very effective drug and further studies of its chemical class led to the development of 
pyrimethamine. Resistance to both monotherapies appeared very quickly (MMV, 2015). 
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The subsequent resistance to these antimalarial drugs was widely feared. As a result in 
hopes of forestalling resistance and increasing drug efficacy, sulfones and sulfonamides 
were combined with proguanil and/or pyrimethamine; however, P. falciparum resistance 
had already emerged by 1953 in Tanzania (MMV, 2015). The combination of 
Sulfadoxine/Pyrimethamine was then introduced in 1967 in Thailand, but resistance was 
encountered in the same year (MMV, 2015). Although at a low level until 1990s, 
resistance to Sulfadoxine/Pyrimethamine spread rapidly throughout South-East Asia. A 
synthetic analogue of QN called mefloquine (MEF) was developed in the 1970s (MMV, 
2015). It was introduced in 1977 and used as a potential agent for the treatment of 
falciparum malaria, however; the first case of resistance was encountered in 1982 in Asia. 
Thereafter, another drug atovaquone (ATOVA) was introduced in 1996 but resistance also 
appeared in the same year (MMV, 2015). Following the treatment failure of the 
aforementioned drugs due to resistance, many new antimalarial drug classes and their 
derivatives were discovered (Figure 1.7). However, due to multidrug resistance and other 
safety issues, many classes of these drugs (i.e. sulfonamides and antifolates) failed and 
are no longer used clinically. Being from different drug classes, all these drugs have a 
different mode of actions and hence the mechanism of resistance also differs (Table 1.3). 
The antimalarial properties of artemisinin and their derivatives i.e. artemether (ART), 
artesunate (AS) and dihydroartemisinin (DHA) were identified by Chinese scientists in the 
1970s (Lin et al., 2010). Their potential as antimalarial compounds was acknowledged and 
appreciated by the rest of the world in 1990s. Since then, artemisinin derivatives have 
served as the frontline antimalarial drug and are used in combination with other drugs in 
artemisinin combination therapies (ACTs). Keeping in view the resistance developed by P. 
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falciparum to other conventional antimalarial drugs, the WHO in 2001 recommended the 
use of ACTs to reduce the load of morbidity, mortality and drug resistance (Table 1.4). 
Currently, ACTs are the foremost option for the treatment of uncomplicated malaria, 
however, non-ACT treatments are still effective up to some extent and should not be 
ignored (Lin et al., 2010; WHO, 2012). The non-ACTs, such as the combination of 
amodiaquine (AQ) and sulfadoxine-pyrimethamine (AQ-SP), used to be effective before 
ACTs and hence the WHO still recommends this combination when ACTs are not 
available.  
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Figure 1.7: The main antimalarial drugs classes approved for use in humans.  
These classes are either based on antimalarials chemical composition (endoperoxides, 4- and 8- 
aminoquinolines, amino-alcohols) or their function (antifolates, antibiotics) and/or both chemical 
composition and function (e.g., sulfonamides, a chemical class of antibiotic used in combined antimalarial 
therapies) (Source-Delves et al., 2012). 
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1
PABA=p-aminobenzoic acid-
2
DHPS= dihydropteroate synthase- 
3
DHFR=dihydrofolate reductase- 
4
DHODase, dihydroorotate dehydrogenase 
5
FV= food vacuole-
6
Fe (III) PPIX=ferrous-protoporphyrin IX 
3
Table 1.3: Antimalarial drug classes; their mode of action and mechanism of resistance 
(Source-Modified from Olliaro, 2001). 
  
Pathway Drug class Target Mechanisms of action Selectivity Mechanisms of resistance 
Nucleic acid 
metabolism 
Type-1 antifolates: 
Sulfonamides, sulfones 
Formation of dihydropteroate from 
PABA
1
 + pteridine catalysed by 
DHPS
2
 
Mimic PABA: compete for 
active site of DHPS 
Parasite can either 
synthesize or salvage 
folate precursors 
Mutations at binding site  
Type-2 antifolates: 
Pyrimethamine, biguanides 
(proguanil, cycloguanil), 
trimethoprim 
Reduction of di- to tetra-hydrofolate 
(cofactor for the biosynthesis of 
thymidylate, purine nucleotides, 
amino acids) by DHFR
3
 using NAPDH 
as cofactor 
Mimic dihydrofolate: compete 
for active site of DHFR 
Mammals have no de 
novo synthesis and 
must rely on dietary 
sources 
Mutations at binding site) 
Naphthoquinones 
(atovaquone) 
Mitochondrial functions (electron 
transport chain), blockade of 
pyrimidine synthesis 
Inhibits DHODase
4
; mimics 
ubiquinone: competes for 
complex III 
Different binding 
constant for parasite 
enzyme 
Mutations at coenzyme Q 
binding site 
Haem 
detoxification 
Type-1 quinolines (4-amino-
quinolines) 
Haem crystallization Inhibition/termination of β-
haematin formation 
Mechanism unique to 
the parasite 
Multi-gene: altered 
accumulation at FV
5
 
(reduced influx or 
increased efflux) 
Type-2 quinolines (aryl-
amino alcohols 
Same as Type-1 Same as Type-1 Same as Type-1 Same as Type-1 
Oxidative 
stress 
Artemisinin-type 
compounds 
Alkylation of unidentified target? 
Hydroxylation? 
Free radical formation through 
activation of the peroxide by 
binding with Fe(II)PPIX
6
 
Environment (FV, 
Fe
2+
) unique to the 
parasite 
Unknown 
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1
ASMQ=artesunate-mefloquine-
2
ASAQ=artesunate-amodiaquine 
4
Table 1.4: Common artemisinin-based combination therapies  
(Source-modified from Lin et al., 2010). 
Artemisinin component Partner drug Coformulation Elimination half-
life of partner drug 
Areas where ACT is commonly deployed 
Artesunate Mefloquine ASMQ
1
 (Far-Manguinhos Institute of 
Pharmaceutical Technology, Brazil) 
2–3 weeks Southeast Asia, South America 
Artemether Lumefantrine Coartem (Coartem; Novartis AG, Basel, 
Switzerland) 
3–4 days Africa, South Asia, Middle East, South 
America 
Artesunate Amodiaquine ASAQ
2
 ∼10 days West Africa 
Artesunate Sulfadoxine-
pyrimethamine 
None 3–7 days South Asia, Middle East, South America 
Dihydroartemisinin Piperaquine (PPQ) Artekin (Holleykin, Guangzhou, China); 
Duocotecxin (Beijing Holley-Cotec, Beijing, 
China); Eurartesim (Sigma-tau Industrie 
Farmaceutiche Riunite S.p.A., Rome, Italy) 
4–5 weeks Southeast Asia, China, Africa 
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However, current reports of artemisinin treatment failure in South-East Asia is yet 
another issue and a significant threat to malaria control (Dondorp et al., 2009). The 
number of existing front line antimalarials seems to be rapidly declining and hence, there 
is an urgent need to identify new small molecule drugs (Burrows et al., 2011; Grimberg 
and Mehlotra, 2011) to seed the antimalarial drug development pipeline.  
1.8 The search for novel scaffolds/chemotypes 
 
Phenotypic screening of massive chemical libraries (over six million compounds) for 
antimalarial activity has been conducted by the Genomics Institute of the Novartis 
Research Foundation (GNF, San Diego, California, USA), GlaxoSmithKline (GSK, Tres 
Cantos, Spain) and St. Jude Children’s Research Hospital, Memphis, USA which yielded 
some 20,000 hits that exhibit sub-micromolar potency against the blood stage of malaria 
parasite P. falciparum (Gamo et al., 2010; Spangenberg et al., 2013). This search resulted 
in a significant progress over the past decade, with many new chemical entities entering 
the pipeline for antimalarial drug development (Table, 1.5) (Wells et al., 2015), However, 
to make this collection accessible for researchers across the globe, a collection of 400 
chemotypes has been assembled and finalised by the Medicine for Malaria Venture 
(MMV) called the “Malaria Box” (Figure 1.8). MMV freely provides this “Malaria Box” 
resource, containing 200 diverse drug-like compounds as starting points for oral drug 
discovery and development and 200 diverse probe-like compounds, for use as biological 
tools in malaria research (http://www.mmv.org; Gamo et al., 2010; Spangenberg et al., 
2013).
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Agent (alternative names) Class Comments 
DISCONTINUED OR ON HOLD 
(+)-Mefloquine (AD-
452, RS(+) mefloquine, 
(+)-erythro-mefloquine) 
Quinine, an amine 
alcohol 
• Studies in healthy volunteers showed that the safety of the single enantiomer was similar to that of 
the racemate and the project was discontinued 
Artemisone (BAY-44-9585) Artemisinin 
derivative 
• Showed promising efficacy for the treatment of uncomplicated falciparum malaria in Phase II 
trials in Thailand (R. K. Haynes, personal communication), but no further development has been 
reported 
• A plan to test it clinically in western Cambodia for activity against artemisinin-insensitive strains 
(ClinicalTrials.gov identifier: NCT00936767) was withdrawn for operational reasons 
N-tert butyl isoquine 
(GSK369796) 
4-aminoquinoline • Investigated in human volunteers (ClinicalTrials.gov identifier: NCT00675064) but showed evidence of 
ECG changes and lower-than-expected plasma exposure 
• GlaxoSmithKline thus returned the project to the Liverpool School of Tropical Medicine, UK, and no 
further development has been reported 
GSK932121 4(1H)pyridine • An electron transport inhibitor related to atovaquone; was tested in human volunteers 
• The project was terminated based on safety data from a soluble phosphate prodrug of the 
candidate, and work on other members of this series was also stopped 
• It was recently suggested that these safety liabilities are associated with GSK932121 
binding at the cytochrome bc Q site rather than the Q  site 1      i                                                            o 
MK4815 (2-
amino- methyl-
3,5-di-tert- 
butylphenol) 
Aminocresol • Characterized, but preclinical safety studies in 2010 showed a relatively small safety window, even 
in higher species 
• There are no current plans to move to first-in-human studies 
SAR97276 
(albitiazolium 
bromide) 
Bisthiazolium • This choline transport inhibitor was discontinued after failing to meet its primary end point 
in Phase II (Sanofi press release; see Further information) 
Tinidazole Nitroimidazole • This approved antibiotic for amoebae, giardia and trichomonas infections was found to be ineffective 
in preventing relapse 
• This result was in line with previous primate data but contradicted anecdotal reports in patients 
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Trioxaquine 
 (PA1103, 
SAR116242) 
4-aminoquinoline with a 
synthetic endoperoxide 
• This is a fusion molecule of an endoperoxide and a 4-aminoquinoline that had entered preclinical 
development in 2007 
• Palumed has stopped working on this series for malaria in 2010 owing to a lack of financial support 
(company website; see Further information) 
IN DEVELOPMENT OR LAUNCHED 
AQ13 Aminoquinoline • In 2006, AQ13 was examined in a single-dose healthy volunteer study 
• In 2013, a Phase IIa study comparing it with the artemether–lumefantrine combination 
(ClinicalTrials.gov identifier: NCT01614964) was started, funded by the US FDA’s Office 
of Orphan Product Development, with a completion date of 2015 
Arterolane–
piperaquine 
combination 
(Synriam) 
Synthetic 
endoperoxide plus a 
4-aminoquinoline 
• Launched in India in 2012 
• Current development plans include trials in African children, the development of a 
paediatric dose strength and discussions on WHO prequalification 
• By December 2014, Synriam was approved in seven African countries 
Artesunate–
mefloquine 
combination 
Artemisinin derivative 
plus a 
4-aminoquinoline 
• Prequalified as a fixed-dose combination by DNDi and its Brazilian partner 
Farmanguinhos in 2012 
• Now manufactured by CIPLA Global 
CDRI 97/78 (REFS 132–134) 1,2,4 trioxane • Originally developed by India’s Central Drug Research Institute, which recently completed a healthy 
volunteer study 
• Has a plasma half-life of 12 hours 
• Work is ongoing to prepare for a multiple-dose study and test the activity against resistant 
malaria strains 
Dihydroartemisinin– 
piperaquine 
combination 
(Eurartesim) 
Artemisinin derivative 
plus a 
4-aminoquinoline 
• Recommended for approval by the EMA’s 1CHMP in June 2011, and then by the EMA in 
Oct 2011 
Ferroquine (SSR97193) Ferrocene− 
4-aminoquinoline 
• Developed by the Institut Pasteur in Lille, France; this drug was being developed by Sanofi in a 
Phase II trial in combination with artesunate (ClinicalTrials.gov identifier: NCT00988507) 
• This project has since been put on hold, and a new project was started combining ferroquine with 
OZ439 (artefenomel) 
• The Phase I drug interaction study is completed and a Phase IIb study is expected to start 
early in 2015  
Fosmidomycin                           Antibiotic 
 
 
 
 
 
 
 
 
 
 
 
• Inhibits DXP reductoisomerase, a key enzyme in the non-mevalonate pathway of isoprenoid 
biosynthesis 
• A clinical trial of fosmidomycin with clindamycin showed poor efficacy in children younger than 3 years 
• Subsequent studies have switched to using piperaquine as a partner drug (ClinicalTrials.gov identifier: 
NCT02198807) with a currently ongoing trial in patients over the age of 5 years 
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KAE609 (cipargamin,                  Spiroindolone 
NITD-609) and                         (KAE609) and 
KAF156 (GNF156)                             imidazolopipera- 
zine (KAF156) 
 
 
 
 
• Developed by Novartis and still in clinical development 
• Both have been tested in early Phase II clinical trials as monotherapies 
 
 
Methylene blue                          Phenothiazin dye 
 
 
 
 
• This compound, first proposed for the treatment of malaria more than a century ago, 
is now being prioritized for its potential role as a transmission-blocking compound, to be 
used in combination with ACTs 
• A trial is ongoing to evaluate its safety in G6PD-deficient subjects in Thailand versus a single 
high dose (0.75 mg per kg) of primaquine (ClinicalTrials.gov identifier: NCT01668433) 
Pyronaridine–artesunate           Chloroquine 
(Pyramax)                                   analogue plus 
an artemisinin 
derivative 
 
• Approved first by the Korean FDA in August 2011, followed by positive scientific opinion from 
combination  
the EMA under Article 58 in Feb 2012, for single use in countries with low malaria endemicity 
• It was then added to the WHO list of prequalified medicines in May 
2012 
• Further data have been submitted to the EMA to support multiple use 
and also to support a 
paediatric formulation 
COMPOUNDS THAT HAVE ENTERED THE PIPELINE SINCE 2012‡ 
ACT451840                                             A hydroxy-                          • Developed by Actelion 
ethyl-amine                          • In a recently published Phase I trial it was well tolerated at all doses tested143 
scaffold-based 
peptidomimetic 
protease inhibitor 
DF02 (Sevuparin)                       Heparin analogue 
with low 
anticoagulant 
activity 
 
• Phase I/II studies failed to meet their primary end point for uncomplicated P. falciparum 
malaria and were prematurely ended 
• A Phase I trial for severe malaria was completed in 2009, and Dilaforette is planning to 
continue development  
 
GSK369796 Isoquine 
 
 
 
 
 
 
 
 
• Development is on hold after the first-in-human study (ClinicalTrials.gov identifier: 
NCT00675064), the only clinical study performed with GSK369796 
• Two factors contributed to this decision: first, a drug-related serious adverse event (generalized tonic-
clonic seizure accompanied by hypotension and ECG changes (QTc prolongation and T-wave abnormalities)) 
occurred in one subject during the study approximately 2 hours after oral administration of 2,000 mg 
GSK369796; the subject recovered fully 
• Second, lower plasma exposures were observed for GSK369796 compared with other 
4-aminoquinolines (based on the literature) and compared with other 4-aminoquinolines 
at equivalent doses (N. Cammack, personal communication) 
NPC1161B                                 8-aminoquinoline                • Discovered and developed at the University of Mississippi, USA 
        • Basic discovery papers have been published, and preclinical activity assessments have been completed 
        • The compound has been tested in the huSCID§ model with G6PD-deficient erythrocytes 
        • NPC1161B was more potent, but the margin for safety in causing haemolysis was not 
significantly better than that for tafenoquine (L. Walker, personal communication) 
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RKA182                                     Tetraoxane                           • Initially planned for full preclinical development, and a Phase I study was initiated in 2011 
        • Some safety issues were reported, and the compound has been replaced by a new 
tetraoxane TDD E209 
CHMP, Committee for Medicinal Products for Human Use; DNDi, Drugs for Neglected Diseases initiative; DXP, 1-deoxy-d-xylulose 5-phosphate; ECG, 
electrocardiogram; EMA, European Medicines Agency; Farmanguinhos, The Institute of Drug Technology, Brazil; FDA, Food and Drug Administration 
5
Table 1.5: The antimalarial drug pipeline over the past five years 
(Source- wells et al., 2015). 
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Figure 1.8: MMV selection process for the 400 Malaria Box compounds 
The resource is freely available from the MMV on request (Spangenberg et al., 2013). 
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This significant progress and development are commendable, however, to eradicate the 
disease, searching for new candidate drugs to cure malaria rapidly and efficiently are no 
longer sufficient (Leroy et al., 2014; White et al., 2014). The new candidate drugs need to 
go beyond treating acute infections to additionally interrupt transmission cycle to help 
support malaria control and elimination strategy (White et al., 2014). To support this, four 
different goals have been set that includes efficient elimination of the liver stage 
hypnozoites, targeting the IE sexual stages in human blood to block disease transmission, 
identification of new small molecule drugs to avoid cross-resistance and minimise the risk 
of emerging resistance and development of molecules that protect vulnerable 
populations (Leroy et al., 2014).  
Typically, drug development for malaria is a lengthy process that takes some 13-15 years 
from finding a hit to registration (http://www.mmv.org). Keeping in view the long 
timelines for the discovery and development of new antimalarial drugs, there is a real 
need to underline the description of the desired product profile of an ideal clinical 
candidate molecule. This will not only accelerate the overall drug discovery and 
development process but also will impact on the cost in this expensive development 
process (Burrows et al., 2013). To support this, MMV has recently defined requirements 
for the potential antimalarial drug candidates called the target product profiles (TPP).  
1.8.1 Target product profiles 
 
With the overall aim to rapidly discover, develop, and deliver safe, efficient, and 
inexpensive new antimalarials to support malaria elimination and eradication agenda, the 
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MMV underlined the description for four-five types of molecules under TPPs that are 
required. These new molecules will have to be suitable for incorporation into 
combination therapies which aim to efficiently cure the disease by rapid clearance of 
parasitaemia in patients. This will not only reduce the risk of resistance but will also 
prevent recrudescence. Furthermore, these new molecules will block transmission and 
eliminate all liver forms of the parasite including dormant hypnozoites (Burrows et al., 
2013; Leroy et al., 2014). This profile corresponds to an “ideal” drug candidate that has to 
be administered for the treatment of uncomplicated malaria in children and adult as a 
single exposure, radical cure and prophylaxis (SERCaP), defined under TPP1. In addition to 
this, a second TPP (TPP2) was also defined. TPP2 should provide Single Exposure 
Chemoprotection (SEC), a new medicine to offer long-lasting chemoprotection. The goal 
of SERCaP to be met by a single molecule looks very ambitious and thus in line with the 
WHO recommendation, this medicine is likely to be a combination of several molecules. 
Thus, this led to the development of Target Candidate Profiles (TCPs) to reduce the risk of 
resistance, whilst SEC will likely need separate molecules (Burrows et al., 2013; Leroy et 
al., 2014). A TCP1 candidate corresponds to “fast clearance” to quickly reduce the initial 
parasite burden. TCP1 will ideally as good or better than artemisinin and at least as good 
as chloroquine and thus, if resistance renders artemisinin ineffective, TCP1 will ideally 
replace them. TCP2 represents candidate drug that could be either fast or slow acting, but 
should maintain a plasma concentration above the minimum parasiticidal concentration 
for 2-4 weeks. TCP2 act as a long-duration partner to complete the clearance of the 
residual parasites not eliminated by TCP-1 medicine. A TCP3 candidate will target 
Plasmodium spp in the non-dividing stages such as TCP3a will prevent relapses from 
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hypnozoites and TCP3b will block transmission to the mosquito. TCP4 also describes a 
compound or compounds that will provide chemoprotection by killing sporozoites and 
liver schizonts or eliminating parasites upon entering the blood stream from the liver 
(Figure 1.9) (Burrows et al., 2013). 
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Figure 1.9: Target candidate profiles (TCP) for future antimalarial drugs  
TCPs are necessary for the proposed target product profiles (TPP) for future antimalarial drug development 
(Source- Burrows et al., 2013). 
1.9 Moving forward: determining key pharmacodynamic properties  
 
To triage the 20,000 candidates that resulted from the massive chemical screens to 
establish priorities to take them forward for development requires additional information 
regarding their activity. Key features among their pharmacodynamic properties are Lethal 
Dose (LD50) and rate-of-kill (RoK) (Paguio et al., 2011; Sanz et al., 2012). To support this, a 
rapid, inexpensive and reliable quantification of the precise potencies and interactions of 
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new and existing drugs is essential to accelerate the drug discovery process and protect 
the efficacy of the current front line drugs against severe disease. To date, virtually all in 
vitro quantifications of antimalarial drugs or drug combination potency have been 
performed using a growth inhibition assay that quantifies in vitro drug potency as an IC50 
value (Bell, 2005; Foley and Tilley, 1998; Foley and Tilley, 1997). IC50 values report the 
concentration of a drug that inhibits the growth of a mass population of parasites by 50% 
relative to untreated control. This means that all previous quantifications of IC50 potency 
were based on both determining the cytostatic and cytocidal potency of antimalarial 
drugs in the absence of additional information regarding their mode of killing. Depending 
upon specific antimalarial drug classes, these may inhibit proliferation by killing some of 
the parasites in a time-dependent fashion while others act by alternative ways, either 
slowing the metabolism and the cell cycle, impeding DNA replication and parasite egress 
etc., without killing the cell. However, this means it cannot be conclusively determined 
from these standard assays whether the IC50 value reveals cytostatic or cytocidal potency 
for distinct classes of antimalarial drugs. That said, it might be useful to develop a precise 
and applicable assay in high throughput screening (HTS) platforms to distinguish between 
cytostatic and cytocidal activities of antimalarial drugs. Thus, the cytocidal activity of 
antimalarial drugs must be quantified by LD50 that is the concentration of drug that kills 
50% of a bulk population of parasites relative to untreated control. In 2011, a probe-wash 
high throughput assay was developed to measure LD50 using the DNA intercalating dye 
Sybr Green-1. Using this approach, Paguio et al., (2011) demonstrated that the LD50 of 
quinoline drugs may be as much as 20-50 fold higher than the IC50. Critically, LD50 potency 
in CQR parasites is not subject to verapamil- reversal, unlike IC50. Moreover, the LD50 is 
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not wholly linked to CQ concentration in the digestive vacuole, but additionally linked to 
genetic loci other than PfCRT (chloroquine resistance gene) in genome-wide association 
studies (Gaviria et al., 2013). Thus, even for a well characterized antimalarial drug 
action/resistance model offered by CQ, LD50 data may provide new insights into the 
mechanism of lethal drug action.  
The RoK has been explicitly identified by MMV as a vital requisite (TCP1) in the TPPs for 
future antimalarial drugs (Burrows et al., 2013; Leroy et al., 2014). RoK is important 
because compounds that kill quickly not only rapidly reduce parasite burden, 
ameliorating the morbidity and mortality of the disease, but also may offer a narrower 
window of suboptimal drug levels during which resistance may evolve. The RoK is 
currently determined in vivo using mouse models or phase IIa humans clinical trials. It is 
determined in terms of two parameters; the parasite reduction ratio (PRR, the reduction 
from the starting parasitaemia after 48 hours of drug action corresponding to one cycle of 
erythrocyte-stage growth) or parasite clearance time (PCT, time to reduce parasitaemia 
by 99.9%). However, there is an urgent demand to identify RoK earlier in the drug 
discovery process, i.e. during in vitro laboratory studies. Earlier accesses to 
pharmacodynamic properties (RoK) would substantially accelerate the antimalarial drug 
discovery process (Sanz et al., 2012).   
To examine the effect of drug treatment on the asexual stages of the parasite, a number 
of in vitro standard techniques have been developed. These are used today for both drug 
development and monitoring resistance (Sanz et al., 2012). These antimalarial drug assays 
typically rely on incorporation of radiolabeled hypoxanthine/ethanolamine and/or 
metabolic precursor as a measure of parasite growth, providing a standard assay format 
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with excellent signal-to-noise (S/N) ratio (Desjardins et al., 1979; Elabbadi et al., 1992; 
Sanz et al., 2012). However, problems regarding the safe disposal of the radiolabeled 
material have restricted these assay formats. Further assays have been recently 
developed which are based on the measurement of enzyme activity or an immunological 
assay of its presence. These assays are relatively expensive although, they avoid use of 
the radiolabeled materials. The enzyme lactate dehydrogenase (pLDH), which is involved 
in the glycolysis pathway, can be used as a marker for parasite presence. In order to 
measure this protein either in vitro and/or in vivo, both colorimetric and 
immunodetection-based assays have been developed (Makler and Hinrichs, 1993; Piper 
et al., 1999). Parasite growth rate can also be accurately estimated by using histidine-rich 
protein 2 (HRP2) measured by immunodetection (Noedl et al., 2002; Sanz et al., 2012). 
New methods such as flow cytometry have also been used to measure light 
depolarization by haemozoin or a determination of DNA content to evaluate drug 
potency. All these commonly used techniques measure the metabolic activity as a proxy 
for parasite viability. However, these approaches are vulnerable to artefacts because 
parasite metabolism and viability are two parameters that are coupled during the life 
cycle of the parasite, but may be uncoupled following drug treatment (Sanz et al., 2012). 
Considering the limitations of traditional approaches, fluorescence-based platforms have 
been developed which use DNA intercalating agents such as Sybr Green I and/or 40, 60-
diamidino-2-phenylindole (DAPI) (Johnson et al., 2007; Ndiaye et al., 2010; Sanz et al., 
2012). Fluorescence-based platforms offer inexpensive, sensitive assay formats and the 
utility of the Malaria Sybr Green I Fluorescence (MSF) assay for single-dose HTS has 
readily been demonstrated (Gamo et al., 2010). Using a fluorescence-based assay of 
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parasite recrudescence, RoK was measured in vitro by Sanz et al., (2012) based on the re-
growth of drug-treated parasites. Following different times and doses of drug treatment, 
this assay provides high-quality RoK data that correlates with in vivo data. However, this 
format is very laborious as the re-growth of parasites over 3-4 weeks poses a significant 
limitation on its feasibility as a medium to HTS assay.  
Keeping in view the limitations of the above-mentioned assay formats; there is a 
significant demand within the drug development community for a quantitative and rapid 
in vitro methodology to provide LD50 and RoK data in a HTS system. Towards this aim, the 
Dd2 strain of P. falciparum has been genetically modified by the insertion of a luciferase 
reporter cassette (Hasenkamp et al., 2012; Hasenkamp et al., 2013; Wong et al., 2011). 
This cassette expresses the bioluminescent reporter luciferase under the control of 
Pfpcna flanking sequence (Wong et al., 2011). This parasite clone exhibit a strong 
temporal peak of luciferase expression during the S-phase of intraerythrocytic DNA 
replication (i.e. mature trophozoites stage), thus acting as a marker of cell proliferation 
(Hasenkamp et al., 2012) (Figure 1.10) distinct to that using a fluorescent DNA 
intercalating agents.  
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Figure 1.10: Schematic representation of luciferase and SyBr-Green-I reactions  
(A) Illustrates the reaction of the firefly Luciferase. The Luciferase enzyme is detected following lysis of 
parasite-infected erythrocytes. In the presence of co-factors, the released luciferase oxidizes a luminogenic 
substrate releasing energy in the form of light. (B) Shows the action of fluorescence (i.e. that is the product 
of a fluorophore-FITC, DyLight dyes) which absorbs the energy from a light source and emits light energy at 
a different wavelength. (C) The action of the DNA intercalating dye SyBr-Green-I dye incorporated into DNA 
(Source: modified from Thermo Fisher Scientific, 2009). 
This novel bioluminescent assay, when compared against the current standard drug 
action assay, based on the fluorescence of a DNA intercalating dye, MSF (Figure 1.11c), 
reveals high concordance in determining IC50 values of antimalarial drugs (Hasenkamp et 
al., 2013). Essentially, both luciferase and the MSF monitor parasite proliferation via DNA 
replication, however, the biomarkers are different. The MSF assay measures DNA content 
directly and the luciferase assay monitors induction of DNA replication proteins 
(Hasenkamp et al., 2012) and thus has distinct properties following death induced by drug 
action. Whilst the MSF assay can be problematic due to the low (4-5) S/N ratio resulting 
from high background signals while the S/N ratio for bioluminescence is between 2500-
17,000 depending upon the luminogenic agent used (Hasenkamp et al., 2012). This 
enhanced working range of bioluminescent assay demonstrates a wide range in the limits 
for reliable detection. The applications of bioluminescence have been readily 
demonstrated in single-dose HTS, small- to medium-sized chemical libraries providing 
evidence that this assay format is a robust and reliable platform for antimalarial drug 
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discovery (Adjalley et al., 2011; Che et al., 2012; Cui et al., 2008; Ekland et al., 2011; 
Franke-Fayard et al., 2008; Lucumi et al., 2010). However, this assay format is more 
expensive and only applicable in genetically modified parasites expressing the luciferase 
reporter gene whilst the MSF assay can be performed in any parasite line. Despite these 
limitations, the bioluminescent assay provides a significantly improved dynamic 
measurement of temporal parasite viability following drug exposure. This immediate 
dynamic response of bioluminescence was previously demonstrated by Hasenkamp et al., 
(2013). When death was induced using super-lethal doses of either the RNA polymerase II 
inhibitor actinomycin-D or the ribosome inhibitor cyclohexamide, the bioluminescence 
assay provided a more dynamic response than fluorescence-based DNA intercalating dyes 
as the expression of luciferase ceases and the protein is turned over. By contrast, the 
intrinsic stability of DNA hampers any attempt at short-term fluorescence-based 
monitoring of cell death. This means that whilst the dead parasite doesn’t express 
protein, it still retains DNA (Figure 1.11). This study also provided evidence that the 
bioluminescence assay can determine relative RoK by investigating the effect of four 
antimalarial drugs, azithromycin (AZ), CQ, DHA and ART at a fixed dose of 3xIC50 
concentration. This initial “Proof of Principle” suggests that bioluminescence assay can be 
developed into a rapid in vitro RoK assay (Hasenkamp et al., 2013).  
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Figure 1.11: The immediate dynamic response of bioluminescence and fluorescence assays of drug 
activity.  
Plot of the time-dependent changes in relative light units (RLU) (bioluminescent and fluorescence when 
compared to untreated control) measured from trophozoite stage Dd2
luc
 (2% parasitaemia, 2% HCT) 
exposed to a supralethal 1μM dose of actinomycin D (filled symbol) or cyclohexamide (open symbol). The 
fraction of mean RLU ± stdev (n = 3) at each time point are shown for a luciferase assay (square) or MSF 
assay (circle).  
 
Aims of this study 
 
Following the demonstration of proof-of-principle that a bioluminescence assay has the 
potential to rapidly provide evidence for the relative Rate-of-Kill of antimalarial drug 
action, this thesis proposes to; 
1. Validate the hypothesis that bioluminescence can be used to monitor a time and 
dose dependent decrease in parasite viability following drug treatment.  
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2. Develop a medium to high-throughput plate based assay format for a 
bioluminescence Rate-of-Kill assay, benchmarked against known antimalarial 
drugs and their in vitro rate of Kill. 
3. Utilize this bioluminescence Rate-of-Kill (BRoK) assay against the compounds 
present in the MMV Malaria Box to establish their relative rate of kill against 
known standards.  
4. Explore the utility of the BRoK assay for longer term, i.e. 48hr, assays of rate of kill  
This work will conclude with a discussion of the relative strengths, weaknesses, 
opportunities and threats to the representation of the BRoK assay in the antimalarial drug 
development pipeline.  
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CHAPTER 2: Materials and Methods 
 
2.1 Materials (stocks and reagents)  
 
Note: The chemicals mentioned in this section and/or elsewhere in this thesis, were 
sourced commercially from either Sigma-Aldrich or VWR unless stated otherwise. 
Plasticware for tissue culture and biological assays were sourced from Star Lab, Greiner 
Bio-One and Sarstedt. 
Blasticidin S hydrochloride: A 10 mg/mL stock concentration was achieved by adding 0.05 
g of Blasticidin S hydrochloride to 5 mL sterile distilled water (sdH2O) (filter sterilised-0.45 
μM). This was stored in 0.5 mL aliquots at -20oC. 125 μL of 10 mg/mL Blasticidin S 
hydrochloride was added to 500 mL complete growth medium to give a final working 
concentration of 2.5 μg/mL. 
Growth medium for P. falciparum culture: To make an incomplete growth medium 500 
mL of Roswell Park Memorial Institute (RPMI) 1640 medium was supplemented with 37.5 
mM HEPES buffer solution, 5 mM sodium hydroxide solution, filter sterilised (0.5 μM) 10 
mM D-glucose, 2 mM L-Glutamine, 100 µM hypoxanthine solution (Sigma) and 25 µg/mL 
gentamicin sulfate (Sigma). For a complete growth medium, the incomplete growth 
medium was supplemented with 8% v/v pooled human serum and 0.2 % albumax-II (w/v 
filter sterilised-0.45 μM in sdH2O) (Invitrogen).  
Glucose solution: To make a 45% w/v glucose solution, 90 g of D-glucose was added to 
200 mL sdH2O and dissolved with the help of a magnetic stirrer. The solution was filter 
sterilised (0.45μM filter) and stored in 10 mL aliquots at 4oC. 
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Glycerolyte freezing solution: Stocks of glycerolyte freezing solution were prepared in 
advance by supplementing 200 mL sdH2O with 142.5 g glycerol, 4 g sodium lactate, 0.075 
g potassium chloride, 0.311 g disodium phosphate (Na2HPO4) and 0.129 g monosodium 
phosphate (NaH2PO4). The pH (6.8) and final volume (250 mL) were adjusted using 10 M 
NaOH and sdH2O, respectively. The solution was filter sterilised (0.45μM filter) and stored 
at 4oC. 
Hypoxanthine solution: To make 1000X hypoxanthine solution, 340 mg hypoxanthine 
was added to a volume of 25 mL 1M sodium hydroxide. The solution was filter sterilised 
(0.45μM filter) and stored in 0.5 mL aliquots at -20oC.  
Malaria Sybr-Green-I Fluorescence (MSF) assay buffer: An appropriate volume of MSF 
lysis buffer was prepared in advance that contained 20 mM Tris pH 7.5, 5 mM EDTA, 
0.008% w/v saponin and 0.08% v/v Triton -100 at final concentrations and stored at room 
temperature (RT).   
WR99210 drug: A 25 mM long-term stock solution was achieved by adding 0.05 g of 
WR99210 to 1 mL DMSO and was stored at -20oC. This was further diluted 1/1000 in 
complete growth medium to achieve a 25 μM short-term stock solution, which was 
stored at 4oC for a week. The required 5 nM final concentration of WR99210 was 
achieved by adding 100 μL of the 25 μM stock solution to 500 mL of complete growth 
medium. 
2.2 Cell culture methods  
2.2.1 Human blood and serum 
 
The Institute for Science and Technology in Medicine (ISTM) at Keele University holds a 
Human Tissue Authority (HTA) license for the use, storage and disposal of human blood. 
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The Horrocks laboratory (HL) within ISTM is an approved user of the National Blood and 
Transfusion Service (NBTS), UK. The HL CAT-III cell culture suite facility is approved by the 
Health and Safety Executive (HSE) for the use and generation of genetically modified 
parasites (GM) and the users of this facility are pre-trained as per rules laid out in the 
CAT-III suite code of practice. Human blood and serum were supplied by NBTS and 50 mL 
aliquots stored at 4oC and -20oC, respectively, until further use.  
2.2.2 P. falciparum clone 
 
The P. falciparum chloroquine resistant (CQR) parasite clone Dd2luc was used throughout 
this study. The Dd2luc transgenic parasite line is a clone of Dd2 which expresses high levels 
of luciferase during the trophozoite stage under the control of Pfpcna flanking sequences 
(Wong et al., 2011). Drug selections of 5 nM WR99210 and 2.5 µg/mL Blasticidin S 
hydrochloride were applied throughout cell culturing to maintain the stability of the attB 
site (Hasenkamp et al., 2013). 
2.2.3 Preparation of normal human red blood cells 
 
NBTS, UK provided whole blood type-O-Rhesus positive (ORh+) human red blood cells 
(RBCs). The blood was aliquoted into 50 mL tubes and stored at 4oC for 2-3 weeks. To 
make a 50 % v/v haematocrit (HCT) solution, the aliquots were centrifuged for 8 minutes 
at 1160 g RT and the serum was removed. An equal volume of the incomplete growth 
medium was added to the packed RBCs. This was resuspended and centrifuged for 5 
minutes at 850 g RT and the supernatant removed. The same centrifugation step was 
repeated to ensure the complete removal of serum, preservatives and white blood cells 
(WBCs). The packed RBCs were resuspended in an equal volume of incomplete growth 
medium and stored at 4oC for up to 10 days.   
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2.2.4 Continuous cell culture of P. falciparum  
 
All the cultures were maintained by standard continuous culture as originally described by 
Trager and Jensen, (1976) and later modified by Freese et al., (1988). On a daily basis, thin 
blood smears were prepared, fixed with absolute methanol and stained with 10 % v/v 
Giemsa. Subsequent assessment of parasitaemia and parasite staging were established by 
light microscopy (oil immersion objective lens) at x1000 magnification (Olympus). The 
appropriate amount of complete growth medium and fresh 50 % v/v HCT washed RBCs 
were added to maintain the cultures between 1-5 % parasitaemia at a 2-4 % HCT. The 
cultures were gassed to maintain an atmosphere of 1 % O2, 3 % CO2 and 96 % N2 (BOC 
special gas) and returned to the incubator at 37oC.   
2.2.5 P. falciparum cell culture synchronisation with sorbitol  
 
A standard sorbitol-lysis protocol, first described by Lambros and Vanderberg, (1979) with 
minor modifications was used for the synchronisation of parasite cultures. Predominantly 
ring stage parasite cultures were collected by centrifugation at 850 g for 5 minutes at RT, 
suspended in 5 volumes of pre-warmed D-sorbitol 5 % w/v (Sigma) and incubated at 37oC 
for 5 minutes. The culture was centrifuged again at 300 g, RT for 5 minutes, the 
supernatant was aspirated, and following this treatment standard cell culture conditions 
were employed.   
2.2.6 Long term storage of P. falciparum cell culture  
 
A predominantly ring stage parasite culture (high parasitaemia ~10%) is suitable for long-
term storage in liquid nitrogen. The ring stage culture was pelleted by centrifugation for 5 
minutes RT at 300 g, the supernatant was aspirated, leaving about 500 µL on top, and 
gently resuspended. The volume of the packed cells was estimated and five volumes of 
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glycerolyte were added to three volumes of cell pellet (i.e. drop by drop) using a sterile 
dispenser or pipette. Following the addition of first volume of glycerolyte, the parasite 
culture was allowed to stand upright for 5 minutes to allow glycerol to permeate cells. 
The remaining 4 volumes of glycerolyte were added slowly to the parasite culture, and 0.8 
mL samples were aliquoted into sterile freezing vials (NUNC). The vials were stored for at 
least 24 hours (hrs) in -80oC before transferring to liquid nitrogen for long term storage.  
2.2.7 Thawing of glycerolyte-frozen P.  falciparum with NaCl 
 
A freezing vial was removed from the liquid nitrogen and placed at 37oC to thaw. The 
infected red blood cells (iRBCs) was transferred from vials to 50 mL sterile tubes and a 
1/5th volume of 12% NaCl was added slowly and incubated at RT for 5 minutes followed 
by gently adding 10 volumes of 1.8 % NaCl. Thereafter, 10 volumes of 0.9% NaCl in 0.2% 
glucose were added, mixed and centrifuged for 5 minutes at 850 g, RT to collect the cell 
pellet. The cell pellet was then transferred to a small flask containing 10 mL complete 
growth medium, gassed and returned to the incubator at 37oC. 
2.3 Drug assays  
 
2.3.1 Drug stocks preparation 
 
Drug stocks were prepared in their required solvents (Table 2.1) and stored at -20oC. 
Antimalarial drugs were sourced from Sigma-Aldrich unless stated otherwise whilst PG-
227 was kindly provided by the Biagini group of the Liverpool School of Tropical Medicine 
(LSTM). All the 400 compounds (200 drug-like and 200 probe-like) of the Malaria Box 
were sourced from the Medicine for Malaria Ventures (MMV) formatted as 20 µL 
solutions at 10 mM concentration in dimethyl sulfoxide (DMSO) (www.mmv.org). The 
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Malaria Box compounds were diluted into 1 mM concentrations, stored at -20oC and 
working stocks were prepared when needed.  
 
6
Table 2.1: Preparation of drug stocks.  
The different drug classes are either based on the antimalarials chemical composition (endoperoxides, 4- 
and 8- aminoquinolines, and amino alcohols), their function (antibiotics) or novel compounds from the 
Malaria Box (200 diverse drug-like and 200 diverse probe-like compounds) are recorded with the solvent 
used and concentration prepared to.
 1
Common abbreviations shown in brackets and used throughout this 
thesis.
 
 
2.3.2 Standard cell culture conditions and format of 96-well microplates for drug assays  
 
Experiments were typically conducted using synchronised early trophozoite stage [17-24 
hours post infection (hpi)] parasites unless stated otherwise.  All the drug assays were 
initially set-up in a 96-multiwell tissue culture plate (SARSTEDT, UK). To minimize edge 
effects from evaporation, 200 µL of incomplete growth medium was added to the 
outermost wells on each plate for each assay. The remaining wells on a 96-multiwell 
tissue culture plate were supplied with 100 µL complete growth medium except the first 
column where appropriate volumes of complete growth medium were added depending 
upon the dilution series of the drug under investigation. An appropriate amount of drug 
was added to the first column, mixed completely by repeated pipetting and serial dilution 
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performed. An equal volume (100 µL) of mastermix containing 1% synchronous 
trophozoite stage culture at a haematocrit was added to each well and homogenised by 
repeated pipetting to give a final 2 % HCT. The same mastermix without drugs served as a 
positive control (i.e. 100 % parasite growth under the same condition) while 2% HCT 
(RBCs) was typically used as a negative control (background signal) on each plate. In 
addition, an internal control of benchmark antimalarial drug was also included (Figure 
2.1). The plate was transferred to a humidified airtight box and the chamber was flushed 
with gas to maintain an atmosphere of 1% O2, 3% CO2 and 96% N2. This was incubated at 
37oC for the appropriate time depending upon the type of assay. For each experiment, 
three technical and three biological replicates were typically employed. 
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1
Loading drug DMSO not > 1% of total volume  
0.1
Figure 2.1: Schematic representation of the plate set-up used for drug assays  
Trophozoite stage parasites (at 1 % parasitaemia and 2 % final HCT) were exposed to multiple 
concentrations of the compound/drug under investigation. Drugs were added (2x final 
concentration) to the loading column and depending on the assay type and drugs, two, three or 
five-fold dilution series were employed as per table B. 100 µL of mastermix was added to each well, 
which reduced the concentration into half (required 1X concentration). A known antimalarial drug 
(usually CQ) was also included as an internal control. (A) This assay format (eight to nine drug doses 
where initial concentration was dependent on the IC50 value of the drug under investigation) was 
mainly adopted for IC50 and LD50 assays and/or unless stated otherwise. (C) This assay format was 
used for the RoK assays. Loading column was supplemented with 18xIC50 dose of the drug (DMSO < 
1% of total volume) under investigation and 3-fold dilution was performed as per table B. 100 µL of 
mastermix was added to each well, which reduced the concentration to 9x IC50, 3x IC50, 1x IC50 and 
0.3x IC50). 
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2.3.3 Standard protocol for luciferase assay  
 
An improved single-step lysis protocol previously described by Hasenkamp et al., 2012 
was used for all luciferase assays. 40 μL samples of Dd2luc culture were transferred to 
wells of a white 96-multiwell plate (Greiner, UK) and 10 μL of 5X Passive Lysis Buffer 
(Promega, UK) was added to each well and homogenised gently by shaking. An equal 
volume (50 μL) of luciferase substrate (SL) was added and mixed by repeated pipetting 
with the lysed parasites. The resultant bioluminescence signal in relative light units (RLU) 
was immediately measured for 2 seconds on a Glomax Multi Detection System (Promega, 
UK). Data were exported into an excel spreadsheet using InstinctTM software (Promega). 
“Graphit” software was used for the normalization of the data and all the graphs were 
plotted in GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego, CA). 
2.3.4 Standard protocol for Malaria Sybr Green I Fluorescence (MSF) assay 
 
This protocol was initially described by Smilkstein et al., (2004). SYBR Green I (1X final 
concentration, from 5000x stock) (Invitrogen, UK) was added to the MSF assay buffer, 
mixed by inversion and placed in an opaque dark box until ready to use. Immediately 
prior to the start of the experiment, 100 µL of MSF assay buffer was added to each well 
on a black 96-multiwell plate (Greiner, UK). To each well an equal volume (100 μL) of 
parasite culture was added with repeated pipetting to lyse and homogenize the cellular 
contents. This was incubated for one hour at RT in the dark (opaque dark box). The 
fluorescent signal, in RLU, was measured using the blue fluorescent module (excitation 
490nm: emission 510–570nm) of a Glomax Multi Detection System (Promega, UK). Data 
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were exported into an excel spreadsheet using InstinctTM software (Promega). “Graphit” 
software was used for the normalization of the data and all the graphs were plotted in 
GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego, CA). 
2.3.5 Determination of the 50% inhibition concentration (IC50) 
 
The protocol used is an adaptation of that originally described by Smilkstein et al., (2004) 
as modified in Hasenkamp et al., (2012). These experiments were employed using the 
Dd2luc P. falciparum strain. For these assays, a two-fold dilution series (unless stated 
otherwise) was employed for a 48hr assay (trophozoite to trophozoite). Each biological 
replicate recorded here comprises three technical replicates on the same 96-well plate. 
Following capture of the fluorescent or bioluminescent signal using standard MSF and 
luciferase assay protocols described above, the percentage growth was calculated as 
follows: 100x[μ(S) − μ(−)/μ(+) − μ(−)] where μ(S), μ(+) and μ(−) represent the means for 
the sample in question and 100 % and 0 % controls, respectively (Hasenkamp et al., 
2013). The percentage growth was plotted against log10 transformed drug concentration 
and the IC50 determined using a nonlinear regression (sigmoidal dose–response/variable 
slope equation) in GraphPad Prism v5.0 (GraphPad Software, Inc., San Diego, CA). 
2.3.6 Determination of the 50% lethal dose concentration (LD50) 
 
The protocol used is an adaptation of that originally described by Paguio et al., (2010). 
These experiments were performed using the Dd2luc P. falciparum strain. Initial starting 
conditions employed were: 1% trophozoite-synchronised culture at a final 4% 
haematocrit. Five-fold dilution series were employed unless stated otherwise (Figure 
2.1a). Following a 6hr drug bolus, the signal was immediately measured (prior to drug 
washing step) using both the standard MSF and luciferase assay protocols described 
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above. Appropriate volumes (200 µL n=3) were transferred to a 96-multiwell tissue 
culture plate (SARSTEDT, UK). The remaining infected erythrocytes were washed three 
times with 5 volumes of complete growth medium, with infected erythrocytes collected 
by high-speed microcentrifugation pulse (20 seconds, 10258 g, RT). Following the last 
wash, parasites were resuspended to the initial 2% haematocrit and 200 µL in triplicates 
were transferred to the same plate as shown in figure 2.2B.  The plate was incubated for 
an additional 42hrs at 37oC (for a total of 48hrs) prior to being processed for their 
fluorescent or bioluminescence signal using the MSF and luciferase assay standard 
protocols. The percentage growth was plotted against log10 transformed drug 
concentration and the LD50 determined using a nonlinear regression (sigmoidal dose–
response/variable slope equation) in GraphPad Prism v5.0 (GraphPad Software, Inc., San 
Diego, CA). 
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CGM= Complete growth medium 
0.2
Figure 2.2: Schematic representation of the modified bioluminescence protocol. 
 (A) Outline the method for measuring In vitro 6hr LD50, and 48hr IC50 and LD50 using both luciferase and 
Sybr-Green-I biomarkers. (B)The plate was incubated for an additional 42hrs at 37
0
C (total 48hrs). 
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2.3.7 Bioluminescent rate-of-kill assays  
 
The Dd2luc parasite line used throughout. The parasitaemia of early trophozoite stage (17-
24 hpi) Dd2Luc culture was assessed by microscopy. A mastermix of 1% trophozoite-
synchronised culture at a final 2% HCT was prepared, with 200 μL aliquots exposed to 
multiples of the IC50 of the compound under investigation (9x IC50, 3x IC50, 1x IC50 and 0.3x 
IC50 unless stated otherwise). Following exposure to these concentrations of compound 
after 3hr and 6hr at 37oC (with the exception of assays performed in chapter 5, where a 
6hr and 48hr assay format was adopted), 40 μL samples were removed and the 
bioluminescent signal was measured using the standard luciferase protocol described 
above. The bioluminescent signal obtained was plotted as a percentage of the same 
volume of an untreated iRBC control. For each experiment three technical repeats were 
employed, the final data plotted is the mean and standard deviation of these data from 
three independent biological replicates (n=9) (Figure 2.3). 
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Figure 2.3: Schematic representation of the BRoK protocol.  
A mastermix at 1% parasitaemia and 2 % final HCT was prepared and added to a 96-multiwell tissue culture 
plate contained serially diluted (three-fold dilution series was employed) drug in complete growth medium 
(9x IC50, 3x IC50, 1x IC50 and 0.3x IC50). Positive and negative controls were used on each plate and an 
addition benchmark drugs were included on each plate as internal controls. The plate was incubated at 37
o
C 
and the bioluminescent signal was captured at 3hrs and 6hrs respectively. 
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2.3.8 Bioluminescence rate of kill assay quality parameters 
 
The assay quality parameters for bioluminescence assays were previously determined by 
Horrocks laboratory and are reported in Hasenkamp et al., (2013). To ensure the 
reliability of drug screening in this study, the following parameters such as Z-Factor, 
coefficient of variation (%CV MAX), Signal-to-background (S/B) and Signal-to-noise (S/N) 
were determined for benchmark drugs and Malaria Box compounds (Table 2.2) using the 
formulas previously reported by Zhang et al., (1999). These parameters are used to assess 
the quality and suitability of an assay for a HTS. For a reasonable HTS assay, its Z-factor 
should be greater than 0.5, low %CV (i.e. indicates high precision), low S/B ratios and high 
S/N ratios.  
 
7
Table 2.2: Bioluminescence assay quality parameters 
μ (+) and σ (+) = mean and standard deviation of the positive control (parasites only, no drug) respectively.   
μ (−) and σ (−) = mean and standard deviation of a negative control (RBCs only or super lethal dose of CQ).  
2.4 Data management 
 
All bioluminescence and fluorescence data developed using Glomax Multi Detection 
System (Promega, UK). These data exported as Instinct software files (Promega) and 
converted into excel (Windows 8.0) spreadsheets for analysis. These raw sequence files 
shared on University desktop and a copy saved on University network. Data from 
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different biological repeats of assays combined in GraphPad Prism v5.0 (GraphPad 
Software, Inc., San Diego, CA) software for production of graphs, regression analyses and 
determination of IC50, LD50 and rate of kill data.  
IC50 data for 396 compounds have been compiled in excel spreadsheet and have been 
submitted to Dr. George Papadatos of EBI for forthcoming release on ChEMBL data 
repository (www.ebi.ac.uk/chembl/malaria/).  
Principle component analysis (PCA) of the 3hr, 6hr and 48hr rate of kill data was 
performed by Dr. Raman Sharma, LSTM. PCA was performed on the 0.3x, 1x, 3x and 9x 
IC50 variables for the 3, 6 and 48hrs bioluminescence assay endpoints using the KNIME 
analytics platform to reduce the dimensionality of these data set, allowing the 
concentration rate Relationship to be captured in one parameter (Michael et al., 2007). I 
then carried out the correlation of PC1 components with IC50 data in GraphPad Prism v5.0 
(GraphPad Software, Inc., San Diego, CA) software. This data will be submitted to ChEMBL 
data repository.  
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CHAPTER 3: Development and Validation of a Rapid In Vitro 
Bioluminescence-Based Rate of Kill Assay 
 
3.1 Introduction   
 
 The Medicines for Malaria Venture (MMV) has defined the attributes of a future 
combination therapy for the treatment of uncomplicated malaria – a Single Exposure 
Radical Cure and Prophylaxis (SERCaP). To meet this challenge, candidates for inclusion in 
this combination therapy must meet at least one of four Target Candidate Profiles 
(Burrows et al., 2013; Leroy et al., 2014). Target Candidate Profile 1 (TCP1) emphasizes 
fast clearance of the initial parasite burden (Table 3.1).  
 
8
Table 3.1: Target Candidate Profile 1 (TCP1) 
 The minimum essential and ideal attributes required for TCP1 candidate antimalarial drug (reproduced 
from- Burrows et al., 2013). 
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TCP1 defines both a “minimum essential” and an “ideal” criterion for the rate of onset of 
drug action. Ideally a candidate has to be as effective, or better, than the very rapidly-
acting artemisinin and at least as effective as rapid-acting 4-aminoquinolines (Burrows et 
al., 2013; http://www.mmv.org/). TCP1 is important because compounds that kill quickly 
not only rapidly reduce parasite burden, ameliorating the morbidity and mortality of the 
disease, but also may offer a narrower window of suboptimal drug levels during which 
resistance may evolve. The rate of kill is currently determined in vivo using mouse malaria 
models or during phase IIa human clinical trials (Burrows et al., 2013; White, 1997). It is 
clinically defined in terms of two parameters; (i) the parasite reduction ratio (PRR), the 
fold-reduction from the starting parasitaemia after 48-hours of drug action 
(corresponding to one cycle of erythrocyte stage growth) and (ii) the parasite clearance 
time (PCT), time to reduce parasites until they are no longer detectable in the peripheral 
blood film, i.e. by 99.9% (Figure 3.1a) (White, 1997). Typically, the PRR and PCT are 
estimated by measuring a change in the peripheral parasitaemia over time by microscopy. 
To characterize the PCT profile during therapeutic assessments, parasite counts at ≤ 6hr 
intervals are required (White, 2011). However, the precision of this assay depends on a 
range of factors such as parasite burden, sequestration of parasites and expertise of the 
observer (White, 2011; White, 1997). By contrast, PRR estimation is much easier, 
requiring only two counts 48hrs apart (White, 1997). The PCT and the PRR are closely 
related as antimalarial drugs with high PRR take less time to eliminate parasites from the 
blood (Figure 3.1). However, PRR varies greatly depending upon the type of infection (i.e. 
sequestering malaria caused by P. falciparum and non-sequestering by P.vivax, P. ovale, 
and P. malariae) and the overall efficacy of antimalarial drugs (White, 2011; White, 1997).  
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Figure 3.1 In vivo PRR and PCT data 
(A) Schematic representation of the PRR and PCT. Essentially antimalarial drugs with < 10
3
 PRR should be 
administered for more than a week to effectively eliminate parasites. (B) In vivo PRR values of different drug 
classes (reproduced from-White, 1997). 
Most antimalarial drugs are predominantly active against the mature trophozoite stages 
of parasite development (schizonticides). Antimalarial drugs such as cycloguanil and 
pyrimethamine, the quinolones and mefloquine have little or no efficiency against the 
early stage circulating parasites (i.e. rings) and thus they are less likely to significantly 
prevent sequestration. Parasitemia-time profiles are affected by the magnitude of 
infection, stage and synchronicity, but generally, those antimalarial drugs that are 
effective against the young parasites (particularly artemisinin and CQ to some extent) 
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rapidly reduce the initial parasite burden. The fast acting drug artemisinin exerts in vivo 
PRR in the order of 103–105 whilst slow acting drugs such as antimalarial antibiotics have 
a PRR of 5-10 (Figure 3.1) (Hien and White, 1993; White, 1997).   
The “fast killing” and “slow killing” profiles, share a link with the cytotoxic and cytostatic 
potential of antimalarial drugs as described in chapter I (see section 1.9) (Gorka et al., 
2013; Paguio et al., 2011). Cytotoxic antimalarial drugs (i.e. artemisinin, CQ) actively kill 
the parasite and hence display a high efficacious profile. In contrast, the cytostatic drugs 
(i.e. ATOVA) may not completely eliminate circulating parasites and this may open a 
window to treatment failure and subsequent resistance (Paguio et al., 2011). Therefore, it 
is important to consider the cytotoxic potential profile in the search of future antimalarial 
drugs.  
Antimalarial drug development is a slow process that takes some 13-15 years. Earlier 
access to pharmacodynamic properties, such as rate of kill, could substantially accelerate 
the antimalarial drug discovery process (Sanz et al., 2012). Towards this aim, rate of kill 
was measured in vitro by Sanz et al. (2012), using a fluorescence-based assay of parasite 
recrudescence, which is based on the re-growth of drug-treated parasites. Briefly, this 
assay establishes an initial inoculum corresponding to 106/mL of parasites at 0.5% 
parasitaemia and 2% haematocrit, which are treated with a 10xIC50 concentration of an 
antimalarial drug. The effect on parasite viability is monitored by removing an aliquot 
corresponding to 105 parasites every 24 hours, washing away the drug before adding 
fresh erythrocytes and performing a limiting serial dilutions into a microtiter plate. This 
plate is maintained for 3-4 weeks and parasite growth determined in each well to enable 
an estimate of the number of viable cells that were present prior to the drug wash step 
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(Sanz et al., 2012). This recrudescence assay provides high quality in vitro rate of kill data, 
i.e. PRR, PCT and information about the lag-phase for onset of drug action (Figure 3.2). 
 
0.2
Figure 3.2: In vitro log PRR and PCT data  
Classic antimalarial drugs and their associated lag phase, PRR and PCT (reproduced from-Sanz et al., 2012). 
 
This in vitro recrudescence assay data, as shown in Figure 3.2, correlates with in vivo 
clinical data, showing the same relative order of antimalarial drugs in terms of their rate 
of kill i.e. ART > 4 aminoquinolines > QN and MEF (Sanz et al., 2012). However, the 
necessary re-growth of parasites over 21-28 days poses a significant limitation on the 
recrudescence assays feasibility as a medium to high throughput assay. This issue 
identifies a development gap for a quantitative and rapid in vitro assay to provide in vitro 
rate of kill data in a HTS system – a gap that is addressed here.  
As described in chapter 1, a genetically modified (GM) parasite line (Dd2luc) is available in 
the Horrocks laboratory that expresses high levels of luciferase during the S-phase 
(trophozoite stage) of the P. falciparum life cycle and thus acting as a marker of cell 
proliferation (Wong et al., 2011).  Hasenkamp et al., (2013) have previously shown that 
luciferase is a more dynamic reporter of immediate drug action than commonly used 
fluorescence based assays of DNA content. The high turnover rate of the bioluminescence 
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reporter protein luciferase provides an opportunity to develop a rapid in vitro assay to 
explore the pharmacodynamic properties of antimalarial drugs. Hasenkamp et al., (2013) 
exploited the immediate dynamic response of bioluminescence against known 
antimalarial drugs to show a time-dependent effect on luciferase signal following drug 
treatment (Figure 1.11B). Critically, this data suggests that the loss of bioluminescence for 
the drugs tested correlates with our available understanding of their relative rates of kill 
from both clinical in vivo studies and the in vitro recrudescence assay.  
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Figure 3.3: Bioluminescence signal loss following drug perturbation is time-dependent  
Plot of the time-dependent changes in mean fraction of Luciferase RLU ± stdev (n = 3) exposed to 3xIC50 
doses of the indicated antimalarial drug; artemether (ART, rapid rate of kill), azithromycin (AZ, slow rate of 
kill), dihydroartemisinin (DHA, rapid rate of kill) and chloroquine (CQ, fast rate of kill) (Hasenkamp et al., 
2013). 
 
Based on this proof-of-principle regarding the potential application of a bioluminescence-
based monitoring of initial rate of kill, the work described in the following chapter sets 
out to;  
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1.  Validate that the bioluminescence response immediately following antimalarial 
drug treatment reflects an actual loss in viability of parasites, and   
2. develop and test a plate-based assay format to estimate the initial rate of kill using 
this bioluminescence assay.  
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3.2. Results  
 
3.2.1 The bioluminescence response following drug treatment is both time and dose-
dependent 
 
Hasenkamp et al. (2013) have previously shown a time-dependent loss of 
bioluminescence signal following Dd2luc exposure to the rapid acting cytocidal drugs DHA, 
ART and CQ for 6 hours. By contrast, the same study reports that exposure to the 
cytostatic drug AZ results in no apparent loss in bioluminescence signal over the same 
timeframe. To extend this observation to include the dose-dependent effect, Dd2luc 
parasites were exposed to equipotent doses of two antimalarial drugs, CQ and ATOVA. 
CQ is a fast acting compound known to exert an immediate cytocidal effect on 
trophozoites. ATOVA is a slow acting compound, with a 48hr lag in its action during which 
it is primarily cytostatic. During drug incubation, samples were removed at 2hr intervals 
and the loss of bioluminescence signal, compared to an untreated control plotted (Figure 
3.4). As expected, Dd2luc exposure to the rapid acting cytocidal drug CQ for eight hours 
showed both a dose and time-dependent loss of bioluminescence signal, whilst the 
bioluminescence signal from parasites exposed to increasing doses of the cytostatic drug 
ATOVA is essentially unaffected over this time. These data supports the contention that 
the bioluminescence assay can differentiate between the cytocidal and cytostatic effect 
of antimalarial drugs.  
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Figure 3.4: Dose and time-dependent effect on luciferase signal following drug perturbation 
The dose and time-dependent effect on luciferase signal exposed to multiples of IC50 doses (i.e. 81xIC50, 
27xIC50, 9xIC50, 3xIC50, 1x IC50) for a fast acting cytocidal CQ (IC50 = 208.8nM) and slow acting cytostatic 
ATOVA (IC50 = 4nM). Samples were removed and luciferase signal was measured at 0hr, 30minutes, 1hr, 2hr, 
3hr, 6hr and 8hrs respectively. The luciferase signal obtained in relative light units (RLU) was normalised to 
untreated control and the dose/time response curves were plotted in  GraphPad Prism v5.0 (GraphPad 
Software, Inc., San Diego, CA). Each data point represents mean RLU ± stdev (n>9). 
3.2.2 Correlating the loss of bioluminescence signal following drug treatment with the 
loss of parasite viability 
 
As described in chapter 1, and illustrated by Sanz et al., (2012), the assumption that in 
vitro measurements of metabolic activity act as a direct proxy for parasite viability is 
vulnerable to artefacts;  whilst parasite metabolism and viability are apparently coupled 
during the life cycle of the parasite, these  may be uncoupled following drug treatment. 
Recently, in vitro assays to measure the loss of parasite viability following drug treatment 
have been reported by Sanz et al., (2012) and Paguio et al., (2011). The Sanz assay utilises 
a drug bolus (multiples of 24 hours), washing off the drug and regrowth of viable 
parasites. This assay provides a low to medium throughput of PRR, PCT and lag phase 
 75 
 
data for antimalarial compounds. By contrast, Paguio reports a 6hr drug bolus-wash assay 
more amenable to scale up for high throughput screening that measures the 50% lethal 
dose (LD50) concentration using a fluorescent DNA intercalating dye SyBr Green-1. The 
drug is extensively washed and the surviving parasites are allowed to recommence 
growth in the absence of drug pressure (+42 hours) for one cell cycle (Figure 3.5A). Thus, 
both these assays measure parasite viability as opposed to metabolic activity. 
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Figure 3.5: Protocols for the determination of in vitro LD50.  
(A) Illustrates schematic of the Paguio’s protocol for the determination of in vitro LD50. (B) Modified bioluminescence protocol to measure in vitro effective dose 
(ED50
6hr
), Lethal dose (LD50
48hr
) and Inhibitory concentration (IC50
48hr
) using both luciferase and SyBr-Green-I fluorescence. Both bioluminisence (Luc) and fluorescence 
(SYBR) green signals for ED50
6hr
 were immediately captured following drug bolus (6hr incubation at 37
0
C). Samples for IC50
48hr
 (before drug wash step .e.g. IC50 requires 
continuous presence of drug for full 48hrs), was removed (incubated for an additional 42hrs). The remaining sample was washed to remove the drug and was also 
incubated for an additional 42hrs to determine LD50
48hr
 (LD50 only requires a drug bolus for 6hrs)
 
 
 
 
 
A B 
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To determine here whether the immediate loss of bioluminescence measures a loss in 
parasite viability, Paguio’s protocol was modified (Figure 3.5B). This modified 
experimental approach offers an opportunity to compare and contrast a range of 
experimental variables; e.g. LD50
48hr against IC50
48hr as well as bioluminescence against 
fluorescence assay and provide an additional opportunity to correlate how the immediate 
loss of bioluminescence signal ED50
6hr (effective dose at 6hr) compares to these variables. 
To reflect a range of chemotypes and mode of drug action, different antimalarial drugs 
were selected which includes the 4-aminoquinoline CQ , the 8-aminoquinoline TFN, the 4-
methanolquinolines mefloquine MEF and QN, the bisquinoline piperaquine PPQ, the 
sesquiterpene lactones DHA and ART and a napthoquinone ATOVA. Using this protocol, 
early trophozoite stage Dd2luc parasites were exposed to a serial dilution of the selected 
antimalarial drugs in a 6hr drug bolus. The drugs were extensively washed after this 
period and the remaining parasites were allowed to recommence growth in the absence 
of drug pressure for an additional 42 hours (48 hours in total) as described above. The 
principle of this assay is that parasites killed during the drug bolus will not divide after 
removal of the drug, whereas those inhibited by the drug will recommence growth on 
removal of drug pressure. Three log dose-response curves, normalised against untreated 
controls, were fitted using data derived from either a bioluminescence assay (Luc) or 
malaria SyBr Green I fluorescence (MSF) assay of DNA content. These curves (Figure 3.6) 
report the following parameters (Table 3.2); a 50% effective dose recorded immediately 
following the drug bolus but prior to drug wash-out (ED50
6hr), a 50% lethal dose estimate 
following drug wash out and re-culture (LD50
48hr) and a 50% inhibitory concentration 
estimate following 48hr of continuous culture in the presence of the drug (IC50
48hr). 
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Figure 3.6: In vitro ED50
6hr
, LD50
48hr
 and IC50
48hr
 determination using luciferase and SyBr-Green-I (MSF) assay formats.  
Each page reports four drugs (indicated on the left-hand panel in each pair), with pairs of graphs reporting the bioluminescent (Luciferase) and Malaria Sybr Green-I 
fluorescence (MSF) data normalised to an untreated control. The data shown is a mean ± Stdev from three biological replicates (n>9 measurements in nM, nd-not 
determined). See also Table 3.2.  
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Table 3.2: Estimates of ED50
6hr
, LD50
48hr
 and LD50
48hr 
using the bioluminescence and MSF assay formats 
These data for ED50
6hr
, LD50
48hr
 and LD50
48hr 
obtained from the curves plotted of luciferase and MSF assays of indicated antimalarials in Figure 3.6. 
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As expected, the majority of drugs show a right shift in the lethal dose curve compared to 
that of the inhibitory dose, reflecting the shorter duration of action of the drug. The lack 
on an apparent shift for the artemisinins DHA and ART likely reflects their formation of 
covalent adducts with their target(s), rendering them resistant to the wash steps (Paguio 
et al., 2012). The IC50
48hr and LD50
48hr assay data developed using either the MSF or 
bioluminescence assay are essentially identical, unlike those data reported immediately 
following the 6hr drug bolus (ED50
6hr). Here, the intrinsic instability of the luciferase 
reporter protein (t½ of approximately 1.5hr) compared to that of the far more stable DNA 
biomarker, offers a more dynamic report of drug action (Hasenkamp et al., 2013). 
Critically, the ED50
6hr values determined using bioluminescence assay is almost identical to 
the LD50
48hr estimated using either assay formats. This, and the observation that the 6hr 
bioluminescence curve closely fits that of the lethal dose curve for the majority of drugs, 
suggests that the 6hr bioluminescence response provides a rapid surrogate determination 
of the lethal action of these drugs. The sole exception, ATOVA, shows no reduction in the 
bioluminescence signal within 6hr, a reflection of its cytostatic action within the first 
intraerythrocytic cycle of its application, commonly reported as a delayed death 
phenotype (Sanz et al., 2012).  
To provide additional confirmation that loss of bioluminescence correlates with loss of 
viability, the assay was repeated using CQ, QN, MEF, DHA and ATOVA at three equipotent 
doses corresponding to 1x, 3x and 9xIC50 for a 6hr bolus and the luciferase signal 
measured at this time. The drug then removed by extensive washing before replacing the 
parasites into culture for an additional 42hr to complete a cycle of intraerythrocytic 
development and the luciferase signal was remeasured. The bioluminescent signal was 
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normalised to an untreated control at the same time point, plotted against drug dose 
(Figure 3.7). The expectation here is that the 6hr luciferase signal immediately following 
drug treatment will be the same as that after the drug wash and regrowth i.e. the 
apparent 6hr lethal effect is the same as the real lethal effect observed after regrowth of 
parasites on removal of drug pressure.  
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Figure 3.7: Loss of bioluminescence correlates with loss of viability 
The bioluminescence
6hr
 signal compared against the bioluminescence
48hr
 signal, obtained after drug removal 
using equipotent doses. Each data point represents mean RLU ± stdev (n=9). 
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The 6hr bioluminescence response appears to provide a rapid surrogate determination of 
the lethal action of CQ, MEF and QN. As expected (i) ATOVA shows no reduction in the 
bioluminescence signal within 6hr, with only moderate effects after 48hr mirroring what 
is known about the delayed death phenotype for this class of drug and (ii) the resistance 
of DHA to removal is illustrated by the continued loss of bioluminescence signal at 48hr. 
Importantly, comparison of the loss of bioluminescence for drugs used at equipotent 
doses  suggests that a ranking order for their effect on loss of viability (at both 6hr and 
48hr) can be measured, and these apparently correlate with their known relative rates of 
kill. 
Finally, confirmation of the loss of parasite viability during the 6hr drug bolus was 
independently verified following morphological inspection of Giemsa-stained thin smears 
of drug-treated parasites. Early trophozoite stage parasites under the same experimental 
conditions were exposed to a fixed dose of 9xIC50 of the drug under investigation for 6hr 
and images were obtained by light microscopy. In comparison to the untreated control, 
DHA and CQ reveal almost exclusively condensed pyknotic parasites (Figure 3.8). Thus, 
the observed loss of viability as determined using the bioluminescence assay is mirrored 
in the very poor morphology of parasites after this length and dose of drug treatment. 
Parasites treated with ATOVA for the same length and equipotent dose (Figure 3.8), 
however, show little difference in gross morphology compared to the untreated control – 
again mirroring the observation in no apparent loss in bioluminescence at this time and 
dose of drug. This independent evidence offers a cautionary tale in the applications of the 
bioluminescent assay for slow acting drugs (i.e. ATOVA) but further strengthens the 
hypothesis that the loss of bioluminescence is a measure of loss of parasite viability.  
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Figure 3.8: Morphological inspection of drug-treated parasites  
Light microscopy images of Geimsa-stained thin blood smears of an untreated control and drug-treated 
trophozoite stage parasites (9xIC50 for 6hr).  
 
3.2.3 The dose and time-dependent loss of bioluminescence following drug treatment 
correlates with the known rate of kill of benchmark antimalarial drugs  
 
As shown above in figure 3.4, a saturation effect is apparent beyond the 6hr window (i.e. 
8 hours) at higher concentrations. This suggests that the 6hr window is sufficient to 
obtain the most useful information regarding the activity of rapid acting drugs. Notably 
some discrimination between the rapid killing profiles of DHA and CQ is apparent, an 
important observation given the specific noting of these drugs in the TCP1 of SERCaP. To 
effectively capture these killing profiles and compare the relative time and dose-
dependent effects of different antimalarial drugs within the 6hr window, a revised 
bioluminescence assay was devised that utilised fold-changes in IC50 concentrations to 
ensure exposure to equipotent doses of drug. Dd2luc parasites were exposed to a three-
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fold serial dilution (81 to 0.33xIC50) for either 3 or 6hrs, plotted against drug dose. 
Bioluminescent signal was normalised to an untreated control at the same time point 
(Figure 3.9). 
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Figure 3.9: The dose and time-dependent effects of different antimalarial drugs 
The dose and time-dependent response curves for the indicated antimalarial drugs at 3hr (closed circles) and 
6hr (open circles) using multiples of IC50 doses (i.e. 81xIC50, 27xIC50, 9xIC50, 3xIC50, 1x IC50 and 0.3x IC50). Each 
data point represents mean RLU ± stdev (n=9). 
These data illustrate an apparent saturation in the lethal effect of drug doses greater than 
9XIC50 for all, except ATOVA, of the drugs tested. This observation is in agreement with 
the findings of Sanz et al., (2012) who suggest that a 10xIC50 dose produces the maximal 
rate of kill for the drugs they tested. Direct comparison between the data shown in figure 
3.9 describes an apparent relative ranking order of artemisinins > CQ > 4-
methanolquinolines > ATOVA. This is identical to the relative order of rates-of-kills 
described both in vivo and in vitro for the same drugs. To explore this correlation further, 
 86 
 
the in vitro estimates of Log PRR and PCT available from Sanz et al. (2012) were plotted 
against the bioluminescent signals produced at each time point and drug concentration 
and a linear regression analysis performed (Figure 3.10).  
Comparison of bioluminescence data against the PCT shows a strong and significant 
correlation at higher doses of the drug and on longer treatment i.e. 81 to 3XIC50 at 6hrs 
with p-values <0.01 (Figure 3.10A). Interestingly, the slope and intercept of the regression 
analysis is essentially unchanged at greater than 9XIC50
 doses reflecting an apparent 
saturation in the rate of kill achieved at these doses. Similarly, comparisons with the Log 
PRR show a strengthening trend with higher doses of drug and longer exposure times i.e. 
81 to 3XIC50 at 6hrs although these just fail to reach a level of significance (p values >0.05) 
(Figure 3.10B). One possible explanation for this is the relative lack of data for the PRR 
comparison as DHA is excluded from the analysis as it is reported as >108 in Sanz et al., 
(2012) and cannot be plotted here (whilst noting that it’s pseudo-positioning at 81XIC50 
follows the general observable trend). 
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Figure 3.10: Correlation of the bioluminescence against in vitro PCT and PRR 
Bioluminescence data (% of untreated control) plotted against available in vitro (A) PCT and (B) PRR (Sanz et al., 2012).  
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3.3 Discussion  
 
This chapter set out to demonstrate that the dynamic response of a bioluminescence assay 
offers a useful biomarker of parasite viability following drug treatment. The principle here is 
that a more dynamic response would be obtained in a bioluminescence assay upon initial 
drug perturbation as a result of the cessation of luciferase expression in dead and dying 
parasites, coupled with the turnover of the intrinsically unstable luciferase reporter protein 
(t½ of approximately 1.5hr, Hasenkamp et al., 2013). By contrast, the intrinsic stability of 
DNA, monitored using the fluorescent DNA-intercalating dye SyBr Green I, hampers any 
attempt at a short-term fluorescence-based monitoring of cell death. Simply put, dead 
parasites don’t make new protein, but they still retain (at least for 6hr) DNA. 
Previous work in the Horrocks laboratory has evaluated, compared and contrasted the 
application of MSF and luciferase assays in the determination of IC50 (Hasenkamp et al., 2012 
and Hasenkamp et al., 2013). Moreover, the application of luciferase assays to measure IC50 
in medium throughput screens of both intraerythrocytic and gametocyte stage P. falciparum 
have been described (Adjalley et al., 2011; Che et al., 2012; Cui et al., 2008; Ekland et al., 
2011; Franke-Fayard et al., 2008; Lucumi et al., 2010; Lucantoni et al., 2013). The luciferase 
assay format, compared to fluorescent assays of DNA content, offers significant advantages 
in terms of the signal to noise ratio with the luciferase assay offering dynamic ranges 
typically exceeding 250 compared to 4-5 achieved using MSF assay (Hasenkamp et al., 2013). 
Critically, however, in screening for IC50 potency, the reliability of the MSF assay format 
(determined as Z’ scores), being essentially the same as that for luciferase assays, coupled 
with its much cheaper cost means that high throughput screening with luciferase is 
economically unfeasible. Another key limitation is the need to GM the parasite strain for 
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luciferase assays; a limitation that is shared in the bioluminescence rate of kill assay 
described here, and will be discussed below.   
The object of the work described in this chapter was to evaluate the potential for a 
bioluminescence assay to measure a distinct pharmacodynamics property, the rate of kill. 
Here, the dynamic response offered by the luciferase reporter offers an opportunity to 
quickly monitor the initial rate of kill – something which cannot be offered by the available, 
albeit cheaper, fluorescence assay. A number of key observations were made. 
First, that the loss of bioluminescence signal is both time and dose-dependent. This 
provides for a means to compare the loss of bioluminescence exposed to equipotent doses 
of different drugs, allowing for a ranking order to be determined. The assay, as described 
here, doesn’t provide a rate of kill in terms of the currently used parameters of PRR and PCT, 
rather it provides for a relative rank of initial rate of kill. The incorporation of benchmark 
drugs, current antimalarials with known PRR and PCT, does provide for an opportunity to 
rank an unknown drug against these benchmarks (and is the topic of the rest of this thesis).  
A limitation revealed here is the apparent lack of response in this assay to drugs that affect a 
slow rate of kill – whether intrinsically slow in mediating their cytocidal effect or displaying a 
lag-phase (i.e. ATOVA). Here, the maximal 6hr window of the assay doesn’t offer sufficient 
time for slower acting drugs to affect a loss in bioluminescence. Thus, the utility of the 6hr 
assay appears limited to drugs with a moderate to fast rate of kill (i.e. PPR>103.5). This limit is 
imposed by the temporal luciferase expression at the trophozoites stage. The 6hr window 
was extended to 12 hours (data not shown). However, analysis of a fall in bioluminescence 
signal caused by loss of viability overlapping with the concurrent temporal loss of luciferase 
expression as the parasites complete S-phase and move into schizogony was difficult (Wong 
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et al., 2011; Hasenkamp et al., 2013). This suggests that whilst the current 6hr assay is useful 
to estimate the rate of kill of fast acting schizonticide antimalarial drugs, it cannot currently 
be used to measure rate of kill in other stages (i.e. rings stage). This issue will be picked up 
again in chapter 5. That said, this assay does provide a means to identify and discriminate 
between the initial rates of kill of moderate to fast-acting drugs – the intended class of 
compounds of interest for a TCP1 component of a potential future SERCaP. 
Second, that the loss in bioluminescence reports the loss in parasite viability. Confirmation 
of the loss of parasite viability during the 6hr drug bolus was independently verified exposing 
Dd2luc parasites to a modified lethality assay adapted from that originally described by 
Paguio et al., (2011) as well as following gross morphological examination of the drug-
treated parasites. In the Paguio bolus-wash-regrowth assay, the LD50
48hr was measured using 
both a luciferase and MSF assay and compared to the ED50
6hr i.e. the bioluminescence 
response immediately following drug treatment (and before any drug washing steps). 
LD50
48hrstrongly and significantly correlates with the ED50
6hr (Figure 3.11). In other work in 
the laboratory (Ali and Horrocks, pers comm), the cytocidal effect of CQ at 9XIC50 has been 
confirmed using both a TUNEL assay of DNA fragmentation and by ultrastructure 
examination using transmission electron microscopy. This latter study reveals extensive 
vacuolization in cytoplasm and loss of digestive vacuole integrity as previously described by 
Ch'Ng et al. (2011) following exposure of P. falciparum to high doses of CQ. Together, this 
evidence suggests that the cytocidal potential of antimalarial drugs certainly plays a role in 
the rate of kill. This also validates that the 6hr bioluminescence response curves are a 
characteristic of “lethal effect” of a drug rather than an “inhibitory effect” on the parasites. 
Importantly, given previous issues regarding the uncoupling of parasite metabolism and 
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growth following drug perturbation (Sanz et al., 2012), the bioluminescence assay described 
here directly measures antimalarial drug activity - providing a rapid distinction between 
cytocidal fast acting and cytostatic slow acting drugs.  
 
0.11
Figure 3.11: Comparison of ED50
6hr
 against LD50
48hr
 
 Linear regression analysis of the bioluminescence ED50
6hr
 against LD50
48hr
 in Dd2
 
parasite clone obtained using 
either MSF (blue) or luciferase (green) assays.  
 
 
Third, the relative order in rate of kill provided by the bioluminescence assay correlates 
with available in vitro and in vivo PRR and PCT data. The bioluminescence assay data 
describes an apparent relative ranking order of artemisinins > CQ > 4-methanolquinolines > 
ATOVA. This relative ranking has been observed in both in vitro and in vivo studies of the 
pharmacodynamics of antimalarial drug action in P. falciparum (Sanz et al., 2012; White, 
1997). Pukrittayakamee et al. (2000) evaluated the therapeutic responses of known 
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antimalarial drugs in P. vivax, which illustrates the same relative order as indicated above. P. 
vivax is not sequestered markedly in the microcirculation and thus PRR represents a more 
readily determined measure of antimalarial drug activity. The relative order of 
bioluminescence data also correlates with the in vivo PRR data of Pukrittayakamee et al., 
(2000) and this essentially suggests that bioluminescence directly measures parasite 
viability. Sanz et al., (2012) has shown that in vitro rate of kill data of antimalarial drugs 
correlate with the standard in vivo PRR and PCT data. The bioluminescence data developed 
here shows a direct correlation with Sanz et al., (2012) in vitro PCT and PRR data (Figure 
3.10). At 6hrs, comparison against PCT data illustrates a strong and significant correlation at 
higher doses of the drug as described above (Figure, 3.10A). Comparisons with the Log PRR 
show a strengthening trend with higher doses of drug and longer exposure times, although 
these just fail to reach a level of significance. The limitations here appear to be the available 
shared data (artemisinins are excluded as Log PRR only reported as >8) and the limited 
distribution in Log PRR for the quinoline drugs used here.  
It has been previously shown by Sanz et al., (2012) that rate of kill has no correlation with 
IC50 values. This is perhaps best illustrated by artemisinin and atovaquone, both drugs with 
single digit nM IC50, yet very different rates of kill. To further explore this correlation, the in 
vitro estimates of Log PRR and PCT were correlated against the IC50
48hr and LD50
48hr data 
developed using the MSF assay (Figure 3.12). Note only MSF data used here because the 
IC50
48hr and LD50
48hr assay data developed using either the MSF or bioluminescence assay are 
identical as described above (Figure 3.6, see  also Table 3.2).  
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Figure 3.12: Comparison of rate of kill against IC50 and LD50 
Linear regression plots of (A) IC50 and (B) LD50 plotted against available in vitro PCT and Log PRR data (Sanz et 
al., 2012). 
 
Comparison of this PCT/ PRR data illustrates no significant correlation with the IC50 potency 
of antimalarial drugs (Figure 3.12A). The finding with respect to IC50 is, not unexpectedly, in 
agreement with that originally described in Sanz et al., (2012). Comparison with LD50, 
however, extends this analysis, and also shows no significant correlation with the available 
PCT and PRR data (Figure 3.12B). Whilst the action of the drug in 6hrs likely solely represents 
the immediate cytocidal activity of antimalarial drugs (remembering that ED50
6hr is 
essentially the LD50), the IC50 reports a mixture of both the cytostatic and cytocidal activity of 
A 
B 
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drugs over 48hrs (See section 1.9 in introduction). In table 3.2, the LD50 for the artemisinins 
DHA and ART is reported as the same as their IC50. One explanation for this is that the drug 
binds covalently to its target and is thus resistant to washing – however, the ED50
6hr (i.e. 
LD50) is determined before the wash steps and suggests that the profound rate of kill has 
already been achieved within the first 6 hours. This contrast with atovaquone, where the 
LD50 is many-fold higher than the IC50, primarily as a result of the delay in kill. The other 
benchmark drugs apparently fall between these two extremes. To explore whether a ratio of 
LD50/IC50, capturing the inherent differences between cytocidal and cytostatic effects of 
drugs (as proposed by Paguio et al., 2011) instead correlates with rate of kill, these ratios 
were determined (Table 3.3) and correlated with the available PRR and PCT data (Figure 
3.13). 
 
10
Table 3.3: Ratios of IC50 and LD50/ED50  
Ratios of IC50 and LD50/ED50 (in Dd2 clone) for the given antimalarial drugs are reported. The data shown is a 
mean ± Stdev from three biological replicates (n>9 measurements in nM, nd-not determined). 
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Figure 3.13: Comparison of LD50/IC50 ratios against Rate of kill  
Linear regression plots of available in vitro PCT and Log PRR compared against both the luciferase and MSF 
ratios of IC50
48hr
 and LD50
48hr
 - Note all the ratios determined either using MSF or luciferase data are obtained 
using Dd2 clone (see Table 3.3).  
 
Comparison of PCT against the IC50/LD50 ratios illustrates a strong and significant correlation 
(Figure 3.13). As expected, based on previous correlations of limited PRR data, there is a 
clearly emerging trend between IC50/LD50 ratios and PRR (Figure 3.13). Nevertheless, this 
PRR correlation is clearly stronger than that observed against either IC50 or LD50 data alone. 
This observation is potentially promising. The bioluminescence assay is only applicable in GM 
parasites expressing the luciferase reporter gene and thus, it cannot be adapted as a 
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screening tool against field isolates. The LD50/IC50 fold change in non-GM parasites could, 
however, provide a surrogate measure of rate of kill. However, given the requirements for 
multiple wash steps and plating it will not be readily applicable for a HTS system.  
Work described here provides a validation of a bioluminescence rate of kill assay that can 
quickly and reliably provide relative ranking data for fast to moderately acting drugs that 
could identify leads for TCP1 compounds. The simplicity of the assay and its inherent 
capacity to be scaled suggests that it offers a tool that would assist in the identification of 
leads for further development. This opportunity is explored in subsequent work described in 
this thesis that utilises the “MMV Malaria Box”.  
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CHAPTER 4: Screening the Malaria Box Using a Rapid In Vitro Bioluminescence 
Rate of Kill Assay 
 
4.1 Introduction   
 
The demonstration of rapid development and global spread of resistance by P. falciparum to 
front-line therapeutics identifies a constant need for the discovery of new chemotypes to 
feed the pipeline of antimalarial drug development (Burrows et al., 2012; Kim et al., 2015; 
Spangenberg et al., 2013). This pressing need has been supported over the last five years by 
the Genomics Institute of the Novartis Research Foundation (GNF, San Diego, California, 
USA), GlaxoSmithKline (GSK, Tres Cantos, Spain) and St. Jude Children’s Research Hospital 
through the phenotypic screening of over six million compounds. This screen yielded some 
20,000 hits (Spangenberg et al., 2013) that exhibit sub-micromolar potency against the blood 
stage of the malaria parasite P. falciparum and have been made available to the wider 
scientific community (Gamo et al., 2010; Guiguemde et al., 2010; Meister et al., 2011; 
Plouffe et al., 2008; Spangenberg et al., 2013). To support academic and industry efforts in 
antimalarial drug discovery, the structure of these chemical starting points have been 
deposited in the open access ChEMBL database (www.ebi.ac.uk/chemblntd). These efforts 
have resulted in significant progress over the past decade, with many new chemical entities 
entering the pipeline for antimalarial drug development (see Table 1.5 in introduction) 
(Wells et al., 2015).  
However, exploiting these screening efforts have been hampered by the unavailability of 
physical samples of these compounds to the wider research community for further 
validation and follow-on studies. To make this collection of over 20,000 compounds more 
accessible for researchers across the globe and to offer a more manageable and presentable 
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set of compounds, the MMV implemented a step-by-step approach to refine a pool of these 
compounds as a freely available community resource termed the “Malaria Box”. The initial 
resource included compounds from St Jude’s (1536 compounds), GSK (13519 compounds) 
and Novartis (5708 compounds) (Gamo et al., 2010; Guiguemde et al., 2010; Meister et al., 
2011). Initially, any compound with a molecular weight >1000 and/or any compound with 
greater than 20 rotatable bonds was removed from these libraries. These datasets were 
then compared to remove any interdataset structure duplicates and some 19876 structurally 
unique compounds present in the three libraries were identified as a compound pool for 
further selection (Figure 4.1A). Analysis of the chemical diversity within these three libraries 
showed that they occupied an almost similar property space. The GSK library, however, 
showed the greatest chemical diversity, explained simply by it being the largest dataset 
among the three of them (Spangenberg et al., 2013). To ensure commercial availability, 
these compounds were searched using the eMolecules website (Rishton, 1997), identifying 
5034 to be readily accessible for follow-up experiments (Spangenberg et al., 2013).  
The drug-like compounds were selected from the commercially available hits (Figure 4.1B) 
considering their compliance with the Lipinski's Rule of 5 (Ro5); physiochemical properties 
that predict acceptable oral absorption (Lipinski et al., 2001; Spangenberg et al., 2013). 
Known toxicophores were removed applying substructure filters and compounds which met 
the criteria of these filters were included in the drug-like set while those failing one or more 
of these filters were assigned to the probe-like category (Spangenberg et al., 2013). This 
analysis split the compounds into drug-like and probe-like categories, each representing 
2693 and 2341 compounds, respectively. 
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Figure 4.1: The initial selection process of St Jude’s, GSK and Novartis antimalarial datasets 
 (A) Shows the overlap of structures within each screening library and (B), profiling of the compounds based on 
physiochemical properties between the three available libraries (Source modified from Spangenberg et al., 
2013). 
To provide a manageable, representative library, the drug-like and probe-like compounds 
were subjected to further analysis with the aim to provide a good balance between potency 
and chemical diversity. With the emphasis on maximising chemical diversity, the inclusion of 
near neighbours or matched molecular pairs was attempted given that they display a 
significant distinct antiplasmodial activity. Finally the ability of 300 drug-like and 300 probe-
like compounds to inhibit the growth of P. falciparum 3D7 and K1 strains was tested using a 
DAPI (4-6-diamidino-2-phenylindole) stain and fluorescent high content imaging assays 
(Duffy and Avery, 2012; Spangenberg et al., 2013).  
Following confirmatory screening of the over 600 compounds in P. falciparum, their 
cytotoxicity (CC50) was measured in the HEK-293 cell line. Of these, a total of 459 compounds 
showed an activity of at least 4 µM against P. falciparum 3D7 and a selectivity ratio of at 
least a 10-fold over the cytotoxicity assay, thus meeting the criteria set by the MMV. Firstly, 
a collection of 200 drug-like were selected through consultation with a group of experienced 
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medicinal chemists (a process termed “wisdom of the crowd”) from the drug-like 
confirmatory set and then the remaining 200 compounds were assigned to the probe-like 
category. This collection was finally assembled into the “Malaria Box (Figure 4.2).  
 
0.2
Figure 4.2: The MMV selection process for the 400 Malaria Box compounds 
(Source- Spangenberg et al., 2013). 
MMV provides this “Malaria Box” resource, containing 200 diverse drug-like compounds as a 
freely available resource of starting points for oral drug discovery and development with the 
200 diverse probe-like compounds provided for use as biological tools in malaria research 
(Burrows et al., 2012; Paiardini et al., 2015; Spangenberg et al., 2013). However, it is noted 
that some of the probe-like compounds might be compliant with the Lipinski's Rule of 5 and 
hence could serve as starting points for drug discovery programmes (Spangenberg et al., 
2013).  
Given the importance of the MMV Malaria Box as a resource to the drug discovery 
community, and an interest of this study in exploring the potential for scaling up the 
application of bioluminescence rate of kill assay, here the use of this assay to identify 
 102 
 
compounds in this resource that are most likely to meet the TCP1 criteria (rapid rate of 
action) is described. This study also explores the potential for scaling the bioluminescence 
rate of kill assay to enable initial screens of larger sets of compounds, for which only limited 
IC50 data is available, in an attempt to reconcile where this assay could fall in future hit 
and/or lead discovery programmes. 
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4.2 Results  
 
4.2.1 Determination of the 50% inhibition concentration (IC50) using the Malaria Sybr 
Green I Fluorescence (MSF) assay 
The application of a microplate-based bioluminescence assay to rapidly identify compounds 
that exert an immediate and rapid rate of-kill against Dd2luc was explored using the 
compounds set available in the MMV Malaria Box. For these 400 compounds the only IC50 
data available is that for genetically-distinct P. falciparum clone 3D7 (www.mmv.org). Using 
a 48hrs MSF assay (see section 2.3.5), IC50 data were developed in the Dd2
luc clone for 396 of 
these compounds; the remaining four compounds omitted as insufficient material was 
available. The IC50 values were obtained from log dose-response curves, with example data 
shown in Figure 4.3. The full set of IC50 data are reported in Table 4.1. These IC50 data have 
been submitted to ChEMBL –Neglected Tropical Disease Open Access Repository.  
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Figure 4.3: Exemplars of log dose response curves for the Malaria Box compounds 
Log dose response curves show determination of IC50 for the indicated Malaria Box compounds. Each data point 
represents the mean with standard deviation (from three biological repeats n=9) indicated by error bars. 
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COMPOUND_ID IC50 
(nM) 
COMPOUND_ID IC50 
(nM) 
COMPOUND_ID IC50 
(nM) 
COMPOUND_ID IC50 
(nM) 
COMPOUND_ID IC50 
(nM) 
MMV019066 976.8 MMV665876 337.7 MMV665891 2001 MMV007617 1494 MMV018984 775.1 
MMV665941 217.6 MMV666023 40.91 MMV665899 1189 MMV665796 1445 MMV000911 1207 
MMV396680 327.7 MMV009063 277.9 MMV665961 424.8 MMV665906 2354 MMV007430 901.3 
MMV666601 489.3 MMV006558 296.8 MMV665929 420.5 MMV665954 1694 MMV007977 1186 
MMV008294 538.5 MMV007160 38.19 MMV666108 1026 MMV019738 1672 MMV020654 701.2 
MMV011259 136.9 MMV006429 160 MMV665948 2992 MMV666075 1100 MMV665883 506.3 
MMV019406 141.3 MMV396703 373 MMV006188 878.1 MMV666070 468 MMV084940 732.5 
MMV006278 2769 MMV006937 1780 MMV001230 2701 MMV142383 4146 MMV396715 262.8 
MMV666688 594.3 MMV085203 9.98 MMV665918 541.2 MMV000788 573.2 MMV000963 90.59 
MMV019110 3500 MMV665820 958.5 MMV665799 810.5 MMV000561 1159 MMV006319 543.8 
MMV006427 298.3 MMV665841 2573 MMV665826 1266 MMV000248 403.8 MMV000972 1027 
MMV666062 397.1 MMV007116 646.9 MMV665807 1088 MMV665879 752.8 MMV020490 1225 
MMV020885 366.5 MMV007384 715.3 MMV665946 1240 MMV665890 903.8 MMV001318 3587 
MMV000570 316.1 MMV020548 664.9 MMV665935 3991 MMV666116 646.7 MMV007978 2719 
MMV020439 468.1 MMV019258 351.4 MMV666102 1239 MMV006913 1484 MMV020660 1328 
MMV396672 466.7 MMV007686 7278 MMV666061 501.8 MMV008127 1487 MMV665904 929.8 
MMV019871 334.7 MMV011256 302.4 MMV008149 82.67 MMV403679 993.8 MMV396632 1301 
MMV085583 179.4 MMV666693 426.4 MMV019074 1854 MMV006545 870.5 MMV007875 1181 
MMV008416 825.3 MMV008956 120.1 MMV665914 913 MMV019700 559.2 MMV006820 1413 
MMV665874 1241 MMV665827 276.3 MMV665798 885.1 MMV019670 741.8 MMV396749 239.4 
MMV006203 308.9 MMV001038 986.6 MMV665902 1106 MMV001344 1883 MMV011576 512 
MMV665977 447.6 MMV007839 369.5 MMV665888 201.7 MMV011795 959.3 MMV020651 1739 
MMV020549 242.1 MMV000662 1258 MMV666067 1188 MMV019124 521 MMV000483 653.5 
MMV001246 1798 MMV396678 1451 MMV665939 1045 MMV006767 883.6 MMV019266 844.4 
MMV666607 241.6 MMV006861 586.7 MMV009060 513.9 MMV007808 365.1 MMV001049 1076 
MMV665915 514.6 MMV006457 719.8 MMV666110 1462 MMV019017 651.8 MMV665806 483.5 
MMV007695 244.4 MMV396693 606.9 MMV019758 614.1 MMV396681 2181 MMV667487 158.3 
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Table 4.1: Reports IC50 data of the 396 Malaria Box compounds obtained using host strain Dd2
luc
. 
These data have been reported back to MMV and provided to the ChEMBL database. 
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4.2.2 Screening the Malaria Box for compounds that exert an immediate rapid rate of 
kill using a single-dose/single timepoint triage assay  
 
Data shown in chapter 3 indicates that compounds that exert a slow rate of kill report 
little or no change in the bioluminescence signal over the 6hr window used in this assay. 
To identify, and exclude, these apparently slow-acting compounds, 370 compounds from 
the MMV Malaria Box were subjected to an initial single-dose/single-time point triage 
assay utilizing a 9XIC50 concentration of drug for 6hrs, with normalised bioluminescence 
signal then plotted against the corresponding IC50 (Figure 4.4). A total of 30 compounds 
were omitted from this screen as insufficient material was available from the MMV 
Malaria Box for this and subsequent experiments as the IC50 of these compounds were 
very high (i.e. >2500nM). To prioritise the rapid rate of kill compounds to take them 
forward for a full analysis, a threshold of 70% of the normalised bioluminescence signal 
was used (i.e. compounds that exert an apparent >30% loss in viability in 6hrs). This 
threshold was selected because it reflects the midway response between quinolones and 
atovaquone and provided an exclusion criterion for approximately half of the available 
compounds.  
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Figure 4.4: Initial rate of kill against the IC50 potency for the Malaria Box compounds 
Scatterplot indicating the initial rate of kill data (9XIC50 concentration of drug for 6hrs) against the IC50 potency for 370 compounds in the Malaria Box. The threshold 
line (70% of untreated control) is indicated using a dotted line. The filled black circles represent known antimalarial drugs, pink and blue circles shows drug-like and 
probe-like compounds, respectively. Each data point represents mean from three biological repeats (n=9). 
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As expected, based on a similar observation by Sanz et al. (2012), there is no apparent 
correlation (r2=0.041) between these initial estimates of rate of kill using the single 
time/dose triage assay and the IC50 of these compounds. Based on this single triage assay, 
31 compounds in the MMV Malaria Box would appear to initially meet the ideal target of 
a rate of kill at least as fast as artemisinins (i.e. data points falls below DHA on y-axis). Of 
note, however, is the limited potency of these compounds, with a mean IC50 of 1340nM 
(range 239-4156) with only four compounds with an IC50 of less than 500nM.  
4.2.3 Exploring the fast acting compounds  
 
To fully explore the relative rate of kill of these 192 faster acting compounds, 
bioluminescence assays were carried out at 3 and 6hrs, using a three-fold serial dilution 
of compounds between 9 to 0.33XIC50. This range was selected to monitor the range of 
rates of kill without the saturation effects observed at higher concentrations as previously 
described in Chapter 3 (Section 3.2.3). An additional 25 compounds from above this 
threshold (i.e. exerted less than a 30% reduction in bioluminescence signal in the triage 
assay) were included in the full analysis with the aim of confirming their apparent slow 
rate of kill in the full bioluminescence rate of kill assay. Log dose-normalised 
bioluminescence signal plots for all 217 MMV Malaria Box compounds, as well as 7 
antimalarial drugs, to act as benchmarks were determined. Representative data are 
shown in Figure 4.5, with the full dataset provided at the end of this thesis in appendix 1. 
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Figure 4.5: Exemplars of estimated fast and slow RoK  
Exemplars of estimated “fast RoK” (MMV665891 and MMV396749) and “slow RoK” (MMV666607). MMV 
Malaria Box candidates against a set of benchmark controls (chloroquine, dihydroartemisinin, atovaquone, 
mefloquine, quinine and piperaquine) are shown. Note – the full dataset developed for 217 MMV Malaria 
Box compounds is provided in Appendix 1. 
 
As expected, the selected fast acting Malaria Box compounds (below the 70% threshold) 
showed a time and dose-dependent loss of bioluminescence signal when exposed to the 
compound (e.g. MMV665891 and MMV396749). By contrast, all the 25 compounds 
predicted to have an initial slow rate of kill were confirmed as such in this more complete 
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analysis, with the normalised bioluminescence signal above 70% at both time points at all 
drug doses (e.g. MMV666607 in Figure 4.5 and a completed list provided in appendix 1).  
With data available for four concentrations at two timepoints for 217 compounds, a more 
meaningful analysis of the correlation between time and dose-dependent effects in this 
assay could be explored. Initially, correlations between bioluminescent signals following 
exposure to different doses of drugs were explored (Figure 4.6A and B); separating the 
data by their timepoint e.g. data developed for each concentration at 3hrs was compared 
against each other. Interestingly, whilst all correlations were highly significant (P<0.001), 
a clear pattern regarding the strength of each correlation emerged. Correlations were 
strongest when datasets for each concentration were compared to those closest to them, 
e.g. the 3xIC50 at both 3hr and 6hr correlates well with 9xIC50 and 1xIC50 than at 0.33xIC50. 
This is perhaps not unexpected given the previous observations regarding the dose-
dependent effect of the benchmark antimalarial drugs (except atovaquone) in this assay 
(See chapter 3, Figure 3.9).   
Correlation of bioluminescent signals following exposure to the same concentration of 
drug at the two different endpoints (3 and 6hr), show a strong (r2 between 0.82-0.83) and 
significant (all P<0.001) correlation between 3 and 6hr endpoints at 9xIC50, 3xIC50 and 
1xIC50 concentrations (Figure 4.6C). At 0.33xIC50 this correlation is weaker, with an r
2 of 
0.6, with the data clearly clustering together. This would suggest that at this low 
concentration of drug only minimal changes in the bioluminescence signal are achieved 
over the time of the assay. Inclusion of this dose, however, does reveal that very fast 
acting compounds (i.e. show a loss in bioluminescent signal greater than that for 
dihydroartemisinin) can be discriminated using this dose over the 3hr and 6hr used in this 
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assay (see datapoints distributed below and to left of dihydroartemisinin in Figure 4.6C 
0.33xIC50
 graph). 
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Figure 4.6: Correlation between time and dose dependent effects in the BRoK assay 
(A-B) Illustrates correlation between 9x IC50, 3x IC50, 1x IC50 and 0.3x IC50 at 3 and 6hrs respectively. (C) 
Comparisons of each concentration across 3 and 6hr endpoints. The filled black circles represent known 
antimalarial drugs, red and green open circles shows drug-like and probe-like compounds respectively. Note 
all correlations are significant i.e. p<0.0001. 
 
Together, these analyses support data presented in chapter 3 regarding the time and 
dose dependent loss of bioluminescence signal for compounds that affect a kill within 6hr 
of exposure to these trophozoite stage parasites. This assay appears to provide a rapid 
means to identify and rank fast acting compounds from the Malaria Box. However, to 
enable a simpler means to utilise the bioluminescence data derived at these different 
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doses and timepoints, a single value is needed that is representative of all four 
concentrations used at each timepoint would be preferred. To achieve this, a Principle 
Component Analysis (PCA) was carried out in collaboration with Dr Raman Sharma of the 
Liverpool School of Tropical Medicine (LSTM). 
4.2.4 Principle Component Analysis (PCA) of bioluminescence rate of kill assay data 
 
Note: All the PCA analyses shown in this work were conducted by Raman Sharma (LSTM), 
using data prepared and formatted by me. Subsequent analyses were done by me and Dr 
Sharma with all data presentation done by me.  
 To capture the concentration rate relationship in a single parameter, the dose/time/drug 
data was collected in a standard format and sent over to Prof. Biagini’s team with Raman 
Sharma conducting the PCA analysis. PCA transforms the original variable set into a new 
variable set of principle component’s that are totally uncorrelated to each other (Figure 
4.7). Principle components (PCs) are ordered by how much variability in the data they 
explain, with the first few PCs usually explaining the majority of the variance in all the 
variables. PCA is used to reduce dimensionality in the data set and also analyze the 
relationship between the variables. PCA was performed on the 0.3x, 1x, 3x and 9x IC50 
variables for the 3 and 6hrs bioluminescence assay endpoints using a KNIME analytics 
platform to reduce the dimensionality of these data sets (Michael et al., 2007), allowing 
the concentration rate relationship to be captured in one parameter.  
As suggested above, the first principle components should represent the majority of the 
variance in the data set, with the last representing the least. Table 4.2 reports the 
proportion of variance in each of the four principle components for PCA carried out on 
the 3hr and 6hr datasets, along with their cumulative sum of variance. Importantly here, 
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PC1 reports the vast majority of the variance in the bioluminescence rate of kill assays. 
PC1 explains 89% of the variance at 3hr end point and has roughly equal positive 
contributions from 9x and 3xIC50 outputs (PC1 = 0.61(9X IC50) + 0.58(3X IC50) + 0.45(1X 
IC50) + 0.29(0.3X IC50)). Similarly, PC1 explains 86% of the variance at 6hr end point and 
has large positive contributions from 9X and 3X IC50 outputs (PC1 = 0.56 (9X IC50) + 0.61 
(3X IC50) + 0.48 (1X IC50) + 0.29 (0.3X IC50) (Table 4.2).  
PC1 determined for each of the 217 Malaria Box compounds and seven benchmark 
antimalarial drugs were plotted against each equipotent dose (9 to 0.33xIC50 at 6 hrs) 
(Figure 4.8). Interestingly, whilst all the correlations were highly significant (P>0.0001), a 
clear pattern regarding the strength of each concentration emerged. As expected, the 
correlation was strong at 3XIC50 doses (r
2 = 0.91), 9XIC50 (r
2 = 0.82) and 1XIC50 (r
2 = 0.78) 
and relatively less correlated at 0.33XIC50 (r2 = 0.53). Note that PC1 plotted against 9XIC50 
illustrated a relatively lower correlation than that of 3XIC50 because of the saturation 
effect of very rapid acting drugs at this concentration – the data clusters at bottom of the 
plot (9xIC50) stretching the regression line towards right and thus affecting slope of the 
curve. Based on my experience, the most useful information regarding the activity of 
drugs in a single-dose/time point triage assay could be obtained using 9XIC50 
concentration.  
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Figure 4.7: Principle component Analysis  
(A) Data in three dimensions is distributed within the grey oval-with dotted lines representing their 
distribution in the three dimensions. (B) The greatest variance within the grey oval is reported as PC1 
(comprising of components from all three of the original dimensions). (C) Representing the grey box on the 
new PC1 (C1) axis, the second principle component (PC2) is at orthogonal to PC1 and again comprises of 
components of these original dimensions. This is repeated to describe all the principle components, with 
each iteration reporting less of the variance in the dataset. 
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Table 4.2: PCA on the estimates of rate of kill data 
This table reports PCA on the estimates of rate of kill data at 3 and 6hr time points respectively (Source-
Raman Sharma, LSTM). 
 
 
 
 
 
 
 120 
 
 
 
 
0.8
Figure 4.8: Comparison between PC1 and loss of bioluminescent signal in the BRoK assay 
Linear regression plots between the PC1 determined for each of the 217 Malaria Box compounds and seven 
benchmark antimalarial drugs and each equipotent dose (9 to 0.33xIC50 at 6 hrs).  The red line shows a linear 
regression curve.  
 
To represent this data graphically, the PC1 determined for each of the 217 Malaria Box 
compounds and seven benchmark antimalarial drugs were zero meaned and plotted 
against their IC50 for the 3hr and 6hr assays (Figure 4.9). This analysis provides a novel and 
simple means to explore the correlation between the IC50 potency and initial rate of kill of 
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the MMV Malaria Box compounds tested here against a series of known antimalarial drug 
benchmarks. Potent, low IC50, compounds with an initial rapid rate of kill are exemplified 
by artemisinins (i.e. DHA) and occupy the bottom left quadrant of this plot. Atovaquone, 
whilst potent in terms of its IC50, is slow acting drug and occupies the upper left hand 
quadrant. This analysis quickly reveals that whilst the 224 Malaria Box compounds display 
a full range of initial rate of kill relative to the benchmarks shown, these compounds are, 
at best, lead development targets (IC50 potency is below that expected of an antimalarial 
drug). It would therefore not be expected to see a distribution of data towards the more 
potent IC50s as reported here for the benchmark antimalarial drugs used. That said, using 
the PC1 value for DHA as the upper limit, 33 and 17 compounds tested demonstrated an 
initial rate of kill greater than that of DHA following PC1 in the 3hr and 6hr datasets, 
respectively. There is a considerable overlap between these two groups, with 14 of the 17 
compounds identified at 6hr shared with the 3hr group (the remaining 3 sit just above the 
PC1 cut-off for DHA). As predicted, there is no correlation between rate of kill, expressed 
here as PC1, and IC50 at either time points (all R
2 <0.01). 
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Figure 4.9: Exploring RoK (PC1) against the IC50 potency of the MMV Malaria Box compounds 
Graphical representation of the (A) 3hr and (B) 6hr PC1 (RoK) data compared to the IC50 potency of the 224 MMV Malaria Box compounds tested in the 
bioluminescence rate of kill assay. The filled black circles represent known antimalarial drugs, pink and blue circles shows drug-like and probe-like compounds, 
respectively. Cutoffs (dotted line) based on PC1 of DHA at (A) 3hr and (B) 6hr respectively. Each data point represents mean from three biological repeats of three 
technical replicates (n=9). 
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At 6hr using the PC1 values, the 36 and 17 compounds  met the minimum essential (RoK > 
CQ) and ideal (RoK >DHA) criteria respectively for TCP1 candidates  are reported below in 
Table 4.3, with the full dataset provided at the end of this thesis in appendix 2. 
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Table 4.3: TCP1 candidates in the MMV Malaria Box  
This list reports the 53 TCP1 candidates identified with an initial rate of kill as good as, or better, than CQ (36 
compounds) and DHA (17 compounds) respectively in the full bioluminescence rate of kill assay.  
 
The 17 compounds that appear to exhibit an initial rate of kill as good as, or better, than 
DHA at 6hrs are shown in Table 4.4. This table also reports the available predicted 
biophysical data relevant to their potential oral bioavailability as a drug (hydrogen bond 
donors/acceptors, numbers of rotatable bonds, partition coefficient and molecular 
weight) as well as their MMV classification as a drug-like or probe-like compound. There 
is an apparent 50:50 proportion of drug-like and probe-like in these rates of kill hits.  
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Molecule MMV number PC1 (6hrs) ALogP Molecular Weight Num_Rotatable Bonds Num_H_Acceptors Num_H_Donors Classification
MMV142383 -106.9 4.6 310.4 3 2 1 Drug-like
MMV009015 -106.3 4.3 367.5 9 4 1 Probe-like
MMV665891 -102.1 4.8 270.3 2 1 1 Drug-like
MMV666021 -101.8 4.2 272.3 1 3 0 Probe-like
MMV665809 -97.5 4.6 395.7 4 3 1 Probe-like
MMV666026 -96.6 3.0 319.4 4 3 1 Probe-like
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Molecule MMV number PC1 (6hrs) ALogP Molecular_Weight Num_RotatableBonds Num_H_Acceptors Num_H_Donors Classification
MMV020243 -95.2 3.8 362.4 5 5 3 Probe-like
MMV396749 -87.2 3.9 368.4 1 4 2 Drug-like
MMV007474 -85.6 7.0 608.7 3 8 1 Probe-like
MMV019555 -77.4 8.1 478.7 9 4 2 Probe-like
MMV006787 -76.2 4.2 310.4 7 2 2 Probe-like
MMV007092 -74.7 4.8 662.9 18 10 2 Probe-like
N
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Table 4.4: Biophysical parameters of hits  
This table reports the 17 hits identified with an initial rate of kill as good as, or better, than DHA in the full bioluminescence rate of kill assay, with key biophysical 
parameters for these compounds indicate (see main text). 
 
 
Molecule MMV number PC1 (6hrs) ALogP Molecular_Weight Num_RotatableBonds Num_H_Acceptors Num_H_Donors Classification
MMV665800 -74.1 4.3 347.8 7 3 1 Drug-like
MMV665826 -73.3 3.7 288.3 2 4 0 Drug-like
MMV665803 -73.0 4.3 377.9 8 4 1 Drug-like
MMV665806 -70.7 4.2 314.5 5 2 2 Drug-like
MMV000483 -69.3 4.4 341.4 5 4 2 Drug-like
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4.2.5 Single point assays using 3D7 IC50 data: A simpler way forward?  
 
The bioluminescence assay described here employs Dd2luc parasites, whilst high 
throughput screening IC50 data are typically reported for the genetically distinct 3D7 clone 
(Barrows et al., 2012; Spangenberg et al., 2013). Thus, reconfirming the IC50 data in Dd2
luc 
parasites is a time-consuming limitation in the assay; in fact, it takes more time to 
determine the IC50 values than in subsequently determining the RoK itself. This raises 
questions regarding the applicability of this assay as a high throughput tool in screening 
large compound libraries (i.e. TCAMS 13,000 compounds) as remeasuring Dd2luc IC50 data 
would perhaps represent a too significant workload to make the approach viable. Here, a 
question is asked whether is it necessary to repeat IC50 measurement in Dd2
luc parasites 
prior to performing the RoK, or whether the widely available IC50 data for the 3D7 clone 
can be used instead.  
The Dd2luc IC50 data obtained for the Malaria Box compounds (396 in total) were initially 
compared against the available 3D7 IC50 data.  Negative log-transformed IC50 data (pIC50, 
to allow ready distribution of data across a wide range of concentrations) for each drug in 
the two clones were plotted and show a reasonable, but significant, correlation (Figure 
4.10, r2=0.4, p< 0.0001). Critically, this correlation is comparable to the one established by 
Spangenberg et al., (2013) between 3D7 and the K1 isolate of P. falciparum.  
The difference in IC₅₀ values observed between 3D7 and Dd2luc could be attributed to 
variations in the different methodologies employed to measure this parameter, rather 
than their genetic background. The 3D7 IC50 data reported by MMV with the Malaria Box 
were prepared during the massive chemical library screening, where compounds are 
screened rapidly for their IC50 potency using large-fold dilution series (e.g. 10-fold 
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dilution), which imposes a limitation on the accuracy of the IC50 estimated from log dose 
response curves. In addition, there is no well-established single fixed endpoint for 
determining an IC50 value, with some laboratories preferring a 48hr assay format whilst 
others prefer a 72hr assay format. The 3D7 IC50 data of the Malaria Box compounds 
resulted from a 72hr assay using DAPI (Spangenberg et al., 2013; Duffy, and Avery, 2012; 
www.mmv.org), which is distinct from the 48hr MSF assay used in this study.  
 
0.10
Figure 4.10: Comparison of Dd2
luc
 and 3D7 IC50 data  
Regression analysis of the pIC50 (r
2
= 0.4 P< 0.0001) determined for 396 compounds in the MMV Malaria Box 
for 3D7 (sourced from www.mmv.org) against those against Dd2
luc 
(developed in this study). 
This level of correlation was determined not to be an issue as comparison between two 
sets of 3D7 IC50 data available for Malaria Box compounds, developed using distinct 
methodologies (DAPI and high content imaging) actually showed a weaker correlation 
(Figure 4.11, r2=0.2, p<0.0001) than observed here when comparing the two fluorescence 
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assay datasets from two genetically distinct clones. This suggests that more variation in 
data can be attributed to the assay method employed than based on the genetic 
background of the parasite. 
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Figure 4.11: Comparison of two independent 3D7 IC50 datasets 
A linear regression plot between two independent 3D7 IC50 datasets [Set A (CHEMBL, high content imaging) 
and set B (Avery, DAPI)] compared against each other. (r
2
=0.2, p value< 0.0001).  
Based on the observation that Dd2luc and 3D7 IC50 data showed limited variation, the loss 
in bioluminescence signal in Dd2luc parasites using the available 3D7 IC50 data (DAPI 
fluorescent assay data provided with the Malaria Box) was determined. All 400 Malaria 
Box compounds were screened at a single-dose/single-time (i.e. 9xIC50 of drug for 6hrs) 
using their 3D7 IC50 concentration, including the 7 benchmark drugs previously employed 
(using 3D7 IC50 data available from Hasenkamp et al., 2013). This bioluminescence rate of 
kill data was plotted against the corresponding 3D7 IC50 values (Figure 4.12).  
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Figure 4.12: Correlating the RoK against the corresponding IC50 data from 3D7 
Scatter plot illustrating rate of kill data (9XIC50 concentration of drug for 6hrs) against the corresponding IC50 
data from 3D7. The threshold line in the middle split compounds into fast acting and slow acting. Each data 
point represents mean percent from three biological repeats (n=9). Note, there is no apparent correlation 
(r
2
=0.06) between the estimates of rate of kill and IC50 of these compounds. 
This distribution of data based on the 3D7 IC50 values was compared to those obtained 
from using their corresponding Dd2 IC50 value (Figure 4.13) in the Dd2
luc triage assay data 
described in Figure 4.4. This analysis shows a strong and significant linear correlation 
(r2=0.88, p<0.0001) between the triage datasets generated using the two different sets of 
IC50 data. This would appear to suggest that an initial triage to identify compounds likely 
to exert a measurable initial rate of kill can be performed using IC50 data from a 
genetically unrelated P. falciparum clone/isolate. To explore the applicability of the triage 
assay, using either Dd2 or 3D7 IC50 data, these data were compared against the 53 
compounds identified in the full bioluminescence rate of kill assay to have initial rates of 
kill (lower PC1 values) greater than chloroquine (i.e. meeting the TCP1 criteria). The 
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percentage of these 53 compounds that would be “discovered” using triage assay 
thresholds set between 10-70% (in 10% increments) was determined and plotted in 
Figure 4.14. Importantly it is observed that, irrespective of the IC50 dataset tested, when a 
70% threshold was set (the original threshold selected) all the 53 compounds that were 
determined to meet the TCP1 criteria of better than chloroquine were identified (the 
actual minimal threshold value is 62%). As this threshold is lowered, the proportion of 
these 53 compounds identified in either triage assay decreases – with the reliability of 
detection falling off more quickly when 3D7 IC50 triage data is used. 
 
0.13
Figure 4.13: Comparison between the RoK obtained using Dd2
luc
 and 3D7 IC50 values 
A linear regression plot between the triage rates of kill data obtained using Dd2
luc
 and 3D7 IC50 values 
respectively. The red line shows linear regression curve and the pink data points illustrates outliers (see 
discussion). 
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Figure 4.14: Single dose and single timepoint triage assay 
Effectiveness of the triage assays in identifying compounds subsequently shown in the full bioluminescence 
rate of kill assay to have rates of kill greater than chloroquine. The y-axis reports the proportion of the 54 
compounds with rate of kill (RoK) activity > CQ identified against the various threshold (x-axis) values 
applied for the single dose (9XIC50) and single timepoint (6hr) triage assay using IC50 data from either 3D7 or 
Dd2. 
 
Given these observations, it would appear that a threshold of 50% in a triage assay, using 
either IC50 value, would identify >90% of the compounds subsequently shown to have an 
initial rate of kill greater than that of chloroquine. Interestingly, lowering that threshold 
to 25% and considering the 17 compounds determined to have an initial rate of kill 
greater than DHA; the Dd2 IC50 triage assay would identify 16 of the 17 (94%), whereas 
the 3D7 IC50 triage assay would identify 14 of the 17 compounds (82%).  
Together these data would suggest that compounds with an initial rate of kill that meets 
the challenge of a TCP1 candidate can be rapidly screened, with >90% hit rate, using a 
single dose (without the need to remeasure the IC50 in Dd2) and single timepoint assay.   
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4.3 Discussion  
 
The gold standard for the determination of a rate of kill in vitro is based on the 
recrudescence growth of parasites following a bolus of drug exposure (Sanz et al., 2012). 
Whilst this assay is complex (multiple wash steps, dilution, and sterile long-term culture) 
and requires a prolonged assay time (21-28 days), it provides a true rate – an effect 
determined over time – and reports both PRR and PCT, values that can be readily 
compared to available in vivo data. That said, the strength of this assay lies mainly in a 
lead validation/development role as the throughput is not sufficient to screen the 
necessary number of compounds to make it a valuable hit/lead discovery assay. 
The bioluminescence assay employed here offers a compromise that meets the challenge 
of a reliable assay, with a good dynamic range of cytocidal effect that is readily scalable 
due to its ease of use in a simple plate-based assay format over 6 hours. The limitation 
that it does not provide absolute data that can be directly compared to PRR and PCT 
parameters is balanced against its ability to readily generate relative data – and it is worth 
noting again that the TCP1 requirements for drugs that are at least as fast as CQ, and 
preferably better than artemisinin, are relative targets. The ease of use of the 
bioluminescence assay and the short time taken to provide the relative rate of kill data 
for the MMV Malaria Box compounds suggest that the utility of this assay lies mainly as a 
tool to complement current hit discovery assays (i.e. screening of many hundreds and 
more compounds) to ask not only what are the most potent hits, but also what are the 
fastest hits. The recrudescence PRR/PCT in vitro assay, along with the in vivo mouse 
modelling of rate of kill will continue to play a leading role in lead development, but with 
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the understanding that compounds being tested have already shown some potential as 
rapidly acting cytocidal compounds in the bioluminescence screen.  
In chapter 3, a comparison of bioluminescence assay data developed for a range of IC50-
fold exposures using against the in vitro PRR and PCT data available for a range of 
benchmark antimalarials suggest a good correlation. Here, using the PC1 data for the 
same benchmark antimalarials, an analysis that combines the data from four different 
drug concentrations, this comparison was explored again (Figure 4.15). The PC1 data 
shows a strong and significant correlation with the PCT, as was the case for the loss of 
bioluminescence signal at higher multiple IC50 doses in chapter 3. This was also the case 
with the analysis in chapter 3; the correlation was stronger using the 6hr assay format. 
Comparison of PC1 against the PRR suggests a reasonable, but not yet significant, trend, 
which also strengthens using the longer 6hr assay format. Again, the same caveats 
regarding the lack of variance in the available PRR data, and the requirement to exclude 
DHA as the PRR is only reported as >8, are true in this analysis.  
It would perhaps not be reasonable to extrapolate an in vitro PRR or PCT from the PC1 
data available, not at least due to the limitations in the diversity of drug classes tested 
and numbers of compounds compared. Access to more in vitro PCT and PRR data, or 
ideally more in vivo data, would be useful in taking bioluminescence PC1 data and making 
predictions regarding their PRR and PCT in vitro or even in vivo.  
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Figure 4.15: Correlation of PC1 against PCT and PRR 
Correlation of PC1 data against available in vitro PCT (hr) and log PRR data (Sanz et al., 2012). 
 
The limitations imposed by the temporal peak of luciferase expression during the 
trophozoite stage directs the use here of a 3hr and 6hr assay format. This is certainly a 
problem if the mode of action of a compound is outside this stage of development (and is 
an issue picked up in the next chapter). However, a 6hr assay window may be relevant for 
two reasons. A dramatic reduction of parasitaemia (>99%) in patients is required over a 
short period of time, usually 24 hours. As such, a reduction in parasite load (loss of 
viability) of >80% in 6hr period typically needs to be achieved, and is within the detection 
limits for this assay (i.e. that observed for DHA). Moreover, in the absence of any 
indication of the pharmacokinetic/pharmacodynamics (PK/PD) properties of the MMV 
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Malaria Box compounds in vivo, this assumption that they will have a long serum half-life 
cannot be made, a limitation with the current fast-acting artemisinins. This assay format 
of 6 hours assumes the worst case PK/PD scenario that a drug has to exert its cytocidal 
action within a narrow time of peak plasma accumulation.  
If, as proposed above, the bioluminescence rate of kill assay has a role to play in hit 
discovery, an important limitation could be the time spent in reconfirming the IC50 of each 
compound to be tested in the Dd2luc clone used here. Single dose/timepoint triage assay 
(9xIC50 for 6hrs either using Dd2
luc or 3D7 IC50 values) data developed here showed a 
significant correlation. Moreover, exploring how the threshold for the triage assay needs 
to be set to ensure discovery of the TCP1 candidates, here full bioluminescence assays 
report with PC1 values less than that of chloroquine, suggest that a 50% threshold would 
be sufficient to “discover” >90% of the TCP1 candidates irrespective of whether Dd2 luc or 
3D7 IC50 data is used in the triage assay. With the general availability of 3D7 IC50 data for 
large compound datasets, for example the TCAMS library of some 20,000 compounds or 
even the proposed new MMV Pathogens Box (pathogensbox.org), this assay offers a 
simple and rapid means to quickly triage and then test compounds of interest as TCP1 
candidates.   
The comparison of triage assay datasets prepared using the Dd2luc and 3D7 IC50 values in 
Figure 4.13 identified seven outliers (in pink). The majority of these compounds, except 
MMV665807, showed an apparent 2-14 fold increase in IC50 in Dd2
luc compared to 3D7. 
The simplest explanation for their apparently greater cytocidal effect in Dd2luc would be 
that a higher concentration of compound was used in the assay. Yet this is perhaps an 
oversimplification as the fold-change in IC50 doesn’t correlate with the change in rate of 
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kill. These seven compounds are listed in Table 4.5. Of note, is that the IC50 from other 
clones of P. falciparum (reported in Van-Voorhis et al., manuscript in preparation) is more 
similar to that of Dd2luc reported here than for 3D7. Given that Dd2luc is chloroquine 
resistant, and 3D7 is chloroquine sensitive, these compounds were compared against the 
β-haematin inhibitors reported by Lee et al., (2015) to be in the Malaria Box. These two 
groups of compounds are completely distinct from one another and provide no simple 
explanation for the differences in IC50 based on β-haematin. However, given that 
chloroquine resistance is principally mediated through Pfcrt, a putative transport protein 
on the digestive vacuole membrane (Ecker et al., 2012; Gaviria et al., 2013; Roepe, 2010; 
Summers et al., 2012), interactions between, or transport by, these seven compounds 
and the different forms of Pfcrt in Dd2 and 3D7 cannot be excluded.  
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Table 4.5: Seven outliers in the Malaria Box compounds 
Illustrate seven MMV Malaria Box compounds that are outliers when comparing the triage data following 
screens of Dd2
luc 
with Dd2 and IC50 concentrations. 
 
In table 4.4 the 17 compounds identified during this study that appear to exhibit an initial 
rate of kill as good as, or better, than DHA at 6hrs are shown. This table also reports 
biophysical data relevant to their potential oral bioavailability based on the Rule of 5 
initially described by Lipinski. These data are also represented for these 17 compounds 
using a radarplot (Figure 4.16) and include the polar surface area (PSA, Ȧ2). The PSA is 
included as a PSA > 130 is generally regarded as an issue for the lipid solubility, and thus 
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bioavailability (particularly through an oral route of administration) due to the extent of 
the charged surface area of these compounds. Within the radarplot, a blue background 
illustrates the optimal region for a compound’s properties in terms of predicted 
bioavailability. As such it can be noted that the majority of these 17 compounds would 
initially appear to be promising in terms of their biophysical properties. However, three 
compounds MMV007474 (LogP and Mw violation), MMV019555 (LogP violation) and 
MMV007092 (Mw and number of rotatable bonds violation) do not fall within this 
optimal region on the radar plot. It is not surprising therefore that these compounds are 
all listed as probe-like in the MMV Malaria Box.   
Through a contribution of data to the MMV Malaria Box manuscript, preliminary access to 
additional data is available for these compounds. This includes high content imaging data 
originally contributed by the Ayoung group in which they have evaluated stage-specific 
activity of the MMV Malaria Box compounds against the clearly morphologically 
distinguishable intraerythrocytic stages of early rings, late rings, trophozoites and 
schizonts (Van-Vooris et al., manuscript in preparation). In their work, they evaluated the 
effect of a fixed dose of 10 µM of each of the 400 MMV Malaria Box compounds on these 
stages, with their effect on subsequent development also monitored.  
 
 141 
 
 
 
0.16
Figure 4.16: Physicochemical property radar plot of the 17 hits compounds.  
ALogP = Octanol-water partition coefficient. PSA = Polar surface area. H-Donors = Hydrogen bond donors 
H-Acceptors = Hydrogen bond acceptors. MW= Molecular weight. RotB = Rotatable bonds 
 
Their application of a fixed dose of 10 µM is distinct to the approach adopted in this study 
of using fold-IC50 concentrations, however, for any compound with an IC50>1 µM, here 
9xIC50 dose would offer a close approximation. A brief summary of the intraerythrocytic 
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stage during which the 17 active compounds highlighted in this study are shown in Figure 
4.17. Of note is that whilst this study specifically explored the cidal activity of these 
compounds in the trophozoite stage, data reported by the Ayoung group clearly reveals a 
preferential stage-specific activity within early rings (9 compounds) or mature rings (12 
compounds) with only five compound reported in their study as affecting trophozoites.  
 
0.17
Figure 4.17: Stage specific action of MMV Malaria Box compounds 
Stage specific action of MMV Malaria Box compounds as reported by Ayoung group. The coloured bar, see 
key, reports the morphological stage activity is reported or if occurring subsequently (downstream) to ring-
stage application. 
 
A detailed interpretation cannot be done prior to the full public release of this data; 
however, the ability to integrate the rate of kill data with additional datasets, such as the 
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stage-specificity of action here, illustrates how this process offers a value-added step in 
evaluating the MMV Malaria Box compound’s as potential leads for further development. 
Another example of comparing these hits against existing data for the MMV Malaria Box 
is illustrated with a comparison against activity to a known target, in this case the plasma 
membrane P-type ATPase (PfATP4) that is involved in sodium ion and osmotic 
homeostasis (Jimenez-Diaz et al., 2014; Lehane et al., 2014; White et al., 2014b). Of the 
28 PfATP4 inhibitors identified in the MMV Malaria Box, data for 26 compounds are 
reported here. Of these, here this study has confirmed rapid action for 21 compounds 
with an initial rate of kill at least as good as, or better, than that of CQ. Of the 17 
compounds reported here with an initial rate of kill greater than DHA, four compounds 
(MMV396749, MMV665800, MMV665826 and MMV665803) are apparent PfATP4 
inhibitors (Lehane et al., 2014). This is a promising observation given that clinical trials of 
the PfATP4 inhibitor NITD609/KAE609 suggest an in vivo rate of kill greater than 
artesunate. The in vitro rate of kill of PfATP4 inhibitors is perhaps not as rapid as the in 
vivo rate (and may thus fall between DHA and CQ), this suggested to be as a result of 
increased iRBC membrane rigidity and exposure of phosphatidylserine following exposure 
to PfATP4 inhibitors enhancing clearance in vivo. Interestingly, the best hit described 
here, in terms of initial rate of kill and IC50 potency is MMV396749 with the second fastest 
kill and an IC50 of 239nM. This compound is a PfATP4 inhibitor and is closely related to the 
NITD609/KAE609 spiroindolone, previously shown to rapidly inhibit ring stage parasites in 
vitro – as has also been shown for MMV396749 (Figure 4.17) .   
The compounds within the MMV Malaria Box were originally selected to represent a 
diversity of chemotypes (Spangenberg et al., 2013). With the structures readily available 
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along with initial rate of kill data, an exploration of whether a chemical informatics 
approach could provide any useful information relating to a compounds likely initial rate 
of kill was carried out with Raman Sharma of the Liverpool School of Tropical Medicine. 
To describe each compounds relatedness to one another, an Extended Connectivity 
Fingerprint (ECFP4) analysis was performed to provide a binary “barcode” for each 
compound, with these barcodes used in a pairwise comparison to provide a Tanimoto 
similarity score for every pair of MMV Malaria Box compounds (80200 pairs). Of these, 
23653 pairs had PC1 data available for both compounds. Taking these pairs, the Tanimoto 
similarity score was plotted against the ΔPC1 – asking only if the compounds shared a 
similar initial rate of kill, not whether they had a fast or slow rate of kill (Figure 4.18). This 
analysis revealed, not unexpectedly, the general unrelatedness of the compounds (with 
Tanimoto similarity scores predominantly <0.3) in the MMV Malaria Box. As such, the 
analysis reveals that unrelated compounds show both a similar and dissimilar initial rate 
of kill to one another. This perhaps best equates to a comparison of chloroquine and 
atovaquone to DHA, all are structurally unrelated, but chloroquine has an initial rate of 
kill more similar to that of DHA than does atovaquone.  
A Tanimoto similarity score of >0.8 is typically regarded as showing significant structural 
similarity. In the MMV Malaria Box, 22 pairs of compounds show such a similarity score. 
For these 22 pairs, Dd2 triage assay data are available for all compounds, with PC1 data 
available for only 9 pairs of compounds (Table 4.6).  
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Figure 4.18: Comparison of Tanimoto similarity score against differences in PC1 
Scatterplot illustrating the similarity between MMV compound pairs (Tanimoto similarity score based on 
their ECFP4 barcode) and the difference in initial rate of kill of these pair of compounds (ΔPC1).  
 
These 22 pairs of more related compounds were investigated more closely, specifically 
asking whether if more closely related compounds are more likely to share a similar initial 
rate of kill. The differences in bioluminescence data from the triage assay (ΔRoK at 9xIC50) 
for these 22 pairs and the ΔPC1 for the 9 pairs were plotted against their Tanimoto 
similarity score (Figure 4.19). This analysis, however, reveals no significant correlation. In 
Table 4.6, the IC50 for all the 44 compounds are recorded, showing a fold-IC50 difference 
of between 1 and 4.4 between the 22 pairs of compounds. Given these differences, one 
explanation for any difference in initial rate of kill between these pairs is that a higher 
concentration of one of the two related compounds provides for a faster initial rate of kill.  
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MMV000445 C23H32ClN3O2 
 
MMV000444 C23H31N3O2 
 
1805 29.59 2346 8.75 -0.01 -59.54 0.980 
MMV009063 C21H26N2O 
 
MMV000848 C20H24N2O 
 
277.9 39.24 452.7 17.45 -10.68 -56.82 0.972 
MMV665857 C19H24ClNO3 
 
MMV396633 C20H26ClNO3 
 
1362 24.10 1908 19.02 -14.47 -42.99 0.875 
MMV006303 
 
 
 
 
 
C19H23N3 
 
MMV665783 C20H25N3 
 
464.9 34.19 60.75 87.89   0.857 
MMV006764 C19H22BrNO6 MMV006656 C21H26BrNO6 789.1 8.55 458.1 9.00 -51.75 -49.34 0.854 
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MMV000653 C27H30N2O3S 
 
MMV000648 C26H28N2O3S 
 
1220 3.65 1143 35.78 -17.64 13.57 0.846 
MMV396678 C17H20ClN5 
 
MMV396680 C22H16ClF3N4OS 
 
1451 111.79 327.7 100.95 98.18 31.50 0.846 
MMV019762 
 
 
 
 
C21H17N3O2 
 
MMV019124 C22H19N3O3 
 
831.5 49.05 521 74.37   0.840 
MMV396680 
 
 
 
 
C22H16ClF3N4OS
 
MMV396679 C22H16ClF3N4O2S 
 
327.7 100.95 2300 109.02   0.838 
MMV666022 C24H18Cl2N2O3 MMV666054 C24H17Cl3N2O3 977.9 78.67 511.9 86.77   0.833 
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MMV020490 C27H25ClN4O 
 
MMV020275 C27H25ClN4O 
 
1225 68.16 1480 60.18 40.77 40.20 0.831 
MMV086103 C21H16O4 
 
MMV006753 C20H14O4 
 
846.4 
 
104.84 606.7 116.09   0.826 
MMV020750 C23H20N2O3 
 
MMV007273 C29H24N2O3S 
 
1544 60.54 734.5 66.75 28.63 39.86 0.818 
MMV396678 C17H20ClN5
 
MMV396679 C22H16ClF3N4O2S
 
1451 111.79 2300 109.02   0.809 
MMV007430 C17H19BrN2O4S MMV006188 C17H19ClN2O4S 901.3 100.75 878.1 94.55   0.808 
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MMV020549 C25H26N4O 
 
MMV020548 C25H27N5O 
 
242.1 81.02 664.9 99.28   0.803 
MMV019758 
 
 
 
C24H27N3O3 
 
MMV019074 C25H30N4O3 
 
614.1 78.70 1854 65.20   0.800 
MMV666101 C42H33NO5 
 
MMV666062 C40H29NO3 
 
190.3 98.85 397.1 107.14   0.800 
MMV019741 C27H30N4OS 
 
MMV007564 C26H28N4OS 
 
1156 53.38 825.6 72.73   0.797 
MMV019762 C21H17N3O2
 
MMV019202 C22H19N3O2 
 
831.5 49.05 1207 78.31   0.796 
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Table 4.6: Similarity scores for 22 pairs of the Malaria Box compounds 
This table reports molecule structure, their respective IC50s, triage rate of kill (9xIC50), PC1 and similarity scores for 22 pairs of the Malaria Box compounds (44 
compounds in total). Note that PC1 data are available only for 9 pairs. 
  
MMV006587 
 
 
 
C17H20ClN5O 
 
MMV019871 C17H20FN5O 
 
617.4 71.75 334.7 91.62   0.789 
MMV665890 C18H17N3O4 
 
MMV020660 C17H14ClN3O4 
 
903.8 18.77 1328 8.54 -25.33 -70.32 0.788 
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Figure 4.19: Correlation of Tanimoto similarity score against difference in RoK  
The difference in the initial rate of kill derived from (A) the triage assay dataset (ΔRok 9XIC50) n=22 pairs and 
(B) PC1 dataset (ΔPC1) n=9 pairs. 
 
Whilst data in chapters 3 and 4 does not suggest that the initial rate of kill correlates with 
the IC50, these comparisons were based on compounds with very different structures. 
Plotting the fold-IC50 difference between the 22 and 9 pairs of compounds against 
difference in triage assay and PC1 data, respectively, however, did not reveal any 
significant correlation, supporting the finding that initial rate of kill is apparently 
independent of the IC50 of the compound tested (Figure 4.20).  
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Figure 4.20: Comparison of PC1 dataset (ΔPC1) against the fold-IC50 difference  
PC1 dataset (ΔPC1) n=9 pairs against the fold-IC50 difference between the compounds in each structurally 
related pair. 
 
Whilst the results of this initial chemical informatics approach are perhaps initially 
disappointing, they are perhaps not surprising. The diversity of chemotypes within this 
collection of 400 compounds is likely a limiting factor in a more meaningful chemical 
informatics study. Screening additional libraries, particularly larger libraries that contain a 
higher proportion of related compounds, such as the 20000 compounds in the TCAMS 
library would be more useful. Moreover, future analyses would be enhanced by exploring 
properties of compounds beyond their immediate structural similarity. For example, 
compounds with biophysical properties that would enhance their immediate access to 
their target may influence their initial rate of kill. For example, more basic compounds   
may have more immediate access to targets in the digestive vacuole, or compounds with 
increased lipophilicity may access targets within subcellular organelles. Exploring these 
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attributes, in light of the simplicity of this assay to readily determine their initial rate of 
kill, offers a potentially novel approach to understanding how compounds can be 
modified to affect their rate of kill. 
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CHAPTER 5: Exploring the Slow Acting Compounds in the Malaria Box Using 
a 48-Hours Bioluminescence-Rate of Kill (BRoK) Assay 
 
5.1 Introduction  
 
In chapter 4 fast-acting cytocidal compounds acting against the trophozoite stages of 
intraerythrocytic development were identified in the MMV Malaria Box. The restriction to 
the trophozoite stage results from the use of 5’ and 3’ flanking sequences from the 
Pfpcna (P. falciparum proliferating cell nuclear antigen, PF3D7_1361900) in the luciferase 
expression cassette (Wong et al., 2011; Hasenkamp et al., 2012). Pfpcna, encoding a 
processivity co-factor for DNA polymerase δ on the leading strand during DNA synthesis, 
shows a strong temporal profile of stage-specific transcription linked to the S-phase of 
intraerythrocytic development (Kilbey et al., 1993; Horrocks et al., 1996, Horrocks and 
Kilbey, 1996; Wong et al., 2011). The strong temporal transcription of the luciferase 
reporter protein from Pfpcna flanking sequences offers advantages in the excellent signal 
to noise ratio for bioluminescence based assays using this expression cassette (see Fig 
5.1, Hasenkamp et al., 2012). However, the narrow window for this strong reporter 
expression in the Dd2luc parasite line, limits the immediate utility of similar assays of drug-
induced loss in parasite cell viability at other major developmental stages during 
intraerythrocytic development. Dd2luc can, therefore, be usefully used for the 3hr and 6hr 
bioluminescence assays in trophozoites reported in chapter 4. This can even usefully be 
extended to explore the loss of viability up to 9hrs (data not shown), however, beyond 
this, the lack of expression of luciferase and the relatively rapid turnover of this reporter 
protein results in greatly diminished bioluminescence signals. 
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Figure 5.1: Strong temporal regulation of the Pfpcna-luciferase promoter cassette during 
intraerythrocytic development. 
 The morphological stages of intraerythrocytic development of P. falciparum are shown at below the chart, 
with the numbering representing hour’s post-erythrocyte invasion. RLU, relative light units (Source-
Hasenkamp et al., 2012). 
 
These limits likely have an impact when two aspects of drug action during 
intraerythrocytic development are considered. First is that of the lag phase; a period of 
time apparent for some classes of drugs, during which maximal kills rates (or sometimes 
even any killing if only cytostatic within the lag phase). The lag phase is not observed in all 
drug profiles, but some drugs have a variable lag phase lasting from 24 to as long as 48 
hours (Sanz et al., 2012; White, 2014) (Table 5.1). The recrudescence rate of kill assay, 
with its application of drugs for between 24 to 120hr allows the effect of these lag phase 
on the determination of PRR and PCT in vitro (Sanz et al., 2012). 
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Table 5.1: The in vitro lag phase of known antimalarial drugs 
(Source-Sanz et al., 2012). 
 
The second issue is the stage during intraerythrocytic development during which the 
applied drug is cytocidal. The arsenal of antimalarial drugs that have been, or are being, 
applied are primarily active against the later stages of intraerythrocytic development with 
the majority having little appreciable effect against early ring stages (see Table 5.2).  This 
would support the application of BRoK that is a trophozoite-stage based viability assay. 
However, it is considered useful to have antimalarial drugs that are also effective against 
early intraerythrocytic parasites. For example, part of the success of artemisinin has been 
linked to its substantial ring-stage activity (White, 1997; White et al., 2011; Wilson et al., 
2013) with the new PfATP4 inhibitors (i.e. NITD609/KAE609 spiroindolone) also 
demonstrating activity against ring-stage parasites (Lehane et al., 2014). To date, only 
artemisinin inhibits parasite egress with no antimalarial drug apparently affecting 
merozoite invasion (Wilson et al., 2013). The ability to target erythrocytic stages of 
development beyond the trophozoite stage potentially offers opportunities in the design 
of novel chemotypes that hit, as yet, novel parasite targets. 
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Table 5.2: Stage specific activity of known antimalarial drugs  
Inhibitory activity of antimalarial drugs during the intraerythrocytic development of P. falciparum (Source- 
Wilson et al., 2013). 
 
In chapter 4, it was apparent that almost half the MMV Malaria Box compounds showed 
little cytocidal effects against trophozoites in a 6hr assay format. This assay format, 
however, doesn’t account for any potential effect of lag phase or rapid cytocidal activity 
at ring, late schizonts, and erythrocyte rupture or erythrocyte invasion. As the MMV 
Malaria Box compounds capture a diverse range of chemotypes, the potential for these 
apparently slow-acting compounds having a delayed or alternative stage-specific cytocidal 
activity was considered in the following results chapter. In recognising the limitations of 
the current 6hr BRoK assay, the activity of these slow-acting schizonticides was explored 
in a 48hr assay format; trophozoites to trophozoites. Importantly, assays on these 
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compounds were carried out at 6hr and 48hr. The addition of the 6hr assay for these 
slow-acting compounds allowed an almost complete set of 6hr BRoK assay data to be 
developed for the MMV Malaria Box. 
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5.2 Results  
 
5.2.1 Summary of the experimental approach 
 
Sufficient materials were available for 178 of the compounds originally determined to be 
slow acting in the 9xIC50/6hr triage assays. These compounds were subjected to a full 
BRoK assay (9x to 0.33xIC50) over 48hr to ensure completion of one full intraerythrocytic 
cycle. Bioluminescence assays were done at 6hr and 48hr, each with three technical 
replicates and with three biological replicates done. Two additional sets of compounds 
were included in the 48hr BRoK assay; seven benchmark antimalarials (DHA, CQ, MEF, 
QN, PPQ, PYR and ATOVA) and ten MMV compounds originally characterised as having a 
fast-acting cytocidal effect on trophozoites. A schematic representing the analysis of 
these data, along with that available from chapter 4, is shown below (Figure 5.2). Example 
plots of the dose-response curves are illustrated in Figure 5.3, with the remaining data 
recorded in Appendix 1.  
 
0.2
Figure 5.2: A schematic for the analysis of the BRoK data 
 Schematic representing the analysis of the 6hr and 48hr BRoK assay data developed in chapter 5.   
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Figure 5.3: Dose-dependent rate of kill of the Malaria Box candidates 
Exemplars dose-dependent rate of kill of the Malaria Box candidates at 6hr against a set of “benchmark” 
controls (DHA, CQ and ATOVA). Note – this level of data has been developed for 178 compounds and is 
reported in Appendix 1. 
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5.2.2 Provision of a full 6hr BRoK assay dataset for the MMV Malaria Box   
 
Initial scatterplot analysis between the bioluminescence signals obtained following 6hr 
exposure to the different doses of “slow-acting” MMV Malaria Box compounds reports, 
as expected, minimal changes in trophozoite stage viability at all doses tested (Figure 5.4). 
The results for the ten “fast-acting” MMV Malaria Box compounds as well as the majority 
of the benchmark antimalarials show dose-dependent loss in parasite viability in line with 
data previously reported in chapter 4.  Whilst not as apparent as the same analysis 
performed in chapter 4 for the “fast-acting” compounds, comparison of the 
bioluminescent data (normalised against untreated control) between the different fold-
IC50 concentrations used reveal better correlation when more similar concentrations are 
used e.g. effects at 9x v. 3xIC50 are more closely related than those between 9x v. 
0.33xIC50 (Figure 5.4).  
This new dataset for 178 “slow-acting” compounds initial rate of kill at 6hr was pooled 
together with the equivalent 6hr data reported for 192 “fast-acting” compounds reported 
in chapter 4. As before, to capture the concentration rate relationship in a single 
parameter, a PCA analysis was conducted (in collaboration with Raman Sharma, LSTM) to 
provide an initial rate of kill assay for a total of 370 of the 400 MMV Malaria Box 
compounds, as well as seven common benchmark antimalarials included in both analyses. 
Here PC1 describes 89% of the variation of the BRoK data (Table 5.3) with PC1 
determined to comprise of; 0.63(9X IC50) + 0.62(3X IC50) + 0.41(1X IC50) + 0.22(0.3X IC50). 
These values were zero-meaned to allow a final plot of PC1 against the IC50 for the 
majority of the MMV Malaria Box (Figure 5.5).  
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Figure 5.4: Correlation between dose-dependent effects in a 6hr BRoK assay 
Comparisons between 9xIC50, 3xIC50, 1xC50 and 0.3xIC50 at 6hrs for 178 slow acting compounds, ten control 
fast acting drugs and seven benchmark antimalarial drugs. The filled black circles represent known 
antimalarial drugs, green and blue circles show drug-like and probe-like MMV Malaria Box compounds, 
respectively. The pink circles represent fast-acting compounds used as an additional control. 
 163 
 
 
19
Table 5.3: Principle Component for 370 MMV Malaria Box compounds (6hr)  
The proportion of the variance, and cumulative variance, of the 6hr BRoK assay data reported in each 
Principle Component for 370 MMV Malaria Box compounds. 
 
To illustrate the relative contributions of PC1 and PC2, accounting for an accumulated 
variance of 97% of the data, these were plotted against each other to illustrate the 
continuation in the distribution of the data i.e. discrete groups were not observed. As 
expected based on the observations made in chapter 4, there was no correlation between 
the initial rate of kill, expressed here as PC1, and IC50 in this more complete PCA of the 
6hr BRoK assay data (Figure 5.5A).  
Comparison of the 53 TCP1 candidates (initial rate of kill > CQ) reported in chapter 4 were 
compared against the proposed TCP1 candidates following this new PCA. Comparison of 
the two lists (Table 5.4) indicates that all 17 compounds indicated to have an initial rate of 
kill greater than DHA in chapter 4 are similarly reported in this new PCA. Comparison of 
the lists for compounds with an initial rate of kill greater than CQ but less than DHA reveal 
that three additional compounds are now included in this space following this new PCA 
(Table 5.4, a full new PCA list for 370 compounds is provided at the end of this thesis in 
appendix 3). It is important to note, however, that these same compounds only just did 
not make the list in chapter 4. Thus, this reanalysis of the data does not significantly 
change the list of potential TCP1 candidates provided from the initial triage assay 
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employed in chapter 4 and supports the assertion that this simplified assay format is 
sufficient for the discovery of potential TCP1 candidates.  
 
0.5
Figure 5.5: Correlating RoK (PC1) for 370 Malaria Box compounds with IC50 and PC2 
(A) 6hr PC1 BRoK data plotted against the IC50 potency for 370 Malaria Box compounds. The blue shadowing 
represents the space occupied by compounds with an initial rate of kill faster than that of chloroquine. (B) 
PC1 data plotted against PC2 illustrating the continuous distributions of rate of kill data across these two 
components (accounting for 97% of the total variance in data). The filled pink, blue and black circles 
represent drug-like, probe-like and benchmark antimalarial drugs respectively. The red filled circles highlight 
DHA and CQ (i.e. TCP1 standards). 
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Table 5.4: Comparison TCP1 candidates (Chapter 4 vs 5) 
Comparison of the 53 TCP1 candidates (initial rate of kill > CQ) reported in chapter 4 against the proposed 
TCP1 candidates following this new PCA. The PC1 data for the TCP1 candidates (rate of kill > CQ) are 
reported in this table while a full list of the new PCA analysis for 370 compounds is provided at the end of 
this thesis in Appendix 4. 
5.2.2 Exploring the slow acting compounds in a 48hr assay format  
 
Accepting the limitations in the 6hr trophozoite assay format applied up to here, the 
rationale of the 48hr assay format was to explore what cytocidal effects could be seen 
following 48hr incubation with drug. In addition to the 178 compounds previously 
characterised as “slow acting” in the 6hr assay, 7 known antimalarial drugs and 10 “fast 
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acting” compounds were tested. Log dose-normalised bioluminescence signal plots for all 
these compounds are provided in appendix 1. As with previous BRoK assays, correlations 
between the loss of bioluminescent signal following incubation at the different fold-doses 
of compounds were first explored (Figure 5.6). 
As expected from previous assays, significant correlations (P<0.001) between loss in 
bioluminescent signals for all comparisons between fold-dose concentrations were 
observed, with stronger correlations between more similar concentrations i.e. 9xIC50 v 
3XIC50 correlates better than the data for 9xIC50 and 0.33xIC50. Importantly, the control 
“fast-acting” compounds, as well as the faster acting benchmark antimalarials, show 
between 95-98% loss in bioluminescence signal compared to untreated controls at the 
two highest doses tested. Interestingly, for the highest doses (3x and 9xIC50) the most 
potent drug appeared to be pyronaridine, not the artemisinin DHA. DHA was actually less 
potent than CQ over the 48hr assay format. This was also seen in the 72hr assay format 
proposed by Sanz et al., (2012) for their recrudescence assay, here they attributed this to 
the DHA being unstable after prolonged incubation at 37°C in an aqueous environment. 
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Figure 5.6: Correlation between dose-dependent effects in the 48hr BRoK assay 
Correlations between loss of bioluminescence signal, compared to untreated control, following incubation 
with 9, 3, 1 and 0.3x IC50 at 48hrs. The filled black circles represent known antimalarial drugs, green and blue 
circles represent drug-like and probe-like compounds, respectively. The pink circles represent ten “fast-
acting” MMV Malaria Box compounds included as an additional control. 
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This same level of loss of bioluminescent signal was not observed for >90% of the 178 
MMV Malaria Box compounds tested (Figure 5.6). These instead appear to split into two 
groups. Group-A shows a dose-dependent loss in bioluminescence signal, falling between 
CQ and ATOV. Group-B instead appears to show no appreciable cytocidal effect at any 
concentration used over 48hrs, these then all falling above and to the right of ATOVA in 
Figure 5.6.  
To provide a more meaningful comparison between these dose-dependent data, the 48hr 
BRoK assay for 178 “slow-acting” and ten “fast-acting” MMV Malaria Box compounds 
along with the seven benchmarks were analysed by Principle Component Analysis. Here 
PC1 describes 84% of the variation of the BRoK data (Table 5.5) with PC1 determined to 
comprise of; PC1 = 0.27(9X IC50) + 0.64(3X IC50) + 0.66(1X IC50) + 0.29(0.3X IC50). Note that 
compared to the 6hr PCA carried out to date, the 48hr PCA was more weighted to data 
provided from the 3x and 1x IC50 assays. 
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Table 5.5: Principle Component for 370 MMV Malaria Box compounds (48hr)  
Reports the proportion of the variance, and cumulative variance, of the 48hr BRoK assay data reported in 
each Principle Component for 188 MMV Malaria Box compounds. 
These values were zero-meaned to allow a final plot of PC1 against the IC50 for these 
“slow-acting” MMV Malaria Box compounds (Figure 5.7) after 48hr. 
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Figure 5.7: PC1 (48hr) data plotted against their IC50 potency- separating “slow-cytocidal” from those with no appreciable cytocidal effect 
Illustrates 48hr PC1 (RoK) data plotted against the IC50 potency for 188 Malaria Box compounds and seven benchmark antimalarials. The filled pink and blue circles 
represent drug-like and probe-like, respectively compounds initially determined to be “slow-acting” MMV compounds. Black and green circles represent MMV “fast-
acting” controls and benchmark antimalarial drugs, respectively. The dotted lines in the middle represent CQ and ATOVA PC1 thresholds. The light blue and yellow 
shaded areas highlight the apparent Group-A and B, respectively, outcomes for the 178 “slow-acting” MMV compounds discussed in the main text. 
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Importantly, the PC1 analysis reveals that after a 48hr assay only one additional 
compound, MMV006250, could be potentially added to the list of TCP1 candidates (Table 
5.6). This compound only just meets the TCP1 threshold, with all others slower than CQ 
and the majority slower than the more moderately acting amino alcohols. 
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Table 5.6: Ranking of the 48hr PC1 data  
This list reports the relative order (fastest first) 48hr PC1 data for 178 Malaria Box compounds and known 
antimalarial drugs.  
The apparent lack of new “fast-acting” MMV compounds after this extended 48hr 
incubation would suggest that a 6 hr BRoK assay is sufficient to quickly identify rapid 
acting cytocidal compounds. Whilst this may need to be tested against a wider range of 
chemotypes, this assertion is certainly true for the MMV Malaria Box compounds.  
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Whilst the 48hr assay does not appear to offer any new indications for rapid acting 
cytocidal drugs, the presence of two apparently distinct extremes in 48hr 
bioluminescence assay data was shown (Figure 5.7). To better represent these two 
groups, the 6hr and 48hr PC1 data for these 178 “slow-acting” MMV Malaria Box 
compounds was plotted against each other (Figure 5.8A). This figure readily identifies 
Group-A and B extremes in the 48hr BRoK assay data; with group A showing cytocidal 
potency similar to benchmark antimalarial drugs and the “fast-acting” MMV Malaria Box 
controls and group B displaying no apparent cytocidal activity even after 48hrs of 
incubation. The 48hr dose-dependent loss in bioluminescence of the top 20 members in 
each group clearly shows the difference in cytocidal activity of the compounds in each 
group (Figure 5.8B). Whilst these are readily identified from the 48hr assay, the relative 
distribution of these groups within the 6hr BRoK assay data was done to see if this earlier 
assay data can provide some predictive indication of compounds that fall into these two 
groups. As both groups are initially defined using the 6hr PC1 data, the 20 compounds 
from each group were mapped on a plot where PC1 was plotted against the second 
principle component PC2 (6hr) data (Figure 5.9C). Note that PC1 and PC2 explained 89% 
and 8% variance in the 6hr data respectively. There is no apparent discrete distribution of 
group-A and B in this analysis and would suggest that no useful predictive information 
regarding cytocidal activity after 48hrs can be determined for these 178 MMV Malaria 
Box compounds based on data available from a 6hr BRoK assay.   
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Figure 5.8: Exploring the top 20 compounds with “slow-cytocidal” activity or no  appreciable cytocidal 
effect 
(A) Correlation between 6 and 48hr PC1 data for 178 Malaria Box compounds (r
2 
=0.148, P < 0.0001). Both 
Group A (green filled circles) and B (blue filled circles) are highlighted in light shaded pink circles. (B) The 48 
hr dose-response curves of the top 20 members in each group (Group A and B), which shows the difference 
in cytocidal activity of the compounds in each group. The black dotted curve represents ATOVA. (C) PC1 6hr 
data plotted against PC2 and 20 members of each group (Group A and B) are mapped (dark pink shaded 
circle). 
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5.3 Discussion  
 
Together with the data developed in chapter 4, work described in this chapter provides 
an analysis of the immediate cytocidal action of 370 (92.5%) of the 400 MMV Malaria Box 
compounds. When the 6hr BRoK assay data were pooled together (i.e. 178 “slow-acting” 
compounds from this chapter with 192 “fast-acting” compounds reported in chapter 4) a 
single Principle Component Analysis was done. This analysis showed that the 53 TCP1 
candidates (i.e. an immediate rate of kill > CQ) reported in chapter 4, were subsequently 
confirmed to be TCP1 candidates when all 370 compounds were analysed. In addition, 
three compounds that were initially determined to be just below the CQ threshold in 
chapter 4 were classified in the second PCA to just fall on the other side of the CQ 
threshold. This is perhaps not unexpected as data for 178 compounds were added to the 
PCA that stretched out the distribution of the PC1 data on the plot, and those compounds 
that fell on either side of CQ do so very closely. Importantly, the 17 ideal TCP1 candidates 
(i.e. immediate rate of kill > DHA) that were reported in chapter 4 were also re-confirmed 
in this analysis with no other MMV compounds moving into this category. The minimal 
change to the classification of potential TCP1 candidates from the MMV Malaria Box 
based on these two PCA of the BRoK data suggests that this is a robust assay for the 
determination of rapidly acting cytocidal compounds against the trophozoite 
intraerythrocytic stage. 
This rapid initial cytocidal activity likely results from two principle contributing aspects of 
the drug’s action. The first aspect considers the target of the drug and how quickly a 
deficit in this target’s function will lead to cell death – perhaps best termed “mode of 
action”. Sanz et al., (2012) considered in their recrudescence assay that compounds with 
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a similar mode of action would result in similar rates of kill. This is certainly supported by 
the evidence presented for the benchmark antimalarial compounds with artemisinins > 4 
amino quinolones > amino alcohols. But this is a limited pool of drugs and also a 
collection of drugs that have been through development to enhance their 
pharmacodynamic/pharmacokinetic properties for optimal clinical use. Given the very 
short timeframe for determining cytocidal action in the 6hr BRoK assay, and the early 
stage of development for the MMV Malaria Box compounds, a second attribute of these 
compounds may influence their immediate rate of kill – ease of access to their target. 
Within this in vitro assay, the compounds need to migrate through up to four membranes 
to access their target, and biophysical parameters based on their size, hydrophobicity and 
charge may contribute significantly to how easily they access their target. Another 
consideration, and one that is important for compounds with a basic charge at 
physiological pH, is that of potential access and concentration within the digestive 
vacuole in the trophozoite parasite, irrespective of whether this is the final site of their 
target. These biophysical properties are considered in predictions of in vivo bioavailability 
through the oral route, again considering that size, hydrophobicity and charge of a 
compound are important in the absorption and distribution of a drug. A set of rules to 
predict compounds most likely to act as an orally active drug was described by Lipinski in 
1997 based on his analysis that demonstrated that commercial drugs tended to be small 
and moderately lipophilic (Lipinski et al., 2001; Lipinski et al., 2012; Lipinski, 2004). These 
analyses developed the Rules-of-5 (Ro5); a molecular weight of less than 500, no more 
than five hydrogen bond donors, less than ten hydrogen bond acceptors and an octanol-
water partition coefficient (LogP) of less than five (Leo et al., 1971). These rules have been 
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slightly modified with other factors considered more informative, e.g. total polar surface 
area, in refining these rules (Ghose et al., 1999; Veber et al., 2002). Given the importance 
of these biophysical parameters in the development of drugs and their potential effect in 
providing access for compounds to their targets, the following parameters were 
determined for the 370 MMV Malaria Box compounds and plotted against the 6hr and 
48hr PC1; molecular weight, Log P, number of hydrogen bond donors and acceptors, total 
polar surface area (Ȧ2), number of rotatable bonds and most basic pKa. In addition, 
common modification of LogP was explored, the distribution coefficient (LogD) which 
considers the octanol-water distribution of the ionized and non-ionized forms of the 
compound at physiological pH (Figure 5.9, appendix 4). 
Regression analyses of these data typically reveal a weak correlation between 6hr, and 
48hr rate of kill and the biophysical properties explored. This is perhaps not surprising 
given the diverse range of chemotypes apparently available in the MMV Malaria Box and 
the potential for a large number of biological processes being targeted. The utility of this 
approach in understanding whether modifications to biophysical properties affect the 
rate of kill will perhaps be best done through the isolation of these properties from the 
intrinsic rate of kill provided when different targets are investigated. Therefore, 
modifications around a core chemical scaffold that presumably hits the same target may 
offer the means to look at how biophysical properties affect rate of kill. Unfortunately, 
the ECFP4/Tanimoto Similarity approach to exploring chemotypes relatedness proved 
fruitless in chapter 4. This issue will be revisited in chapter 6 where medicinal chemist 
expertise was used to cluster related compounds based on their chemotype.  
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Figure 5.9: Correlating biophysical properties against the RoK   
 A, B and C reports linear regression plots of biophysical data plotted against rate of kill (PC1). ALogP/D = 
Octanol-water partition coefficient. TPSA = Total Polar surface area. H-Donors = Hydrogen bond donors. H-
Acceptors = Hydrogen bond acceptors. PKa= Acid-base dissociation constant. 
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Comparison of the relative order of rate of kill of the MMV compounds after 6hr and 
48hr, compared to the benchmark antimalarials, revealed only one additional compound 
that had been characterised as “slow-acting” in the 6hr assay format as now having a 
48hr cytocidal activity similar to CQ. This would suggest that for the determination of 
rapidly acting cytocidal drugs (i.e. potential TCP1 candidates); the 6hr format is sufficient 
to provide a list of potential targets. The 48hr assay does not provide any further 
information in the selection of potential TCP1 candidates, and therefore means that the 
additional time and costs of this 48hr format are not necessary. The key information 
provided by the 48hr assay seems to be the description of two distinct groups of 
compounds. The first, group A, are compounds that after 48hr show a cytocidal activity 
comparable to the “fast-acting” and benchmark antimalarial controls. Group B, by 
contrast, shows little cytocidal activity up to 3xIC50 doses of drug after 48hr and anything 
between 0-80 % kill at 9xIC50. 
Given the potential for cytocidal activity at intraerythrocytic stages other than 
trophozoites in the 48hr assay, the stage-specific activity data available from a high 
content imaging screen (Ayoung et al, in the Van Hooris publication) was compared for 
the top 20 compounds in each of group A and B (Figure 5.10). Of immediate note is that 
that 45% of group A and 20% of group B compounds report trophozoite stage activity, 
contrasting with my own observation of the apparent lack of cytocidal activity at this 
stage. Both groups report a range of stage-specificities that would be captured in the 48hr 
assay format, but no clear correlation that could help understand the different cytocidal 
activities between these two groups. One observation of note, however, is that a 
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classification of no activity was made for 25% of group B with no compounds showing no 
activity in group A. 
 
0.10
Figure 5.10: Stage specific action of Group A and B compounds  
Stage specific action was reported by Ayoung group. The coloured bar, see key, reports the morphological 
stage activity is reported or if occurring subsequently (downstream) to ring-stage application. 
These data would suggest that the cytocidal activity observed in group A cannot be 
readily attributed to a specific stage-specific activity. Whilst it may well be the case that 
the different compounds in group A target a range of different developmental cycles – 
the similar distribution of stage-specific activities recorded for group B, where no 
appreciable cytocidal activity was shown, would perhaps place a caution on this 
interpretation. Instead, it may will be that group A compounds are those that have a 
mode of action that includes a lag phase, after which the compound shows good cytocidal 
 181 
 
activity (e.g. pyrimethamine, Sanz et al., 2012). Thus, given the absence of apparent 
activity after 6 hours, and the known lag phase for ATOVA, an estimate would suggest a 
lag phase of between 6 and 48 hrs may account for the rate of kill activity of the group A 
compounds. The implication for this is that whilst these compounds may not be suitable 
as a rapid-acting TCP1 component of a SERCaP medicine, these compounds may, 
depending upon their PK/PD properties, be able to act as a “long lasting” TCP2 
component. Alternatively, if they show an excellent clinical safety profile, they may meet 
the TCP4 requirement for a long lasting TPP2 for potential mass drug administration.  
Group B compounds may be subject to a prolonged lag phase of up to 48hr (one 
complete cycle of development), noting that these compounds are slower than ATOVA 
which has a 48hr lag phase. A clue to their apparent lack of cytocidal activity after 48hr is 
provided by the comparison of the 48hr dose response in Figure 5.8B. Here it is clear that 
cytocidal activities were only shown for some compounds when a 9xIC50 dose was 
applied. In chapter 3 it was shown that whilst the apparent rate of kill doesn’t correlate 
with the inhibitory or lethal doses of the antimalarial compounds tested, the rate of kill 
did correlate with the lethal dose/inhibitory (LD50/IC50) dose ratio. Fast acting compounds 
like artemisinins have an LD50/IC50 of 1, 4-aminoquinolines of between 5 to 10 and that of 
atovaquone is greater than 50. For those compounds that are exceptionally slow, the 
9xIC50 dose applied for 48hr may not reach the threshold for lethal activity of the drug – 
and thus, whilst the inhibitory effect can be measured (i.e. in a standard 48hr MSF assay) 
the cytocidal activity cannot. Confirmation of this proposal, however, requires that the 
BRoK assay be utilised at much higher concentrations (likely, at least, up to 100xIC50) and 
currently insufficient materials are available in my MMV Malaria Box resource (or the 
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concentration available is too low) to test this hypothesis. The implications for this group 
of compounds, however, are clear. These are not TCP1 candidates, nor, given their 
apparent lack of significant cytocidal activity at up to 9xIC50 doses, are they likely to be 
TCP2 or TCP4 candidates. Outside of the scope of this thesis, is their potential as a 
compound that target either the intrahepatic (TCP3a) or gametocyte (TCP3b) stages of 
the P. falciparum lifecycle. 
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CHAPTER: 6 Discussion  
 
Massive phenotypic screens using some 2 million compounds from the small molecule 
libraries of GlaxoSmithKline (GSK), Novartis and St. Jude have identified a set of 20,000 
compounds that exhibit sub-micromolar potency against the intraerythrocytic stages of P. 
falciparum (Gamo et al., 2010; Guiguemde et al., 2010; Plouffe et al., 2008). These 
compounds, particularly novel chemotypes, are required to seed the antimalarial 
development pipeline to meet the demands for future antimalarial medicines such as the 
Single Exposure Radical Cure and Prophylaxis (SERCaP) target product profile outlined by 
MMV. Whilst these screens have pump-primed the drug development pipeline, efficiently 
exploiting this new resource relies on new assays for candidate components of a future 
SERCaP. Whilst these include assays for gametocidal and hepatocyte stages (Burrows et 
al., 2013), this thesis has focused on Target Candidate Profile 1 (TCP1), drugs that exhibit 
rapid and potent cytocidal activity.  
There are a number of rate of kill assays that offer the opportunity to identify TCP1 
candidates. The first in vitro rate of kill assay was the recrudescence assay developed at 
the GSK Tres Cantos site (Sanz et al., 2012). This assay perhaps represents the gold 
standard in the in vitro assay of rate of kill, providing data on PRR, PCT and lag phase. 
These data allow for the discrimination between minimum TCP1 candidates (better than 
chloroquine) and ideal candidates (better than artemisinins), although the challenging 
technical aspects of the dilution and parasite recrudescence over a 21-28 day assay limits 
the applicability of this assay to small scale lead validation assays (Baragaña et al., 2015; 
Hameed et al., 2015; Mcconville et al., 2015). A South Africa/Swiss collaboration led to 
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the report of a rate of kill and stage specificity assay based on repeated daily 
determination of IC50 over three days using the highly sensitive [
3H]-hypoxanthine 
incorporation assay (Le Manach et al., 2013). Whilst offering the advantage of a relatively 
simple assay format, the assay does not discriminate between minimum and ideal TCP1 
candidates as well as having limited appeal based on the requirements for scintillation 
counting equipment and disposal of radioactive waste. 
The GSK team have developed two further rate of kill assays, one published just as this 
thesis was being completed (Bahamontes-Rosa et al., 2012; Linares et al., 2015). The first, 
based on real-time PCR of mRNA isolated from drug-treated parasites proved useful only 
in discriminating between cidal and static activities. The 10 day assay, as well as the 
technical molecular processing steps, has limited the development and application of this 
assay. More recently, Linares et al., (2015) reported a rate of kill assay based on 
reinvasion of parasites that have been subjected to a 24hr or 48hr 10xIC50 drug bolus. 
These drug-treated parasites are used to infect uninfected fluorophore labelled 
erythrocytes, with flow cytometry used to identify the proportion of living parasites that 
are capable of reinvading on the basis of their dual labelling with a DAPI nuclear stain. As 
with the original recrudescence assay, the assay is not dependent on changes in 
metabolic activity in dead and dying cells, a concern for some chemotypes, particularly 
those that inhibit DNA metabolism (Sanz et al., 2012). The assay does, however, take 
between 3-4 days to complete and again offers no ability to discriminate between the 
minimum and ideal categories of TCP1 candidates. The report describing the invasion rate 
of kill assay provided data on the relative (fast, moderate, slow) rate of kill for a small 
number of MMV Malaria Box compounds as well as benchmark antimalarial drugs used in 
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this study. To explore the correlation between the bioluminescence and invasion rate of 
kill assays, a scatterplot of PC1 data from 6hr and 48hr BRoK assay data was plotted and 
the reinvasion assay data overlaid. Figure 6.1 clearly shows the related distribution of 
data using these two assay techniques and provides a second independent validation of 
the BRoK assay (in addition to that presented in Chapter 3).  
 
0.1
Figure 6.1: Comparison between BroK and reinvasion rate of kill assay data.  
The 6hr and 48hr BRoK PC1 for compounds also assayed using the reinvasion assay (Linares et al., 2015) are 
plotted and then overlaid with the invasion assay rate of kill outcome (see Key; black, blue and red filled 
circles show slow, moderate and fast definitions in the invasion assay). The box at the bottom left quadrant 
of the plot to represent the region that the BroK assay would define as being TCP1 candidates (note this box 
does not include all compounds categorized as “fast” in the invasion assay). 
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It is perhaps worth noting that the issue regarding the ability to discriminate between 
minimum and ideal TCP1 candidates is not limited to the assays described above. The 
same issue is also evident in the 48hr BRoK assay data (Chapter 5). This would suggest 
that there is some merit in exploring the utility of a reinvasion type assay that specifically 
uses a 6hr drug bolus prior to reinvasion – much like that initially explored here in 
Chapter 3 with the lethal dose estimation assays. 
These varied assay formats offer a range of advantages and disadvantages (Table 6.1). 
The bioluminescence rate of kill assay developed here, validated in Chapter 3 and tested 
against the MMV Malaria Box compounds in Chapters 4 and 5, appears to offer a quick, 
robust and reliable assay for rapid cytocidal activity. Importantly, this 6 hr assay offers the 
level of discrimination between minimum and ideal TCP1 candidates that are only offered 
elsewhere in the 21-28 day recrudescence assay. The BRoK assay scalability was 
demonstrated in Chapter 4 by the application of a single timepoint/single IC50 dose triage 
assay to the MMV Malaria Box. Currently, this is a 96-well microplate assay, using 200µl 
of a 2% haematocrit and 1% parasitaemia trophozoite stage culture, where only 40µl is 
taken for any bioluminescence assay. Given that 30µl cultures can be readily maintained 
for 6hr in a 384-well microplate, this offers significant opportunities for semi-automation 
of the BRoK assay to scale up to screen the 20,000 Tres Cantos Antimalarial Set (TCAMS). 
A quick calculation in Horrocks laboratory suggested that an investment of £250,000 
would provide semi-skilled users and consumable costs to determine the TCP1 candidates 
in this library. In a facility with automation and bioluminescence detection for 1536-well 
microplates, the 10µl capacity of these wells, will likely still provide the robustness and 
sensitivity levels necessary for a successful high throughput assay. The opportunity 
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afforded through the rate of kill data for this compound library, with wider and deeper 
coverage of the chemotypes currently available in the MMV Malaria Box, is exciting given 
the potential to apply a chemical informatics approach to this important 
pharmacodynamic property of antimalarial drug action. 
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Table 6.1: Advantages and disadvantages of current in vitro rate of kill assays for P. falciparum. 
 
In 2011, the MMV launched the Malaria Box as an open access resource to pump-prime 
lead development from the TCAMS library. This scheme recognised that whilst medicinal 
chemistry expertise principally lay within the pharmaceutical industry sector, the 
academic sector provided expertise in the biology of malarial parasites (Spangenberg et 
al., 2013). To facilitate this interaction, the Malaria Box provided free access to a subset 
of the TCAMS that was optimised to reflect the diversity of chemotypes available, but also 
triaged to identify those that were drug-like or probe-like. This library has now been 
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provided to some 200 groups worldwide for screens against malaria parasites, other 
parasites and even cancer cell lines (Van Voorhis submitted to PLoS Medicine). The 
significance of this resource will be demonstrated by comparison between the data freely 
shared by the many contributing laboratories on the same compound library. The Dd2 
IC50 data developed for 396 of the compounds during this study have shared with ChemBL 
data repository. Moreover, the 6hr BRoK data for 370 of the MMV Malaria Box 
compounds (92.5%) will be shortly submitted to ChemBL. Within chapters 4 and 5, the 
utility of this open access resource was shown by comparison of the BRoK data against 
what has been determined regarding the stage of kill data provided by the Ayoung team 
from high content imaging screens. As a second example of the utility of this sharing of 
data, Horrocks laboratory has collaborated with the Llínas laboratory (Princeton 
University, USA) to compare the BRoK data against their metabolomic profiling data. The 
Llínas team has mapped the metabolic profile of 65 metabolites following a 48hr 
exposure to a 10xIC50 dose for 80 compounds from the MMV Malaria Box. From their 
work they have identified a metabolic fingerprint that they suggest is indicative of an 
atovaquone-like mode of action (Figure 6.2). Atovaquone inhibits the bc1 mitochondrial 
complex blocking the transfer of electrons through the mitochondrial electron transfer 
chain. The enzyme dihydroorotate dehydrogenase (DHODH) requires a functioning 
electron transport chain to facilitate recycling of the FMN/FMNH2 cofactor. Without this, 
DHODH no longer reduces dihydroorotate to oratate which blocks the de novo synthesis 
of pyrimidines. As P. falciparum lacks a pyrimidine salvage pathway, it is reliant on the de 
novo synthesis of pyrimidines for DNA metabolism. The Llínas laboratory has shown that 
atovaquone inhibition results in the accumulation of dihydroorotate and its precursor N-
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carbamoyl-L-aspartate. This metabolic-fingerprint was also observed in 22 other 
compounds they screened, and they have suggested that these compounds share a 
related mode of action to atovaquone. Here, BRoK data indicate that atovaquone is a 
slow acting drug. To provide independent support for this metabolic-fingerprint, the 6hr 
PC1 BRoK data for the same 80 compounds were plotted against fold-changes in the 
levels of dihydroorotate and N-carbamoyl-L-aspartate (Figure 6.3).   
Here, this analysis offered data for 22 compounds, of which 21 compounds also share a 
slow rate of kill. Whilst, not absolute proof that these compounds inhibit the 
mitochondrial electron transfers chain, there is a circumstantial link provided by the BRoK 
data regarding the lack of an immediate cytocidal kill. Interestingly, one compound 
demonstrates a rapid cytocidal activity, MMV666021. It may be the case that this 
compound doesn’t target the mitochondrial electron transport chain, but instead targets 
the DHODH itself. However, a recent report describing DSM265, a triazolopyrimidine-
based inhibitor of PfDHODH, the first DHODH inhibitor to reach clinical development for 
the treatment of malaria, indicates an in vitro rate of kill similar to that of atovaquone 
(Philips et al., 2015).   
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0.2
Figure 6.2: Metabolic fingerprints of selected Malaria Box compounds 
Heat map showing metabolic fingerprints of Malaria Box plate A compounds and atovaquone control. 
Hierarchical clustering was performed on log2 fold changes in metabolites scaled from -3 to +3. A large 
cluster of compounds exhibited an atovaquone-like signature (indicated in blue) characterized by 
dysregulation of pyrimidine biosynthesis.  The atovaquone internal control is shown in yellow. (Figure kindly 
provided by the Llínas laboratory).   
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Figure 6.3: Correlation between RoK and fold-changes in the metabolites DHO and NCLA 
This plot shows correlation between rate of kill (PC1 data from 6hrs) and the fold-change in dihydroorotate 
(DHO) and N-carbamoyl-L-aspartate (NCLA). Fold changes for these metabolites are shown for 80 MMV 
Malaria Box compounds (red and green, respectively) and atovaquone (black and blue, respectively). 
 
This thesis has primarily considered the role for the BRoK assay in the hit identification 
stage of the drug development process. Here the utility of the screen provides a simple 
and quick means to identify rapid acting cytocidal drugs from a large library dataset. The 
utility of the potency of a hit to be monitored in terms of both its IC50 and rate of kill 
potency simultaneously offers opportunities for this assay to be used in the latter stages 
of the pre-clinical drug development stages. Whilst the rate of kill is an intrinsic issue 
 192 
 
related to the mode of action (Sanz et al., 2012), biophysical properties that effect rapid 
access of drugs to the target are potentially important and can be readily explored in this 
simple cell based assay.  
The principle for an intrinsic rate of kill is illustrated by a pilot study I conducted in the 
laboratory on four derivatives of 4-aminoalcohol quinolines for a collaborator Demailly-
Mullié (University of Marseille, France). This class of compound includes mefloquine, a 
highly potent schizonticide with excellent PK/PD properties (Simpson et al., 2000). 
Unfortunately, this drug consists of a racemic mix of stereoisomers, where the (-) erythro 
enantiomer is less potent against P. falciparum but does interact with the adenosine 
receptors within the central nervous system to cause neurological side-effects for this 
drug (Toovey, 2009). The Demailly-Mullié team has prepared stereospecific compounds 
to further explore the potential to develop new 4-aminoalcohol quinolones that lack 
these side effects and show greater potency that mefloquine (Dassonville‐Klimpt et al., 
2013; Mullié et al., 2012). However, given that these compounds all share the same 
target, just with different IC50, here this study collaborated to explore whether the iso-
fold IC50 doses used in the BRoK assay would mean that similar rates of kill would be 
observed for two stereoisomers of two compounds that have 5 carbon or 7 carbon chains 
added to the C11 position of a 4-aminoalcohol quinolones backbone. The BRoK assay data 
shown in Figure 6.4 would seem to support the assertion that these four related 
compounds share a similar immediate cytocidal effect, supporting the proposal that they 
share a common target in the parasite.  
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0.4
Figure 6.4: Stereoisomers (R,S) of 4-aminoalcohol quinolines show the same rate of kill in the BRoK assay 
 (A) BRoK plots for R and S isomers of pentyl or heptyl subsituted 4-amino-quinolines with their (B) structures illustrated along with their IUPAC terms. 
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This observation was also extended into my work on the MMV Malaria Box compounds. 
In a recent collaboration with MedSynDesign Ltd, Dr Tony Mete, a medicinal chemist with 
over 20 years’ experience within the pharmaceutical sector, has been working with 
Horrocks laboratory to provide a classification of the compound library by related core 
scaffold structure. This medicinal chemist “expert” view is distinct to the chemical 
informatics approach previously done in chapter 4, which was based on similarity scores 
of computationally-derived extended chemical fingerprints. As an example of this 
approach, the 6hr PC1/IC50 plot of the 370 MMV compounds have been overlaid with four 
scaffold structures; diamino-glycerols, benzyl-benzoates, 8-hydroxyquinolines and 
triazolopyrimidine (Figure 6.5). These plots clearly reveal an intrinsic rapid cytocidal mode 
of action for the diamino-glycerols and benzyl-benzoates, with slow acting/cytostatic 
action for the 8-hydroxyquinolines and triazolopyrimidine. It is noting that the slow acting 
DSM235 is based on the triazolopyrimidine scaffold.  
Whilst still in its early stages, Dr Mete’s classification has also described chemical scaffold 
clusters which contain compounds that exhibit a wide range of immediate rate of kill. This 
distribution of rates of kill would suggest that either (i) these very similar compounds 
have different targets with different rates of kill or (ii) that the intrinsic rate of kill of a 
target is also modified by factors that affect the access of the drug to the target (as 
discussed in the discussion to chapter 5). The second option suggests an interesting 
opportunity, that as well as using medicinal chemistry to optimise IC50, the same may also 
be true for rate of kill for some chemical scaffolds. This effect was also observed by Haddi 
Mybe, an MPhil student in the Horrocks laboratory (MPhil thesis entitled “The 
antimalarial properties of N-phenyl-3-(pyridyl)-4 substituted pyrazole scaffolds”, 2015). In 
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her thesis, she initially characterised, using the same BRoK assay, the initial rate of kill for 
28 compounds in three related pyrazole scaffolds with a range of minor substitutions to a 
phenyl ring substituent. Interestingly, the SAR for the IC50 did not correlate with that for 
the rate of kill, with amino substituted phenyl rings having some of the highest IC50, but 
were potential TCP1 candidates in terms of their 6hr rate of kill. 
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Figure 6.5: Examples illustrating related compounds in the Malaria Box that share a similar rate of kill 
 (A) Represent two scaffolds that appear to show intrinsic rapid cytocidal kill with (B) two scaffolds with 
intrinsic slow/cytostatic mode of action. The Blue circles represent the members of each scaffold projected 
against grey (370 compounds from MMV Malaria Box) and red (benchmark antimalarials) circles. Shown 
against each plot is an exemplar compound from this scaffold. 
 
Plotting 6hr PC1/IC50 plot of the 370 MMV compounds overlaid with information for two 
additional scaffolds (tetrahydroisoquinolines and acridines) show how the 5 compounds 
in each cluster are distributed between chloroquine and atovaquone in terms of their 
immediate rate of kill (Table 6.2). These clusters are shown in figure 6.6, with their 
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biophysical properties plotted against the 6hr PC1 rate of kill (Figure 6.7). Whilst these 
comparison plots reveal no significant correlations, as they only represent 5-6 compound 
clusters, some trends appear potentially interesting. The LogP and pKa, with LogD (a 
derivative of these values) for tetrahydroisoquinolines, show a potentially inverse trend 
between rate of kill and these parameters. That is, tetrahydroisoquinolines that are more 
basic and lipophilic are faster acting. Comparison between two, MMV008956 (IC50 120nM 
and PC1 of 75.9 [slower than atovaquone]) and MMV000483 (IC50 653nM and PC1 of -
69.3 [similar to chloroquine]), share the same structure with minor substitutions to one 
phenyl ring (Table 6.2). Ideally, a TCP1 lead would have an IC50 better than MMV008956 
with an initial rate of kill better than MMV000483. As a starting point, additional 
tetrahydroisoquinolines in the TCAMS library would be sought to refine the IC50 and PC1 
SAR, using the IC50 and PC1 plots first described in this thesis (19 related compounds in 
the TCAMS library). Using this information, a medicinal chemistry guided synthetic 
programme could design a series of compounds to test this SAR to design a viable lead. Of 
note, this may address the role for a bis-tetrahydroisoquinoline given the exceptional rate 
of kill, close to artemisinin, shown by MMV007474. 
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Acridines (Cluster 1) 
MMV019555 
PC1 = -77.40 
IC50= 545.3 nM 
 
MMV006172 
PC1 = -53.56 
IC50= 1596.0 nM 
 
 
MMV006513 
PC1 = 57.09 
IC50= 200.0 nM 
 
MMV000448 
PC1 = 45.14 
IC50= 236.8 nM 
 
 
MMV000304 
PC1 = 10.62 
IC50= 1668.0 nM 
 
TetraHydro-IsoQuinoline (Cluster 2) 
MMV007474 
PC1 = -85.60 
IC50= 691.5 nM 
 
 
MMV000481 
PC1 = -17.13 
IC50= 1607.0 nM 
 
MMV000478 
PC1 = -5.60 
IC50= 1699.0 nM 
 
MMV008956 
PC1 = 75.91 
IC50= 120.1 nM 
 
 
MMV000483 
PC1 = -69.30 
IC50= 653.5 nM 
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Table 6.2: Structure of compounds within the acridines and tetrahydroisoquinoline clusters 
The table reports MMV name, PC1 (rate of kill, 6hr) and IC50 for each compound. 
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Figure 6.6: Examples illustrating related compounds in the Malaria Box that show variation in their 
rates of kill 
The scaffolds appear to show both intrinsic rapid/cytocidal and slow/cytostatic mode of action. The Blue 
circles represent the members of each scaffold projected against grey (370 compounds from MMV Malaria 
Box) and red (benchmark antimalarials) circles. Shown against each plot is an exemplar compound from this 
scaffold. 
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Figure 6.7: Correlating biophysical data against rates of kill for Acridine and Tetrahydroisoquinoline 
scaffolds in the Malaria Box   
A, B and C - linear regression plots of biophysical properties plotted against the 6hr PC1 rate of kill for two 
scaffolds (tetrahydroisoquinoline and acridines) of medicinal chemistry interest. LogP/D = Octanol-water 
partition coefficient. TPSA = Total Polar surface area. H-Bonds-D = Hydrogen bond donors. H-Bonds-A = 
Hydrogen bond acceptors. PKa= Acid-base dissociation constant 
The utility of this bioluminescent assay of cell viability has been demonstrated here for hit 
discovery, with the potential for hit-to-lead development illustrated. The ease of the 
bioluminescence assay to measure cytocidal effects offers significant opportunities for 
the future development of this assay format. The current Pfpcna luciferase cassette limits 
the temporal window for assays to the trophozoite stage of intraerythrocytic action. 
Subcloning of 5’ and 3’ intergenic regions that flank a strongly expressed gene in the ring 
stage parasite, e.g. the gene expressing the knob associated histidine rich protein (kahrp), 
may provide a luciferase expression cassette to explore cytocidal drug action at this stage 
(Lanzer et al., 1992) – and may be of particular interest given artemisinin’s predicted 
action at this developmental stage. In addition, the work described here is only reported 
for the multidrug resistant line Dd2. It would be of benefit to genetically modify 
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additional parasite clones (e.g. chloroquine sensitive 3D7) or even laboratory adapted 
field strains in future studies. These additional genetically modified parasites offer the 
opportunity to screen, or validate, the findings described here for the MMV Malaria Box 
compounds (or additional libraries screened in the future) in a different genetic (and 
potentially drug resistant) background. Moreover, the microplate format may allow more 
interesting studies that explore synergy in rate of kill to parallel the recent advances that 
have been made by Prof Paul Roepe of Georgetown University, USA, with his work on 
synergy with lethal doses of antimalarial drugs (Sherlach and Roepe, 2014). Of particular 
interest to my laboratory is the ability to use these bioluminescent parasites to define and 
titrate a cytocidal kill within 6hr for a range of antimalarial drugs. This allows comparative 
studies on the ultrastructure, transcriptomic, proteomic, metabolomics and biochemical 
markers associated with cell death (mitochondrial membrane potential, nuclear DNA 
fragmentation, calcium redistribution, and caspase activity and phosphatidylserine 
redistribution) between different classes of antimalarial drugs – allowing the team to 
start to address just how parasites die when exposed to equivalent cytocidal effects.  
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Appendix 1 (Chapter 4, Chapter 5) 
These graphs show dose (9 to 0.33XIC50) and time response (3, 6 and 48hr) curves of the 370 Malaria Box compounds and 7 benchmark 
antimalarial drugs. D1-D13 and P1-P12 represents the drug-like and probe-like compounds. Each data point represents mean RLU ± stdev 
(n>9). 
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Appendix 2 (Chapter 4) 
This table reports full PC1 dataset of the Malaria Box compounds (data reported in Chapter 
4). The compounds are categorised by RAG (Red, Amber and Green). Green-TCP1 candidates 
with initial rate of kill > DHA: Amber -TCP1 candidates with initial rate of kill > CQ and < 
DHA. Red- slow acting compounds.  
6hr PC1 (Chapter 4) 
MMV_ID PC1 MMV_ID PC1 MMV_ID PC1 MMV_ID PC1 
MMV142383 -106.9 MMV008455 -49.0 MMV665857 -14.5 MMV011944 23.4 
MMV009015 -106.3 MMV006429 -48.8 MMV666025 -14.4 MMV396704 23.6 
MMV665891 -102.1 MMV396794 -48.8 MMV666102 -13.4 MMV019918 24.1 
MMV666021 -101.8 MMV007224 -48.5 MEF -13.3 MMV019313 24.8 
MMV665809 -97.5 MMV007181 -48.4 MMV665953 -13.1 MMV666020 25.4 
MMV666026 -96.6 MMV000356 -47.7 MMV000704 -12.2 MMV000753 27.8 
MMV020243 -95.2 MMV006704 -46.0 MMV009063 -10.7 MMV000604 28.0 
MMV396749 -87.2 MMV665864 -45.6 MMV006558 -9.7 MMV396797 28.4 
MMV007474 -85.6 CQ -45.3 MMV007978 -6.8 MMV020750 28.6 
MMV019555 -77.4 MMV665918 -44.6 MMV665812 -6.7 MMV007875 28.7 
MMV006787 -76.2 MMV019662 -44.5 MMV666071 -6.3 MMV019266 28.8 
MMV007092 -74.7 MMV007113 -44.4 MMV000478 -5.6 MMV001318 29.2 
MMV665800 -74.1 MMV665949 -43.4 MMV665902 -5.5 MMV665888 29.9 
MMV665826 -73.3 MMV396633 -43.0 PPQ -5.5 MMV006203 31.1 
MMV665803 -73.0 MMV665807 -42.4 MMV665906 -4.0 MMV019064 31.6 
DHA -70.9 MMV007907 -41.3 MMV019406 -3.5 MMV085583 31.7 
MMV665806 -70.7 MMV396669 -40.6 MMV665881 -3.5 MMV019741 32.5 
MMV020660 -70.3 MMV006303 -40.6 MMV006455 -3.4 MMV001041 33.3 
MMV000483 -69.3 MMV009108 -39.8 MMV008829 -2.5 MMV665946 33.7 
MMV007617 -66.8 MMV020505 -39.5 MMV000443 0.0 MMV665913 36.3 
MMV667491 -65.4 MMV666124 -37.4 MMV000445 0.0 MMV000570 36.5 
MMV665796 -62.6 MMV000442 -36.4 MMV128432 1.1 MMV001230 36.8 
MMV666109 -60.8 MMV006087 -35.1 MMV007285 1.6 MMV011522 37.0 
MMV396736 -59.6 MMV666060 -34.6 MMV396632 1.8 MMV000561 37.3 
MMV000444 -59.5 MMV665785 -33.8 MMV665944 2.3 MMV019738 37.6 
MMV665831 -58.8 MMV007654 -31.6 MMV667488 2.4 MMV011895 37.7 
MMV001049 -58.8 MMV666061 -29.6 MMV011436 2.6 MMV665894 38.6 
MMV019127 -57.5 MMV665817 -28.9 MMV019995 3.6 MMV665969 38.8 
MMV667490 -57.4 MMV306025 -27.9 MMV396663 4.2 MMV007273 39.9 
MMV000848 -56.8 MMV665928 -26.0 MMV665897 7.7 MMV665943 39.9 
MMV665882 -56.5 MMV665890 -25.3 MMV019780 9.6 MMV020275 40.2 
MMV000248 -55.4 MMV665830 -24.1 MMV666599 9.9 MMV000326 40.5 
MMV020788 -55.3 MMV665789 -23.9 MMV007363 10.5 MMV006522 40.7 
MMV666079 -54.5 QN -22.6 MMV000304 10.6 MMV020490 40.8 
MMV007591 -53.9 MMV665794 -22.4 MMV006882 12.5 MMV000498 41.2 
MMV006172 -53.6 MMV007020 -21.9 MMV006169 13.0 MMV020500 42.8 
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MMV006545 -53.4 MMV000986 -21.0 MMV000648 13.6 MMV000619 43.6 
MMV665805 -53.0 MMV019881 -20.5 MMV020654 15.5 MMV006825 43.8 
MMV006764 -51.8 MMV666116 -19.7 MMV020912 18.6 MMV000448 45.1 
MMV019017 -51.7 MMV000620 -19.3 MMV000634 19.0 MMV665987 45.5 
MMV011795 -51.2 MMV080034 -18.8 MMV666689 19.2 MMV665971 46.4 
MMV665929 -51.1 PYR -18.7 MMV666069 20.6 MMV000760 48.1 
MMV000839 -50.9 MMV000653 -17.6 MMV665786 20.7 MMV666110 50.4 
MMV000917 -50.2 MMV006706 -17.5 MMV666604 21.1 MMV665875 51.8 
MMV665878 -49.5 MMV007275 -17.3 MMV274073 21.7 MMV020549 53.1 
MMV006656 -49.3 MMV000481 -17.1 MMV001038 23.1 MMV665841 53.2 
        MMV_ID PC1 MMV_ID PC1 MMV_ID PC1 MMV_ID PC1 
MMV665914 53.9 MMV011099 72.5 MMV665915 82.4 MMV396678 98.2 
MMV006513 57.1 MMV001246 74.3 MMV007199 82.5 MMV666070 105.7 
MMV666080 57.2 MMV666125 74.5 ATOVA 84.4 MMV006389 110.7 
MMV665979 57.5 MMV000720 74.8 MMV666072 87.2 MMV006937 112.0 
MMV665941 59.3 MMV008956 75.9 MMV666607 90.4 MMV666022 114.9 
MMV665917 60.9 MMV007557 76.3 MMV019066 90.9 MMV006457 121.7 
MMV006587 65.7 MMV073843 79.5 MMV001344 91.3 MMV000787 127.2 
MMV008149 69.9 MMV007228 81.9 MMV020492 94.5 
  MMV011259 71.8 MMV667487 82.2 MMV665810 97.2 
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Appendix 3 (Chapter 5) 
This table reports full PC1 dataset of the all the 370 Malaria Box compounds (data reported 
in Chapter 5). The compounds are categorised by RAG (Red, Amber and Green). Green-TCP1 
candidates with initial rate of kill > DHA: Amber -TCP1 candidates with initial rate of kill > CQ 
and < DHA. Red- slow acting compounds.   
6hr PC1 data (Chapter 5)  
MMV Name  6hr PC1 MMV Name  6hr PC1 MMV Name  6hr PC1 MMV Name  6hr PC1 
MMV142383 -131.5 MMV000839 -79.5 MMV665953 -46.4 MMV665786 -7.8 
MMV009015 -129.9 MMV011795 -79.1 MMV666102 -46.0 MMV396704 -7.4 
MMV665891 -127.0 MMV006429 -79.0 MMV000481 -45.8 MMV001038 -7.3 
MMV666021 -126.9 MMV396794 -77.1 MMV665857 -45.5 MMV274073 -6.8 
MMV666026 -122.4 MMV007181 -76.9 MMV006706 -43.7 MMV019918 -6.6 
MMV665809 -121.7 MMV007113 -76.4 MEF -42.4 MMV011944 -5.5 
MMV011522 -121.2 MMV665949 -76.1 MMV009063 -40.5 MMV019313 -5.5 
MMV396749 -114.9 MMV000356 -75.9 MMV000704 -40.5 MMV001318 -5.5 
MMV007474 -112.2 MMV006704 -75.6 MMV007978 -39.0 MMV000604 -3.5 
MMV019555 -106.3 MMV665918 -74.7 MMV665902 -37.7 MMV019266 -2.5 
MMV665800 -103.1 MMV665864 -73.8 MMV665812 -37.1 MMV396797 -2.3 
MMV006787 -102.8 CQ -73.7 PPQ -37.0 MMV666020 -2.1 
MMV665803 -102.1 MMV007907 -72.5 MMV006558 -36.6 MMV000753 -1.5 
MMV007092 -101.9 MMV396633 -72.2 MMV000478 -35.8 MMV665888 -1.3 
MMV665826 -101.5 MMV665807 -71.9 MMV019406 -35.1 MMV007875 -1.1 
MMV020660 -99.0 MMV019662 -71.2 MMV008829 -35.0 MMV020750 0.0 
MMV665806 -98.6 MMV666124 -70.2 MMV006455 -33.6 MMV019064 0.2 
DHA -97.4 MMV396669 -69.2 MMV666071 -33.3 MMV019741 0.5 
MMV000483 -95.7 MMV019110 -67.1 MMV665906 -32.8 MMV665954 0.9 
MMV007617 -95.5 MMV006303 -66.9 MMV665881 -32.5 MMV665946 1.1 
MMV667491 -93.3 MMV006087 -66.5 MMV000445 -31.4 MMV006203 1.9 
MMV665796 -91.4 MMV020505 -66.2 MMV000443 -31.3 MMV085583 2.5 
MMV666109 -88.3 MMV009108 -65.7 MMV011436 -28.4 MMV018984 2.7 
MMV000444 -88.1 MMV666060 -65.2 MMV396632 -28.0 MMV000570 3.4 
MMV396736 -87.6 MMV000442 -64.3 MMV665944 -27.9 MMV001041 4.1 
MMV667490 -87.0 MMV665785 -61.2 MMV128432 -26.8 MMV000561 5.1 
MMV001049 -86.8 MMV666061 -60.4 MMV667488 -26.7 MMV665913 6.2 
MMV666079 -86.5 MMV306025 -59.7 MMV007285 -26.1 MMV020243 6.6 
MMV665831 -85.9 MMV665817 -58.8 MMV019995 -25.7 MMV666067 6.6 
MMV000848 -85.0 MMV007654 -57.8 MMV396663 -25.0 MMV665797 7.6 
MMV000248 -84.3 MMV665928 -57.1 MMV666599 -24.0 MMV011895 8.0 
MMV019127 -83.9 MMV665890 -57.1 MMV019780 -22.3 MMV001230 8.5 
MMV665882 -83.6 MMV665789 -55.5 MMV000304 -21.1 MMV665969 8.9 
MMV006764 -83.4 MMV665794 -55.0 MMV665897 -19.9 MMV665943 8.9 
MMV007591 -82.8 MMV000986 -53.1 MMV007363 -18.9 MMV396703 9.1 
MMV665805 -82.1 MMV080034 -52.2 MMV000648 -16.4 MMV019738 9.2 
MMV000917 -82.1 QN -52.0 MMV020654 -15.8 MMV020275 9.4 
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MMV008455 -81.2 MMV665830 -52.0 MMV006882 -15.7 MMV665899 9.5 
MMV006656 -81.0 MMV000653 -51.9 MMV006169 -15.0 MMV665948 9.7 
MMV019017 -80.9 MMV019881 -51.1 MMV000634 -14.6 MMV006522 10.1 
MMV006545 -80.6 MMV007020 -51.1 MMV666689 -13.6 MMV019746 10.6 
MMV020788 -80.2 MMV666116 -51.1 MMV008270 -13.3 MMV665894 10.7 
MMV007224 -79.8 MMV007275 -50.6 MMV020912 -13.1 MMV666057 10.7 
MMV665878 -79.8 MMV666025 -47.4 MMV396715 -11.6 MMV007273 10.8 
MMV665929 -79.8 PYR -46.9 MMV666604 -11.1 MMV000326 11.0 
MMV006172 -79.6 MMV000620 -46.4 MMV666069 -9.8 MMV001255 11.1 
        MMV Name  6hr PC1 MMV Name  6hr PC1 MMV Name  6hr PC1 MMV Name  6hr PC1 
MMV020490 11.5 MMV403679 28.4 MMV666692 43.4 MMV666693 54.7 
MMV008127 12.7 MMV011438 28.5 MMV665883 43.5 MMV009127 54.8 
MMV000498 13.0 MMV006962 28.5 MMV019871 43.9 MMV019690 54.9 
MMV019124 13.4 MMV665908 28.6 MMV666054 44.0 MMV007808 55.0 
MMV000619 13.5 MMV011832 29.1 MMV000720 44.3 MMV007881 55.2 
MMV020500 13.7 MMV009085 29.9 MMV666081 44.3 MMV667487 55.2 
MMV006825 14.0 MMV006319 30.3 MMV665820 44.4 ATOVA 55.4 
MMV000448 14.4 MMV665799 30.8 MMV665840 44.4 MMV008294 55.5 
MMV019202 14.5 MMV665798 31.0 MMV020548 44.6 MMV006188 55.9 
MMV665971 15.0 MMV665917 31.1 MMV020942 44.6 MMV007199 56.0 
MMV666108 15.1 MMV020651 31.3 MMV000563 44.8 MMV396595 56.6 
MMV665987 15.7 MMV085203 31.7 MMV666596 45.8 MMV007839 56.8 
MMV006427 16.1 MMV665783 31.9 MMV007791 45.9 MMV667489 58.2 
MMV665898 16.8 MMV075490 32.2 MMV001246 46.0 MMV666103 59.2 
MMV019074 16.9 MMV665814 32.8 MMV019258 46.6 MMV007574 59.6 
MMV007764 17.0 MMV008416 33.1 MMV007557 46.7 MMV008160 60.6 
MMV665909 17.2 MMV638723 33.5 MMV008956 46.9 MMV666072 61.0 
MMV665961 17.2 MMV000972 33.6 MMV007430 47.2 MMV019700 62.6 
MMV007977 18.9 MMV009060 34.1 MMV666125 47.5 MMV667492 62.7 
MMV019758 19.3 MMV006587 34.5 MMV396664 48.0 MMV007577 63.3 
MMV000963 19.9 MMV396594 35.3 MMV666688 48.0 MMV019066 63.7 
MMV665939 19.9 MMV007041 35.3 MMV396652 48.0 MMV396680 65.1 
MMV666106 20.4 MMV396665 35.4 MMV006278 48.2 MMV001344 65.3 
MMV666022 20.6 MMV396723 35.8 MMV007374 48.2 MMV665994 65.5 
MMV008212 20.9 MMV084940 36.8 MMV000662 48.3 MMV396679 67.5 
MMV000760 21.0 MMV665901 37.6 MMV020439 48.4 MMV011099 68.0 
MMV000699 22.2 MMV007906 38.5 MMV019762 48.6 MMV006250 68.4 
MMV666110 22.5 MMV665876 38.8 MMV665843 48.9 MMV665810 69.6 
MMV666105 22.6 MMV396726 39.3 MMV000642 49.1 MMV665836 69.7 
MMV665875 22.8 MMV396672 39.3 MMV011259 49.1 MMV665923 70.2 
MMV666009 23.0 MMV665850 39.3 MMV007116 49.1 MMV007396 70.3 
MMV666075 23.0 MMV007160 39.6 MMV665934 49.2 MMV396678 70.4 
MMV665874 23.1 MMV000788 39.8 MMV665915 49.6 MMV006753 71.1 
MMV665841 23.2 MMV011256 40.1 MMV086103 51.3 MMV011576 71.2 
MMV006767 24.9 MMV007384 40.4 MMV396770 51.6 MMV665977 72.6 
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MMV020549 24.9 MMV020700 40.7 MMV666600 51.7 MMV006820 72.8 
MMV665914 24.9 MMV665782 40.7 MMV020885 51.9 MMV665827 73.0 
MMV665879 24.9 MMV000911 41.4 MMV666601 52.3 MMV007127 73.1 
MMV665940 25.2 MMV666093 41.7 MMV073843 52.3 MMV665886 75.3 
MMV006513 25.8 MMV396693 42.0 MMV085471 52.3 MMV006913 75.6 
MMV665941 26.2 MMV665916 42.2 MMV396705 52.5 MMV006861 75.6 
MMV396681 27.2 MMV007571 42.5 MMV007695 52.9 MMV666070 77.0 
MMV665980 27.3 MMV020492 42.6 MMV666062 53.1 MMV645672 79.4 
MMV019241 27.5 MMV666023 42.7 MMV665904 54.1 MMV006457 80.0 
MMV007564 27.7 MMV008149 42.7 MMV666607 54.3 MMV006389 82.2 
MMV665979 28.2 MMV006309 42.8 MMV007228 54.4 MMV666095 82.4 
MMV666080 28.4 MMV666101 43.4 MMV019670 54.5 MMV665927 84.8 
MMV084434 85.54573 MMV006937 86.45927 MMV498479 86.74462 MMV000787 95.48005 
MMV666691 100.8948 
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Appendix 4 (Chapter 5) 
Table reports biophysical properties for the 400 Malaria Box compounds.  MW= Molecular 
weight, LogP/D = Octanol-water partition coefficient, TPSA = Total Polar surface area, RotB 
= Rotatable bonds, PKa= Acid-base dissociation constant, LE= Ligand efficiency, LLE= ligand-
lipophilicity efficiency, H-D = Hydrogen bond donors, H-A = Hydrogen bond acceptors and 
Ro5-V= rule of 5 violation.  
MMV-Code MW LogP LogD TPSA Rt_B pKa LE LLE H_A H_D Ro5_V 
MMV000248 421.4 4.2 2.7 53.8 8 8.9 0.3 1.9 5 2 0 
MMV000340 216.3 2.8 -0.6 27.1 1 11.7 0.5 3.4 2 1 0 
MMV000356 379.3 3.8 3.9 26.7 4 7.0 0.4 2.2 3 1 0 
MMV000443 303.8 4.2 4.2 21.7 4 3.9 0.4 2.1 3 0 0 
MMV000444 367.5 4.5 4.4 59.8 9 6.5     5 2 0 
MMV000448 279.4 3.1 -0.4 28.2 5 9.6 0.4 3.6 3 1 0 
MMV000478 347.8 3.2 2.9 50.7 5 9.0 0.4 3.0 4 2 0 
MMV000481 391.9 3.9 3.6 60.0 7 7.7 0.3 2.0 5 2 0 
MMV000483 341.5 4.4 3.6 50.7 5 8.2 0.3 1.8 4 2 0 
MMV000498 363.5 5.0 4.9 54.5 6 6.6     5 1 0 
MMV000561 458.6 4.3 1.5 68.6 12 10.3 0.3 1.5 7 1 0 
MMV000563 371.5 5.0 3.7 41.8 2 0.5 0.3 1.1 3 1 0 
MMV000620 343.9 4.7 2.5 23.5 5 9.6     2 1 0 
MMV000634 450.6 4.5 2.5 49.6 6 9.5 0.3 1.7 5 1 0 
MMV000648 448.6 4.6 4.6 58.6 7 -1.1     5 1 0 
MMV000653 462.6 5.0 5.0 58.6 8 -1.1 0.2 0.9 5 1 0 
MMV000662 434.6 4.9 4.9 58.6 6 -1.1 0.3 2.5 5 1 0 
MMV000704 420.5 5.0 4.3 66.9 7 8.0 0.3 0.9 7 1 0 
MMV000760 416.3 4.1 4.0 39.6 3 6.8     4 1 0 
MMV000787 426.0 4.2 3.9 48.8 7 8.7 0.3 2.2 5 1 0 
MMV000788 426.0 4.1 3.8 48.8 6 8.7 0.3 2.1 5 1 0 
MMV000839 330.4 4.0 2.5 37.2 6 8.9 0.3 1.9 3 2 0 
MMV000848 308.4 3.7 1.1 37.2 5 10.1 0.4 2.5 3 2 0 
MMV000911 278.7 4.4 4.4 41.1 2 -4.7     3 2 0 
MMV000917 398.5 4.6 4.6 51.1 3 1.1 0.3 1.3 5 0 0 
MMV000963 356.4 5.2 5.2 59.1 6 5.1 0.3 1.1 5 2 0 
MMV000972 282.2 2.8 2.0 46.5 2 -5.1     3 1 0 
MMV000986 335.4 3.8 3.4 64.5 3 7.6 0.3 2.1 6 2 0 
MMV001038 308.4 3.9 3.9 70.1 5 5.1 0.4 2.4 5 3 0 
MMV001041 349.2 4.1 4.1 70.1 5 4.8 0.4 2.1 5 3 0 
MMV001049 269.4 3.9 2.3 32.3 6 9.0 0.4 2.0 2 2 0 
MMV001230 395.5 4.7 4.7 55.3 6 4.8     5 0 0 
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MMV001239 400.5 4.0 4.0 79.1 5 4.8     6 0 0 
MMV001241 414.5 4.5 4.5 79.1 5 4.8     6 0 0 
MMV001246 327.4 4.2 4.2 54.9 4 1.2 0.4 2.4 4 1 0 
MMV001255 384.5 3.8 3.7 66.5 5 -3.5 0.3 2.5 5 1 0 
MMV001318 325.6 4.5 4.5 41.1 2 -4.6     3 2 0 
MMV001344 286.2 4.1 4.1 20.3 1 -1.1 0.5 2.1 2 0 0 
MMV006087 277.8 2.9 0.7 28.2 6 9.4 0.5 4.3 3 1 0 
MMV006169 326.4 5.3 5.3 49.8 5 4.9 0.3 0.8 4 2 0 
MMV006188 382.9 1.9 1.9 79.6 4 -1.3 0.3 4.1 6 1 0 
MMV006203 319.5 3.6 1.6 28.2 4 9.1 0.4 2.9 3 1 0 
MMV006250 348.4 5.3 5.3 68.3 6 5.8 0.4 1.2 5 1 0 
MMV006278 200.3 2.9 -0.5 27.1 1 12.6 0.6 3.5 2 1 0 
MMV006303 293.4 3.3 0.8 28.2 6 9.4 0.4 3.1 3 1 0 
MMV006309 292.3 3.3 3.3 41.9 3 4.7 0.5 4.0 4 0 0 
MMV006319 308.4 4.2 4.1 49.8 5 7.1 0.4 1.9 4 2 0 
MMV006427 464.0 3.5 3.5 72.9 4 -4.1 0.3 3.6 6 0 0 
MMV006429 409.5 4.2 4.2 75.4 5 -0.5 0.4 3.3 6 1 0 
MMV006455 370.5 4.1 1.7 61.8 11 9.8 0.3 2.7 5 2 0 
MMV006457 293.3 4.2 4.2 59.4 4 2.0 0.4 2.7 4 1 0 
MMV006522 357.3 4.7 4.0 34.2 4 8.0 0.4 1.6 3 1 0 
MMV006545 362.3 3.1 1.2 56.8 6 9.3 0.4 3.0 5 2 0 
MMV006558 287.8 5.1 5.1 12.5 2 4.5 0.5 1.5 2 0 0 
MMV006587 345.8 2.1 1.9 66.1 5 7.2 0.4 4.1 6 2 0 
MMV006656 468.3 3.6 3.6 74.3 10 -4.2 0.3 2.6 7 0 0 
MMV006704 291.4 3.7 1.9 28.2 5 8.9 0.3 1.7 3 1 0 
MMV006706 359.5 3.9 2.5 47.6 2 8.8 0.3 2.2 5 0 0 
MMV006753 318.3 4.1 4.1 56.5 2 -2.9     4 0 0 
MMV006764 440.3 2.9 2.9 74.3 8 -4.2 0.3 3.4 7 0 0 
MMV006767 323.4 3.3 3.3 86.5 4 5.4 0.4 2.7 6 2 0 
MMV006787 310.4 3.9 1.4 37.2 7 10.0 0.4 2.4 3 2 0 
MMV006820 245.3 3.6 3.6 42.4 4 2.2 0.4 1.7 3 1 0 
MMV006825 320.4 3.9 3.8 59.1 6 7.1 0.4 2.4 5 2 0 
MMV006861 355.4 4.4 4.3 37.4 3 7.1 0.3 2.2 4 1 0 
MMV006882 335.8 3.3 1.3 54.5 8 9.4 0.4 2.6 5 1 0 
MMV006913 199.3 3.1 3.1 33.1 2 3.1 0.6 2.8 2 1 0 
MMV006937 279.3 4.3 4.3 50.4 1 1.8 0.4 2.1 4 1 0 
MMV007020 321.4 4.0 3.3 37.4 5 8.1 0.3 1.4 4 1 0 
MMV007041 341.4 5.1 4.5 63.6 3 0.9 0.3 0.3 5 1 0 
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MMV007116 245.3 3.8 3.8 59.4 4 1.7 0.5 2.7 4 1 0 
MMV007285 298.8 4.4 4.3 34.2 4 6.5 0.4 1.0 3 1 0 
MMV007363 232.7 3.2 3.0 16.1 1 7.2 0.5 2.8 2 0 0 
MMV007374 267.3 3.3 3.3 55.1 3 1.2 0.4 2.1 5 1 0 
MMV007430 427.3 2.1 2.1 79.6 4 -1.3 0.3 4.0 6 1 0 
MMV007564 444.6 5.6 5.6 50.2 6 5.9 0.3 0.4 5 1 0 
MMV007571 301.4 3.3 3.3 42.2 6 -2.7 0.4 2.9 3 1 0 
MMV007591 496.7 5.0 0.3 76.7 15 10.1     6 2 0 
MMV007617 335.5 3.7 3.7 46.9 6 5.2 0.3 2.0 4 1 0 
MMV007686 334.4 3.2 3.2 67.4 8 -6.6 0.4 3.7 5 2 0 
MMV007764 256.4 4.7 1.3 27.1 5 12.7 0.5 1.4 2 1 0 
MMV007791 357.4 1.3 1.3 75.0 6 4.5     7 1 0 
MMV007808 274.3 4.3 4.3 69.2 5 -0.3 0.4 1.7 6 1 0 
MMV007839 312.2 2.7 2.0 55.8 3 -4.7 0.4 3.9 4 1 0 
MMV007875 298.8 4.1 3.4 34.2 3 8.0 0.4 1.6 3 1 0 
MMV007881 378.5 3.8 3.8 79.6 9 -3.1     6 1 0 
MMV007906 274.3 3.4 3.4 64.4 6 -0.7     5 1 0 
MMV007907 267.4 4.5 4.5 37.8 3 1.2 0.5 2.0 3 1 0 
MMV007977 283.7 3.8 3.8 38.7 2 -5.4 0.4 2.2 3 0 0 
MMV007978 319.4 3.4 3.4 47.6 8 -2.2     4 1 0 
MMV008127 331.4 3.1 2.6 47.6 1 7.8 0.3 2.3 5 0 0 
MMV008138 361.2 1.9 1.6 65.1 2 7.6 0.4 4.6 4 3 0 
MMV008149 376.4 4.7 4.7 47.2 5 -1.1     4 1 0 
MMV008212 280.3 3.1 2.5 54.4 3 8.0 0.4 2.9 4 2 0 
MMV008270 265.3 3.8 3.8 50.4 1 1.8     4 1 0 
MMV008294 380.4 5.9 5.9 69.7 7 5.9 0.3 0.7 6 1 0 
MMV008416 228.3 3.8 0.4 27.1 3 12.6 0.5 2.8 2 1 0 
MMV008474 405.5 3.6 3.1 54.9 6 7.6     6 0 0 
MMV008829 393.5 2.5 2.5 88.9 4 1.0 0.3 3.4 7 2 0 
MMV008956 377.9 3.8 3.6 60.0 6 7.3 0.3 2.6 5 2 0 
MMV009015 367.5 3.9 3.2 49.8 9 8.0 0.3 2.3 4 1 0 
MMV009060 274.4 3.8 3.8 32.3 5 5.4     3 1 0 
MMV009063 322.5 4.1 1.4 37.2 5 10.2 0.4 2.4 3 2 0 
MMV009085 410.4 0.6 0.6 115.2 8 -2.4 0.3 5.5 8 2 0 
MMV009108 415.6 5.6 5.6 62.3 6 2.4 0.3 0.6 5 1 0 
MMV009127 406.5 3.4 3.4 62.7 3 9.4 0.3 2.6 5 1 0 
MMV011099 275.3 2.9 2.9 55.1 2 0.4 0.4 3.8 5 1 0 
MMV011256 327.7 4.0 4.0 55.1 3 -0.6 0.4 2.7 5 1 0 
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MMV011259 321.3 4.4 4.4 55.1 3 -0.5 0.4 2.6 5 1 0 
MMV011522 284.8 4.4 4.4 63.8 2 5.1 0.4 1.0 4 2 0 
MMV011567 389.8 3.4 3.4 95.7 6 -3.1 0.3 2.9 8 1 0 
MMV011576 445.5 2.6 2.6 82.7 6 -2.0 0.3 3.3 7 1 0 
MMV011795 358.5 4.4 4.1 26.7 5 8.0 0.3 1.8 3 1 0 
MMV011832 289.3 3.8 3.7 60.9 3 6.9 0.4 2.4 4 3 0 
MMV011944 310.4 2.8 2.8 79.3 6 4.8 0.4 3.3 6 3 0 
MMV018984 278.3 3.9 3.9 55.1 3 -0.7 0.4 2.3 4 1 0 
MMV019017 367.3 3.5 1.7 46.4 7 9.2 0.3 2.5 4 2 0 
MMV019064 493.6 4.5 4.5 62.6 7 6.0 0.2 1.3 7 1 0 
MMV019066 359.4 2.2 2.2 87.7 6 -2.2 0.4 4.6 7 2 0 
MMV019074 434.5 4.3 3.6 66.9 6 8.0 0.3 1.4 7 1 0 
MMV019110 250.3 3.8 3.8 63.8 2 5.1 0.5 2.6 4 2 0 
MMV019124 373.4 4.1 4.1 76.2 5 5.2 0.3 1.9 6 2 0 
MMV019127 403.4 3.2 2.4 26.7 6 9.8 0.3 3.0 3 1 0 
MMV019199 266.3 3.2 3.2 73.1 3 5.0 0.4 2.2 5 2 0 
MMV019202 357.4 4.6 4.6 67.0 5 5.2     5 2 0 
MMV019258 397.5 4.4 4.4 65.4 7 4.8 0.3 2.4 6 1 0 
MMV019266 312.4 5.2 5.2 54.5 2 3.7 0.4 1.0 4 1 0 
MMV019313 397.5 3.0 0.8 52.7 5 9.6 0.3 3.2 5 1 0 
MMV019406 367.5 4.0 3.3 41.5 7 10.8 0.4 2.8 3 2 0 
MMV019662 465.6 4.3 4.3 63.3 7 6.6 0.2 1.6 7 1 0 
MMV019670 377.5 4.7 3.9 35.6 5 8.0 0.3 1.3 4 1 0 
MMV019700 383.7 4.2 4.2 45.5 3 2.1 0.4 2.0 4 1 0 
MMV019738 391.5 3.8 2.6 48.1 5 8.5 0.3 2.3 4 2 0 
MMV019746 495.1 4.5 4.0 67.5 7 7.7 0.2 1.4 7 2 0 
MMV019758 405.5 5.0 4.9 63.7 5 6.6     6 1 0 
MMV019762 343.4 4.2 4.2 67.0 4 5.2     5 2 0 
MMV019780 497.8 4.4 1.7 51.7 7 10.0 0.2 1.8 6 1 0 
MMV019871 329.4 1.6 1.4 66.1 5 7.2 0.4 4.8 6 2 0 
MMV019918 383.7 3.6 -0.9 37.2 5 10.4 0.4 2.5 3 2 0 
MMV019995 462.4 2.8 0.1 44.8 6 10.0 0.3 3.5 5 1 0 
MMV020243 362.4 4.1 4.1 82.2 5 6.1 0.3 1.8 7 3 0 
MMV020275 457.0 4.4 3.3 58.1 5 8.5 0.3 1.6 5 1 0 
MMV020439 459.6 4.4 4.1 53.4 7 7.5 0.3 1.9 6 1 0 
MMV020490 457.0 4.4 3.3 58.1 5 8.5 0.3 1.6 5 1 0 
MMV020492 309.8 3.5 3.5 29.5 1 -2.4 0.5 4.1 3 0 0 
MMV020500 249.7 1.9 -1.0 37.0 5 10.2 0.6 5.2 3 2 0 
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MMV020505 310.8 3.0 0.9 28.4 7 9.5 0.4 3.1 3 1 0 
MMV020548 413.5 3.4 2.6 64.3 5 8.1 0.3 3.1 6 2 0 
MMV020549 398.5 4.2 2.6 61.0 4 9.1 0.3 2.4 5 2 0 
MMV020651 431.3 4.6 4.5 54.7 5 6.8 0.3 1.1 5 1 0 
MMV020654 368.7 4.6 4.6 49.3 4 -3.1 0.4 1.6 3 2 0 
MMV020660 359.8 3.6 3.6 86.5 5 -3.1     7 1 0 
MMV020700 349.5 5.2 5.2 54.9 5 -1.5 0.4 0.9 4 1 0 
MMV020788 271.4 2.5 1.8 32.3 4 10.8 0.5 5.2 2 2 0 
MMV020942 307.4 2.0 2.0 73.3 6 -0.3     6 1 0 
MMV056726 279.4 3.0 3.0 29.5 3 -1.1 0.4 2.4 3 0 0 
MMV073843 309.4 3.8 3.8 28.1 4 4.5     4 0 0 
MMV075490 268.4 4.3 4.3 15.7 3 -2.0 0.4 1.8 3 0 0 
MMV080034 254.3 3.5 3.5 63.8 2 4.9 0.4 2.5 4 2 0 
MMV084434 358.4 3.5 3.5 59.9 4 -1.1 0.3 2.7 5 1 0 
MMV084940 287.3 2.1 2.1 72.3 2 0.8 0.4 3.9 6 1 0 
MMV085203 362.4 4.0 3.0 62.1 3 2.4 0.4 4.3 5 1 0 
MMV128432 321.8 2.9 1.8 50.7 7 9.7 0.4 2.8 4 2 0 
MMV142383 310.4 5.4 5.4 42.0 3 -0.7     3 1 0 
MMV274073 280.3 3.1 2.6 54.4 3 8.0 0.4 3.0 4 2 0 
MMV306025 341.3 1.1 1.1 104.0 4 -4.2 0.3 5.0 9 0 0 
MMV396595 380.5 4.1 4.0 62.9 5 5.9 0.3 1.9 6 1 0 
MMV396632 335.8 3.3 2.1 50.7 8 8.6 0.4 2.7 4 2 0 
MMV396633 363.9 4.0 2.8 50.7 9 8.7 0.3 1.9 4 2 0 
MMV396665 420.5 5.0 5.0 69.7 5 -0.7 0.3 1.1 6 1 0 
MMV396669 401.5 4.9 4.9 70.2 7 6.1 0.3 1.0 6 2 0 
MMV396672 396.5 4.8 4.0 32.3 6 8.1 0.3 1.6 3 1 0 
MMV396681 472.4 5.2 5.2 78.3 5 2.5 0.3 0.8 7 1 0 
MMV396693 254.3 -2.8 -2.8 49.0 3 2.1 0.5 9.3 4 2 0 
MMV396703 317.8 3.0 1.1 56.8 6 9.3 0.4 3.4 5 2 0 
MMV396704 301.8 2.7 2.3 48.1 1 7.6 0.4 3.2 5 1 0 
MMV396705 392.4 3.2 3.2 76.9 5 -3.7 0.3 2.7 8 0 0 
MMV396715 311.4 5.1 5.1 29.9 1 4.7 0.3 0.7 3 1 0 
MMV396719 341.4 4.9 4.9 39.1 2 4.7 0.3 1.0 4 1 0 
MMV396723 431.4 4.5 3.6 50.6 6 8.2 0.3 1.4 5 1 0 
MMV396736 393.3 3.9 2.0 46.4 6 9.4 0.3 2.0 4 2 0 
MMV396744 405.5 4.8 4.8 85.8 6 1.7 0.3 1.3 6 2 0 
MMV396749 368.4 4.2 4.2 68.2 1 4.7 0.3 1.9 6 2 0 
MMV396770 352.4 3.9 3.9 73.4 5 5.8 0.3 2.0 7 2 0 
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MMV396794 348.3 4.6 2.1 41.5 8 10.0 0.4 1.3 3 2 0 
MMV396797 309.3 1.2 1.2 98.5 3 2.5 0.4 5.1 7 1 0 
MMV403679 465.5 3.2 3.2 119.3 4 2.5 0.2 2.8 10 2 0 
MMV498479 245.3 3.8 3.8 59.4 4 1.6     4 1 0 
MMV638723 243.2 -2.8 -2.8 128.6 2 -0.1 0.5 9.2 8 4 0 
MMV645672 341.4 4.4 1.4 29.1 1 -2.5 0.3 1.6 2 1 0 
MMV665782 324.4 2.4 1.0 45.6 4 8.9 0.4 4.9 4 1 0 
MMV665783 307.4 3.4 0.3 28.2 7 9.9     3 1 0 
MMV665785 261.4 3.4 2.4 32.3 4 10.6 0.5 3.4 2 2 0 
MMV665786 396.9 3.9 2.0 41.6 6 9.3 0.3 2.2 4 1 0 
MMV665789 261.8 2.9 2.6 32.3 4 9.3 0.5 3.3 2 2 0 
MMV665796 422.3 4.2 4.2 56.8 8 -1.1 0.3 1.6 5 1 0 
MMV665798 366.3 5.7 5.7 50.7 4 0.9     4 1 0 
MMV665799 381.8 3.4 3.4 80.3 5 5.6     6 2 0 
MMV665800 347.8 4.2 4.2 47.6 7 -1.0 0.3 1.7 4 1 0 
MMV665803 377.9 4.0 4.0 56.8 8 -1.1 0.3 2.1 5 1 0 
MMV665805 367.4 4.2 4.2 86.5 7 -3.1 0.4 2.7 7 1 0 
MMV665806 314.5 4.2 1.4 37.2 5 10.4 0.4 1.9 3 2 0 
MMV665807 315.7 4.2 3.9 49.3 3 -4.3     3 2 0 
MMV665809 395.7 4.3 4.4 26.7 4 6.9     3 1 0 
MMV665810 348.4 1.6 -1.9 89.9 4 9.5 0.3 4.4 7 4 0 
MMV665812 255.4 3.6 2.0 32.3 6 9.0     2 2 0 
MMV665813 336.4 4.2 4.1 60.5 7 6.6     5 1 0 
MMV665817 319.5 4.4 1.9 41.5 8 10.0     3 2 0 
MMV665820 293.5 2.9 2.9 35.5 2 -4.7 0.5 3.4 3 0 0 
MMV665824 286.3 4.3 4.3 34.9 2 3.0     3 0 0 
MMV665826 319.4 3.1 3.1 67.1 4 -4.8 0.3 2.9 5 1 0 
MMV665827 346.4 3.6 3.6 49.9 5 0.7 0.4 3.4 5 0 0 
MMV665830 292.5 3.4 -0.1 15.3 6 10.6 0.4 2.6 2 1 0 
MMV665831 426.5 4.2 4.1 78.9 9 10.3 0.3 2.5 6 2 0 
MMV665836 310.4 3.5 3.5 50.7 3 -0.5 0.4 2.8 4 1 0 
MMV665841 273.3 2.1 2.1 49.8 2 7.1 0.5 4.8 4 1 0 
MMV665843 199.3 3.2 3.2 33.1 0 3.3     2 1 0 
MMV665850 273.7 3.3 3.3 60.9 3 6.9     4 3 0 
MMV665857 349.9 3.7 2.4 50.7 8 8.7     4 2 0 
MMV665864 294.4 3.7 3.1 74.8 8 8.0 0.4 2.4 6 3 0 
MMV665874 341.7 4.5 4.5 55.1 3 -0.6 0.5 3.7 5 1 0 
MMV665875 395.9 2.8 1.2 60.5 6 8.8 0.3 3.4 6 2 0 
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MMV665876 326.4 4.6 4.6 43.1 4 -0.9 0.4 2.0 4 0 0 
MMV665878 367.4 3.8 3.8 87.7 5 -4.8 0.4 3.0 7 2 0 
MMV665879 412.5 5.4 5.4 86.9 5 5.1     6 3 0 
MMV665881 479.5 3.0 3.0 98.1 7 1.0 0.2 3.0 8 2 0 
MMV665883 422.4 4.5 4.5 100.0 5 5.1 0.3 1.6 7 3 0 
MMV665886 385.9 5.2 5.2 55.4 6 -4.6 0.3 0.8 4 1 0 
MMV665888 440.5 5.1 5.0 107.9 6 -3.4     7 4 0 
MMV665890 339.4 3.5 3.5 86.5 5 -3.1     7 1 0 
MMV665891 270.3 4.9 4.9 28.7 2 5.1 0.4 1.0 2 1 0 
MMV665894 303.4 3.3 3.3 71.1 3 -1.8 0.4 3.0 5 2 0 
MMV665897 189.2 1.2 1.2 61.0 1 5.0     4 1 0 
MMV665898 403.4 3.9 3.9 85.5 6 5.2 0.3 2.0 7 2 0 
MMV665899 340.8 4.8 4.8 33.2 4 2.5     3 0 0 
MMV665901 441.3 4.2 4.1 54.7 5 6.8 0.3 1.7 5 1 0 
MMV665902 443.4 3.9 2.3 53.8 6 9.0 0.3 2.1 5 2 0 
MMV665904 218.3 1.0 1.0 41.9 3 3.3     4 0 0 
MMV665906 440.5 3.4 3.4 115.4 4 1.2 0.3 2.8 8 3 0 
MMV665908 453.6 3.9 3.9 63.3 8 6.6     7 1 0 
MMV665909 360.2 4.4 4.4 54.9 3 1.2 0.4 1.5 4 1 0 
MMV665913 416.5 4.1 4.1 85.4 6 -0.5     6 1 0 
MMV665914 487.0 3.6 3.6 74.8 7 5.6     7 1 0 
MMV665915 420.5 4.2 4.2 85.4 6 -0.5 0.3 2.2 6 1 0 
MMV665916 353.4 2.3 2.3 87.7 6 -2.2 0.4 4.8 7 2 0 
MMV665917 357.8 2.0 2.0 78.7 2 1.7     8 1 0 
MMV665918 423.4 3.3 3.3 90.6 5 1.3     8 1 0 
MMV665923 290.2 4.7 4.7 51.8 2 -1.0     4 1 0 
MMV665924 286.8 4.2 4.2 26.3 4 -4.8 0.4 1.8 2 0 0 
MMV665927 282.6 2.6 2.6 38.3 5 -4.8 0.5 3.7 3 1 0 
MMV665928 338.3 4.9 2.6 32.3 6 9.7 0.4 1.3 2 2 0 
MMV665929 338.3 4.9 2.7 32.3 7 9.7 0.4 1.1 2 2 0 
MMV665934 337.2 4.1 4.1 42.9 1 0.0 0.4 1.9 3 0 0 
MMV665935 290.2 3.4 3.4 50.7 3 0.4     4 1 0 
MMV665939 346.4 4.6 4.6 58.2 4 -2.2     4 2 0 
MMV665940 293.3 3.4 3.4 47.9 4 -4.6 0.4 2.9 4 0 0 
MMV665941 389.5 5.0 5.0 30.0 6 5.2 0.3 1.6 4 1 0 
MMV665944 312.4 2.6 2.4 35.9 5 7.8 0.4 3.4 4 1 0 
MMV665946 388.5 4.4 2.9 61.0 5 8.9 0.3 1.6 5 2 0 
MMV665948 348.2 4.6 4.6 62.5 3 -3.1     4 2 0 
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MMV665949 281.1 4.3 4.3 40.5 2 -6.0     2 2 0 
MMV665953 333.6 5.1 5.1 41.1 2 -4.6 0.4 0.6 3 2 0 
MMV665954 390.5 4.6 4.6 51.2 4 4.7 0.3 1.2 4 1 0 
MMV665961 368.9 5.3 2.8 41.1 8 9.9     4 1 0 
MMV665971 485.0 4.9 4.9 88.4 6 2.4 0.3 1.4 7 1 0 
MMV665977 456.5 4.4 4.4 68.3 10 0.6 0.3 2.3 7 0 0 
MMV665979 362.4 4.4 2.2 15.3 7 9.5 0.3 1.7 2 1 0 
MMV665994 268.1 3.8 3.8 33.1 2 3.0 0.5 2.3 2 1 0 
MMV666009 268.3 3.7 3.7 24.9 1 -2.3 0.4 2.3 4 0 0 
MMV666020 265.4 3.3 0.7 41.5 10 10.0     3 2 0 
MMV666021 272.3 3.8 3.8 42.9 1 0.0 0.5 3.2 3 0 0 
MMV666025 500.2 5.5 5.5 55.9 4 0.5 0.3 0.4 5 1 0 
MMV666026 288.3 3.2 3.2 52.1 2 0.1     4 0 0 
MMV666057 420.7 4.8 4.7 71.1 4 5.6     5 2 0 
MMV666060 393.4 3.7 3.3 49.8 6 9.0     4 1 0 
MMV666061 384.5 2.9 2.0 35.9 5 9.7 0.3 3.4 4 1 0 
MMV666067 480.0 4.8 3.0 62.8 8 9.2 0.3 1.3 6 2 0 
MMV666069 418.6 4.3 1.5 33.5 9 9.4 0.3 1.5 5 0 0 
MMV666070 445.5 4.8 2.9 44.4 7 9.3     4 2 0 
MMV666071 413.5 4.3 3.5 61.3 5 8.1     5 2 0 
MMV666072 438.9 3.5 3.3 50.8 8 7.0     5 1 0 
MMV666075 254.3 3.9 3.9 15.7 2 -2.0     3 0 0 
MMV666079 287.4 4.7 4.7 51.8 0 5.8 0.4 1.2 3 1 0 
MMV666080 354.4 4.4 4.4 62.2 4 4.4 0.3 1.5 4 2 0 
MMV666081 201.3 3.4 3.4 33.1 2 3.5     2 1 0 
MMV666093 386.5 2.7 2.7 80.3 6 4.8     8 0 0 
MMV666095 280.2 4.1 4.1 33.1 2 2.6 0.5 1.8 2 1 0 
MMV666102 252.3 2.6 2.5 57.9 2 6.8     4 2 0 
MMV666103 441.9 4.8 4.8 61.8 6 1.6 0.3 1.2 5 1 0 
MMV666105 494.7 4.8 4.8 67.9 12 -3.1 0.2 1.2 6 1 0 
MMV666108 401.0 3.7 2.2 45.5 7 8.9 0.3 2.2 4 1 0 
MMV666109 383.5 3.8 3.0 59.0 8 8.4     5 1 0 
MMV666110 411.6 3.8 1.0 35.6 9 10.0 0.3 1.9 4 1 0 
MMV666116 354.5 2.8 1.9 26.7 4 10.1 0.3 3.5 3 1 0 
MMV666124 403.9 4.6 4.6 72.0 6 -0.2     5 1 0 
MMV666125 335.3 3.1 3.1 94.4 4 -7.1 0.4 3.3 6 0 0 
MMV666599 328.2 4.0 4.0 38.7 2 -5.4     3 0 0 
MMV666607 281.3 3.7 3.7 96.2 4 5.7 0.5 3.1 7 2 0 
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MMV666686 334.4 3.9 3.9 73.9 6 5.0 0.3 2.2 5 1 0 
MMV666687 394.4 3.6 3.6 92.4 8 5.0 0.3 2.5 7 1 0 
MMV666691 340.4 3.4 3.4 62.6 4 0.8 0.4 3.3 5 1 0 
MMV666693 309.3 2.9 2.9 57.1 4 -4.5 0.5 4.7 5 0 0 
MMV667486 261.3 1.3 0.3 89.2 3 8.4     6 2 0 
MMV667487 260.3 1.2 -0.1 83.2 2 8.8     6 2 0 
MMV667488 494.6 2.2 2.2 111.0 7 4.8 0.2 4.2 9 2 0 
MMV667490 493.6 3.8 3.8 85.0 7 6.8 0.2 1.9 8 1 0 
MMV667491 440.5 4.1 3.0 61.2 6 8.5 0.3 1.8 6 1 0 
MMV667492 313.4 2.1 2.1 78.8 4 -1.0 0.4 3.8 6 1 0 
MMV000304 314.4 5.1 4.1 34.2 4 8.5 0.3 0.8 3 1 1 
MMV000326 316.3 5.1 4.3 24.9 3 8.1 0.4 0.8 2 1 1 
MMV000442 315.8 5.6 5.6 12.5 3 4.2 0.4 0.9 2 0 1 
MMV000445 381.5 4.9 4.9 59.8 10 6.5 0.3 1.0 5 2 1 
MMV000570 278.4 5.3 5.2 45.2 3 6.6 0.4 1.4 3 2 1 
MMV000604 417.4 4.6 4.6 48.0 4 3.9 0.3 1.5 5 0 1 
MMV000617 432.0 5.2 4.9 41.9 9 7.3     4 1 1 
MMV000619 422.4 5.6 5.4 32.7 8 7.3 0.3 0.2 3 1 1 
MMV000621 399.6 5.5 5.2 32.7 10 7.4     3 1 1 
MMV000642 469.0 5.5 5.5 58.6 6 -1.1 0.3 2.2 5 1 1 
MMV000720 447.5 6.1 6.0 67.3 7 7.3 0.2 -0.1 5 2 1 
MMV006172 368.5 4.9 3.2 31.4 3 8.6 0.3 2.0 4 1 1 
MMV006389 359.4 5.5 5.5 29.4 1 0.6 0.3 0.9 2 0 1 
MMV006513 337.4 5.1 3.6 40.7 4 9.2 0.4 1.4 3 2 1 
MMV007092 662.9 4.0 3.3 90.3 18 7.8 0.2 1.9 10 2 1 
MMV007113 358.4 7.2 7.2 24.7 2 0.6 0.3 -1.1 2 0 1 
MMV007127 420.3 5.9 4.4 32.6 1 0.5 0.3 0.3 2 1 1 
MMV007181 356.4 5.9 5.9 54.4 5 6.6 0.3 0.2 4 2 1 
MMV007199 434.5 5.3 5.3 62.6 6 0.8 0.3 1.0 5 1 1 
MMV007224 470.2 6.9 6.9 49.8 4 2.3 0.3 -0.9 4 2 1 
MMV007273 480.6 7.0 7.0 67.4 7 4.9 0.3 -0.6 5 2 1 
MMV007275 354.8 7.1 7.1 41.1 4 -1.6 0.4 -0.8 3 2 1 
MMV007384 460.5 6.4 6.4 75.8 6 5.7 0.3 0.4 6 2 1 
MMV007396 426.6 6.3 6.3 51.2 7 1.1 0.3 -0.2 4 1 1 
MMV007574 413.6 6.8 6.8 29.1 4 -5.0 0.3 -0.7 2 1 1 
MMV007577 420.6 6.4 6.4 51.2 7 1.1 0.3 -0.5 4 1 1 
MMV007654 308.4 6.8 6.8 24.9 3 2.4     2 1 1 
MMV008160 387.5 6.2 6.2 31.9 2 3.5 0.3 0.1 3 1 1 
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MMV008173 480.6 5.2 5.2 76.2 6 -4.5 0.2 0.6 7 0 1 
MMV008455 484.6 5.4 5.4 67.9 6 -1.0 0.2 0.5 6 1 1 
MMV019241 442.3 6.1 6.1 57.8 3 5.0 0.3 0.2 4 2 1 
MMV019555 478.7 7.2 4.5 49.8 9 9.2 0.2 -0.7 4 2 1 
MMV019690 470.6 5.0 3.8 43.5 5 8.4 0.2 1.0 5 2 1 
MMV019741 458.6 6.2 6.1 50.2 6 5.9 0.2 -0.3 5 1 1 
MMV019881 727.0 4.5 1.1 97.0 12 9.0 0.2 1.7 9 3 1 
MMV020403 496.0 6.8 6.8 47.7 5 -3.9     5 1 1 
MMV020750 372.4 4.9 4.9 67.4 5 4.9 0.3 1.1 5 2 1 
MMV020912 420.5 6.8 6.8 58.3 6 3.0     4 2 1 
MMV085471 465.6 8.1 8.1 39.9 7 6.5 0.2 -2.3 4 0 1 
MMV086103 332.4 4.6 4.6 56.5 2 -2.9 0.3 1.4 4 0 1 
MMV396594 490.7 6.9 6.9 58.6 4 4.0 0.2 -0.9 6 0 1 
MMV396652 487.7 7.5 7.3 35.6 6 7.4 0.2 -1.6 4 1 1 
MMV396663 485.7 6.5 5.9 58.4 7 7.9 0.2 -0.5 5 1 1 
MMV396664 489.5 5.7 5.7 85.2 10 -4.5 0.2 0.5 8 0 1 
MMV396678 462.9 5.6 5.6 59.3 6 1.6 0.3 1.0 5 1 1 
MMV396679 492.9 5.5 5.5 68.5 7 1.7 0.3 1.6 6 1 1 
MMV396680 476.9 6.1 6.1 59.3 6 1.7 0.3 0.9 5 1 1 
MMV396717 492.0 5.9 5.8 78.5 6 1.1 0.2 0.2 6 2 1 
MMV396726 484.6 6.7 6.4 56.3 6 7.2 0.2 -0.7 5 0 1 
MMV665794 448.4 7.1 7.1 49.8 6 2.2 0.3 -0.6 4 2 1 
MMV665797 364.4 4.9 4.2 60.5 8 8.0 0.3 1.4 5 1 1 
MMV665814 419.5 5.7 5.6 67.3 6 6.5 0.3 0.3 5 2 1 
MMV665840 382.2 5.6 5.6 57.8 3 5.2 0.3 0.5 4 2 1 
MMV665852 350.0 5.5 5.5 41.1 2 -4.7 0.4 0.4 3 2 1 
MMV665936 460.6 6.2 6.2 78.3 7 0.5     6 0 1 
MMV665943 430.5 5.0 5.0 109.4 4 5.8 0.2 0.8 6 4 1 
MMV665969 432.9 5.4 5.3 71.5 5 3.6 0.3 1.0 5 2 1 
MMV665972 401.9 5.8 5.8 49.3 5 -2.6 0.3 0.1 3 2 1 
MMV665980 332.5 4.5 4.5 44.3 3 -2.8     3 3 1 
MMV665987 314.4 5.6 5.4 46.5 5 -7.0 0.4 0.6 3 1 1 
MMV666022 453.3 5.5 5.4 71.5 5 3.6 0.3 0.6 5 2 1 
MMV666023 453.5 8.7 8.7 54.6 6 1.6 0.3 -1.3 5 1 1 
MMV666054 487.8 6.1 6.0 71.5 5 3.6 0.3 0.2 5 2 1 
MMV666106 436.6 4.9 4.9 62.6 8 -3.0 0.3 1.1 5 1 1 
MMV666123 412.0 5.8 5.8 46.9 4 1.2     4 1 1 
MMV666596 468.1 9.2 9.2 28.0 4 1.5 0.3 -2.3 3 0 1 
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MMV666597 451.6 8.2 8.0 70.5 7 4.2 0.3 -2.0 5 2 1 
MMV666600 459.9 7.3 7.3 57.5 8 -6.7 0.3 -0.7 5 0 1 
MMV666688 476.0 7.5 7.5 37.6 4 3.2 0.3 -0.9 4 0 1 
MMV666689 472.5 6.1 6.0 159.7 9 3.6 0.3 0.2 12 4 1 
MMV666692 431.6 7.5 7.2 59.4 8 -0.5 0.3 -1.1 4 1 1 
MMV667489 389.9 5.6 5.6 38.3 3 1.0 0.3 0.4 3 1 1 
MMV000699 559.6 6.2 6.1 53.4 6 7.0 0.2 0.1 6 1 2 
MMV000753 636.7 9.6 9.5 111.0 6 5.3 0.2 -3.1 7 4 2 
MMV006962 501.4 6.7 6.7 86.9 5 5.1     6 3 2 
MMV007160 621.8 8.8 8.8 78.0 3   0.2 -1.2 7 0 2 
MMV007208 554.5 6.7 6.7 55.8 4 -1.1 0.2 -0.7 5 0 2 
MMV007228 659.7 7.2 7.2 91.4 5 -2.0 0.2 -0.7 8 0 2 
MMV007474 608.7 5.8 5.1 72.9 3 8.2 0.2 0.1 8 1 2 
MMV007557 586.7 5.7 5.7 84.9 9 -1.3 0.2 0.5 7 1 2 
MMV007695 657.8 7.9 7.9 80.8 7 -2.1 0.2 -1.1 6 0 2 
MMV011436 579.1 8.9 8.8 52.9 4 1.8 0.2 -2.9 4 1 2 
MMV011438 546.6 6.8 6.6 79.2 5 1.8 0.2 -0.3 6 1 2 
MMV011895 524.6 5.9 5.9 127.9 6 5.8 0.2 0.1 8 4 2 
MMV020885 510.4 6.9 6.9 38.3 3 2.2 0.3 -0.2 3 1 2 
MMV085583 592.7 7.4 7.2 71.4 9 1.8 0.2 -0.7 6 1 2 
MMV396635 520.0 5.2 4.2 62.5 6 8.4 0.2 0.8 6 1 2 
MMV665882 574.2 6.0 3.3 37.2 5 10.2 0.3 0.4 3 2 2 
MMV666062 571.7 8.0 8.0 54.5 5 -2.0 0.2 -1.4 4 0 2 
MMV666101 631.7 7.6 7.6 72.9 7 -2.0 0.2 -0.8 6 0 2 
MMV666601 637.7 7.3 7.3 82.4 9 3.1 0.2 -0.5 8 0 2 
MMV666604 500.6 5.3 5.3 88.4 6 2.9 0.2 0.6 7 1 2 
 
 
 
 
 
 
